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ABSTRACT 
 
The discovery and development of novel small molecules as anti-cancer agents plays an 
integral role in the fight against cancer. Such efforts will lead to the development of the therapies 
of tomorrow. Potentially useful molecules may be discovered through cell-based toxicity 
screens, enzyme-based in vitro screens or developed from computational design against proteins 
of interest. The elucidation of the mechanism of action of small molecules discovered in cell-
based screens remains a challenging endeavor. Whole genome transcript profiling and genome-
wide shRNA screens are tools that have recently become available to the researcher and their use 
in aiding mechanism elucidation is reviewed in Chapter 1. Also presented herein is the 
development and investigation of the mechanism of action of several novel small molecules that 
exhibit anti-cancer activity. Genome-wide technologies are employed to characterize the 
mechanism of several of these molecules. Chapter 2 focuses on the mechanism of a rapid inducer 
of caspase-dependent apoptosis. Chapters 3 and 4 investigate novel triphenylmethyl containing 
anticancer agents and compare their mechanisms of action to known agents. The development of 
lactate dehydrogenase-A (LDH-A) inhibitors as a novel anticancer strategy is discussed in 
Chapter 5. In Chapter 6, the mode of action of anti-cancer quinones is described. And finally, the 
discovery of triazole-containing small molecules as tubulin-targeting agents is narrated in 
Chapter 7.  
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CHAPTER 1.  IDENTIFYING SMALL MOLECULE MECHANISMS AND 
THERAPEUTIC POTENTIAL USING TRANSCRIPT PROFILING AND 
RNA INTERFERENCE 
 
The information and contents for this chapter were reproduced in full with permission from 
Palchaudhuri, R.; Hergenrother, P. J. "Transcript Profiling and RNA Interference as Tools to 
Identify Small Molecule Mechanisms and Therapeutic Potential" ACS Chem. Biol. 2011, 6, 21-
33. Copyright 2011, American Chemical Society. 
 
1.1 Introduction 
The elucidation of the precise biological mode-of-action of small molecules remains a 
considerable challenge in chemical biology and drug discovery.  Information about the 
mechanism of novel small molecules greatly facilitates the use of such compounds as tools for 
the investigation of fundamental biological processes. As our understanding of targets and 
biochemical pathways grows at an ever increasing rate, small molecule “tool” compounds may 
serve as a starting point for drug development efforts.
1-3
 Furthermore, at the dawn of the age of 
personalized medicine, knowledge of the target and availability of companion diagnostics will be 
critical in the development of novel therapies.
4, 5
 
Traditional approaches using affinity “pull down” reagents have been successful in 
identifying the biological targets of multiple small molecules.
6, 7
  While quantitative proteomic 
mass-spectrometry techniques have significantly aided the distinguishing of low-abundance 
protein targets from high abundance non-specific small molecule-protein interactions,
8
 there 
remain fundamental drawbacks associated with affinity reagent based target identification 
 
 
 2 
strategies. Such projects are typically labor-intensive, with no guarantee of success. For success 
in affinity pull down experiments, the compound must have considerable affinity for its target 
(and ideally bind to the target covalently), and modified versions of the compound (e.g, with 
biotin attached) that retain biological activity need to be synthesized.  In addition, identification 
of certain types of targets (i.e. membrane-bound proteins) remains a challenge. 
Another set of tools that has recently emerged to facilitate rapid mechanism-of-action 
studies are genome-wide transcript profiling and RNAi screens. These methods can be successful 
regardless of compound affinity and are relatively easy to implement as they involve no synthetic 
overhead (no need for the construction of a probe reagent). Furthermore, even if the information 
returned does not immediately reveal the molecular target, the data set received is still highly 
informative. The focus of this chapter is to highlight how these approaches have been used to 1) 
aid compound mechanism-of-action studies, and 2) enable the identification of compounds that 
may be relevant to particular diseases/physiological processes.  
 
1.2  Global transcript profiling to assist target identification 
Whole-genome transcript profiling has emerged as a powerful tool to investigate the 
effects of small molecules on cells. While the list of altered transcripts may shed light on 
compound mechanism by analysis of the pathways affected, our understanding of pathways, how 
they interact with one another, and their consequences in various cell types is far from complete. 
Thus, it is typically not possible to identify the molecular target of a small molecule from a 
simple analysis of its transcript profile. However, pathway-independent approaches have recently 
emerged, in which the transcript profile data of a compound of interest is compared to analogous 
data that has been collected on hundreds of compounds with known molecular targets.  
 
 
 3 
The Connectivity Map database, developed at the Broad Institute, is a publicly accessible 
database comprising gene expression data of cells treated with small molecules.
9
 In most cases, 
the MCF-7 (breast cancer) cell line is used, but there are many instances from HL-60 (human 
leukemia), PC-3 (prostate cancer), and SK-MEL-5 (melanoma) cell lines.
9, 10
 The expression 
profiles were obtained by treating cells for six hours with the small molecules (to maximize 
primary effects) at various doses. The first version (build 01) of the Connectivity Map database 
contained 164 molecules with 453 signatures, while the second version (build 02) contains 1309 
small molecules with 6100 signatures. As the database contains data for compounds that have 
considerable mechanistic characterization (FDA approved drugs and non-drug bioactive “tool” 
compounds), matches to the query signature would suggest possible mechanisms-of-action and 
molecular targets.
9, 10
 
 
Figure 1.1 Gene expression signatures of small molecule with unknown mechanisms may be used to 
query the Connectivity Map database, to identify compounds that elicit similar transcriptional effects. 
Parts of the figure were adapted from Lamb et al.
9
 
 
It should be emphasized that this is a pattern matching approach to target identification, 
with the pattern of up/down regulated transcripts of paramount importance, where (for 
Connectivity Map purposes) the identity of the transcripts is not taken into consideration. This 
process is outlined in Figure 1.1. Users obtain transcript profile data with their compound of 
interest in cells with a six hour treatment time. A “query signature” of up- and down-regulated 
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genes is generated by the user, input into the Connectivity Map database, and scored based on 
how well compounds in the database match the input query. Scores of 1 represent a perfect 
match, 0 represent a null match and -1 indicates perfect anti-correlation to the input signature. 
The number of genes and the methods for selecting the genes (e.g. based on p value or fold 
change) for constructing the query signature are at the user‟s discretion. Although (as mentioned) 
several cell lines are represented in the Connectivity Map database, for the purposes of 
mechanism identification, the use of MCF-7 may be advantageous (provided the compound 
elicits the desired phenotype) as the profiles in the Connectivity Map are predominantly obtained 
in this cell line.  
Other pattern matching techniques have been utilized in an attempt to group small 
molecules according to their mode-of-action.
11, 12
 Perhaps the most well-known method is the 
COMPARE analysis, in which the pattern of toxicity of compounds to the NCI 60 cell line panel 
is compared.
11, 13
 Compounds that have similar patterns of toxicity are highly correlated in the 
COMPARE algorithm; such a result suggests the compounds have a similar mechanism-of-
action, and indeed COMPARE has been successfully used in target identification studies.
14, 15
 In 
practice, however, the nature of the cytotoxicity screens is that there is a significant amount of 
variability, even amongst replicate evaluations of the same compound. Thus, the correlations 
returned from COMPARE are usually not high and may therefore limit the utility of this method. 
The Connectivity Map database has been utilized in mode-of-action studies of several 
small molecules.  Connectivity Map experiments with six compounds (shown in Figure 1.2) are 
described below. These examples have been selected as they correspond to situations that many 
chemical biologists find themselves in, namely, through high-throughput screening a compound 
has been identified that elicits an interesting cellular phenotype, but the precise mode-of-action 
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and cellular target is unknown. If the transcriptional profile induced by the compound of interest 
matches compounds in the Connectivity Map, then downstream biological experiments to 
confirm the mechanism are typically straightforward.   
 
 
Figure 1.2. Small molecules (listed with their biological mode-of-action) whose mechanisms were 
identified with the aid of the Connectivity Map database. 
 
1.2.1 Epoxy anthraquinone   
The gene expression signature of an epoxy anthraquinone (EAD, Figure 1.2) in 
neuroblastoma SK-N-As cells had topoisomerase I/II inhibitors and DNA intercalators as 7 of 
the top 10 Connectivity Map correlations.
16
 Follow up experiments confirmed EAD induces 
DNA alkylation and inhibits topoisomerase I and II in vitro.
16
   
 
1.2.2 Droxinostat  
Droxinostat (Figure 1.2) was identified from a screen for sensitizers of resistant cells to 
CH-11 Fas-activating antibody.
17
 Through use of the Connectivity Map it was revealed that the 
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transcript profile of droxinostat in the resistant cell line matched the HDAC inhibitors vorinostat 
and trichostatin A. Through a series of cell-based and in vitro assays, it was determined that 
droxinostat, which contains a hydroxamic acid moiety like other pan-HDAC inhibitors, is a 
novel HDAC inhibitor that is selective for HDAC3, HDAC6, and HDAC8.
17
 While other pan-
HDAC inhibitors are also able to sensitize resistant cells to Fas induced apoptosis,
18
 HDAC 
knockout mice studies suggest isoform selective inhibitors may alleviate undesired toxicity.
19-21
  
 
1.2.3 15-Deoxy-Δ-Prostaglandin J2 (PGJ2)   
The Connectivity Map has also enabled further mechanistic characterization of molecules 
in the database itself.  15-Deoxy-Δ-prostaglandin J2 (PGJ2, Figure 1.2), an endogenous anti-
inflammatory cytokine present in the Connectivity Map (Build 02), was found to match the gene 
expression signature of 3 out of 4 novel small molecules that downregulate HIF2α.22 PGJ2 was 
found to inhibit translation of HIF2α protein (rather than transcription) through an mTOR-
independent manner not affecting global translation. Using luciferase reporter constructs it was 
discovered that the PGJ2-induced decrease of HIF2α expression is dependent on a 50 bp segment 
of the 5‟-UTR that contains an iron regulatory element (IRE). Downregulation of the IRE 
binding iron regulatory protein IRP1, but not IRP2, mitigated PGJ2-induced downregulation of 
HIF2α suggesting an IRP1-dependent mechanism. This study illustrates the first example of an 
endogenous small molecule regulator of HIF2α translation and assigns a novel mechanism as to 
how PGJ2 elicits an anti-inflammatory effect.  
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1.2.4 Gedunin and celastrol 
A high-throughput cell-based screen identified gedunin and celastrol (Figure 1.2) as 
inhibitors of androgen receptor (AR)-activated signaling in prostate cancer.
23
 Transcript profiling 
of these agents and query of the Connectivity Map database yielded strong matches to the heat 
shock protein 90 (HSP90) inhibitors, geldanamycin, 17-dimethylamino-geldanamycin and 17-
allylaminogeldanamycin.
23
 As the androgen receptor is a client of HSP90 and inhibition of 
HSP90 induces AR degradation, gedunin and celastrol may inhibit AR signaling by inhibiting 
the HSP90 pathway. Consistent with this hypothesis, treatment of LNCaP prostate cancer cells 
with celastrol and gedunin induced the downregulation of AR and several other HSP90 client 
proteins (FLT3, EGFR, and BCR-ABL1). Further experiments showed that while celastrol and 
gedunin inhibit HSP90 ATP binding activity in cells, they do not compete with the ATP-binding 
site and are therefore mechanistically distinct from the geldanamycin-based HSP90 inhibitors. 
 
1.2.5 Akt inhibitor off-target effects 
One of the challenges of drug development is the identification of off-target effects of 
biologically active small molecules. Inhibition of the Akt pathway is an attractive anti-cancer 
strategy for which various compounds have been developed, including SH-5 (Figure 1.2) and 
SH-6 (not shown in Figure 1.2), which are competitive inhibitors of phosphatidyl inositol 
(3,4,5)-trisphosphate (PIP3).  PIP3 is an endogenous product of PI3 kinases that activates AKT 
signaling. The off-target effect of these inhibitors was investigated by Krech and coworkers 
using human colorectal cancer cell lines in growth media containing 10% FBS.
24
 Under these 
conditions SH-5 and SH-6 are unable to inhibit the AKT pathway but induced the formation of 
binuclear cells in SW480 cells by inhibiting abscission, the last step of cytokinesis (cell line 
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specific effect). Subjection of the gene transcript profile to Connectivity Map analysis revealed 
matches to compounds that interfere with PIP2 (Resveratrol), Ca
2+
 (Thirodiazine) and protein 
kinase C (PKC) signaling (Rottlerin). As PIP2 hydolysis and Ca
2+ 
levels affect the production of 
diacylglycerol (DAG), a metabolite required for PKC signaling, it was hypothesized that 
binucleation is related to PKC inhibition. Similar to SH-5 and SH-6, treatment of SW480 cells 
with resveratrol and rotterlin resulted in the production of the binuclear cells thus supporting 
interference of PKC signaling as a cause of the AKT-independent binucleation phenotype 
induced by SH-5 and SH-6. 
 
1.3  Using the connectivity map to identify compounds that modulate 
physiological or disease phenotypes    
Another major challenge in drug discovery is determining which small molecules may be 
best suited to treat a disease or modulate a physiological phenotype. Using disease- or 
physiological process-specific signatures as the query, small molecules in the Connectivity Map 
database that have positive or negative correlations can be readily identified (Figure 1.3).
9, 10
 
Small molecules whose signatures negatively (i.e. anti-) correlate with disease-specific 
signatures may prove useful in reversing disease-specific phenotypes and aid the rational 
selection of candidate therapeutics for further investigation. On the other hand, compounds 
whose signatures positively correlate with phenotype-specific signatures may be able to induce 
the phenotype (Figure 1.3). Highlighted below are notable examples where this strategy has 
aided the identification of therapeutic candidates for the treatment of various cancers, and 
compounds that can modulate other physiological processes, such as hair growth (Figure 1.4). 
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Figure 1.3. Phenotype-specific genes may be used to query the Connectivity Map database to identify 
small molecules that may be able to induce or reverse the phenotype. Parts of the figure were adapted 
from Lamb et al.
9
 
 
1.3.1 Hepatocellular carcinoma vascular invasion  
The identification of compounds that modulate hepatocellular carcinoma (HCC) vascular 
invasion was performed using an invasion-specific 73-gene signature obtained from comparing 
38 HCC tumors displaying the vascular invasion phenotype to 43 tumors lacking in this 
phenotype.
25
 Input of the 47 up- and 26 down-regulated genes into the Connectivity Map 
identified two small molecules (resveratrol, and 17-AAG) with significant anti-correlation to the 
input signature (p value <0.05). These agents were able to inhibit the invasive nature of two HCC 
cell lines HepG2 and PLC/PRF-5 at non-cytotoxic concentrations (10 μM). Follow up 
experiments confirmed these compounds revert the expression levels of several genes involved 
in invasion, adhesion, and angiogenesis.  
 
1.3.2 Neuroblastoma 
In order to identify candidate therapeutics for neuroblastoma, an integrative meta-
analysis of gene copy number was performed using expression profiles of 146 primary 
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neuroblastoma tumors and normal fetal neuroblasts to construct a list of 132 tumor-specific 
genes.
26
 Five of the top six compounds proposed by the Connectivity Map were able to 
significantly reduce cell viability in five neuroblastoma cell lines; compounds included HSP90 
inhibitors (17-AAG and monodern), an HDAC inhibitor (trichostatin A), an mTOR inhibitor 
(rapamycin) and a phenotriazene (fluphenazine).  While the toxicity of these compounds may not 
be restricted to neuroblastoma, this approach provides a rational basis for the selection of 
therapeutic candidates for neuroblastoma clinical trials.  
  
1.3.3 Acute myelogenous leukemia stem cells (AML-SC) 
The role of cancer stem cells (CSC) in blood cancers (such as acute myelogenous 
leukemia, AML) has been well characterized.
27
  Selective toxicity against AML stem cells 
(AML-SCs) has been observed in vitro using parthenolide (PTL).
28, 29
 The ability of this agent to 
kill AML-SCs has been attributed to its ability to simultaneously inhibit NF-κB signaling and 
induction of oxidative stress.
28
 PTL‟s selective toxicity against AML-SC versus normal 
hematopoietic stem and progenitor cells served as a tool to identify novel compounds capable of 
inducing AML-SC death.
30
  By obtaining gene expression signatures of CD34+ AML cells 
(isolated from 12 patients) treated with PTL and compared to non-treated cells, a 150-gene 
signature was used to query the GEO and Connectivity Map databases for agents inducing 
similar signatures.  In addition to agents known for their anti-AML-SC activity (MG-132 and 
prostaglandin), celastrol was identified in both database searches and three other compounds, 
hemin, HNE, and gedunin were identified from the GEO database search. Similar to PTL, 
treatment of CD34+/CD38- AML cells with celastrol and HNE gave selective toxicity at the 
bulk, progenitor, and stem cell levels versus CD34+/CD38- normal bone marrow cell, normal 
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myeloid, and erythroid cell populations. These agents were shown to simultaneously inhibit NF-
κB and induce Nrf2-oxidative stress response.  This study further enforced the link between 
simultaneous NF-κB and oxidative stress induction for efficacy against AML-SCs and identified 
two novel agents (celastrol and HNE) that exhibit toxicity towards AML-SCs.   
 
1.3.4 Colorectal cancer with microsatellite instability 
Microsatellite instability may be a suitable marker to categorize colorectal cancers, as 
approximately 15% of sporadic colorectal cancers have high frequency instability
31, 32
 and 
exhibit differential sensitivity to chemotherapy.
33, 34
  By analyzing the signature of 38 
microsatelite stability (MSS) and 13 high frequency microsatellite instability (MSI-H) tumors, a 
list of 71 probes were found to be differentially expressed between the two groups.
35
  This 
signature was used to query the Connectivity Map, and inhibitors of HDAC, HSP90 and PI3K-
mTOR populated the best hit compounds that exhibited anti-correlation to the input signature.
35
 
Subsequent toxicity experiments identified the mTOR inhibitors, rapamycin and LY-294002, to 
exhibit selective toxicity (4-fold and 1.5-fold respectively) towards MSI-H cell lines versus MSS 
cell lines in culture while the HDAC and HSP90 inhibitors did not demonstrate selective 
toxicity. This approach identified MSI-H colorectal cancers as more sensitive to the effects of 
mTOR inhibition than MSS colorectal cancers, warranting further investigation of the link 
between the microsatellite instability phenotype and the PI3K pathway.   
 
1.3.5 Aggressive lung adenocarcinoma 
Many adenocarcinomas are treated identically even though they exhibit a high degree of 
morphological and clinical diversity.
36
  In a study by Ebi and coworkers, gene set enrichment 
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analysis (GSEA) was performed on transcript profile data from two different studies that 
categorized lung carcinoma based on patient post-surgical survival rates.
37
 Statistically 
significant gene sets were identified that correlated with fatal outcome which included a gene set 
downregulated by rapamycin (an mTOR inhibitor), and those associated with glucose, leucine 
and glutamine metabolism, processes that are also regulated by the mTOR/PI3K pathway. The 
Connectivity Map database was queried and revealed several compounds that target the mTOR 
and PI3K pathway as those that would be able to negatively regulate genes specific to poor 
prognosis. While several PI3K inhibitors and the mTOR inhibitor rapamycin were active against 
adenocarcinoma in toxicity assays, a particular PI3K inhibitor, PI-103, was found to exhibit 
toxicity that correlated with cumulative deregulation scores across the various cell lines 
investigated in culture. This further supported a functionally relevant connection between 
adenocarcinoma and the PI3K/mTOR pathway. Transcript profiling of treated cells confirmed 
PI3K inhibitors were able to revert the GSEA derived signature associated with poor prognosis.  
 
1.3.6 Glucocorticoid resistance 
The efficacy of dexamethasone, a glucocorticoid used for the treatment of acute 
lymphoblastic leukemia (ALL) in children, is compromised by resistance.
38
 A gene expression 
signature associated with dexamethasone resistance was obtained by comparing bone-marrow 
leukemia cells from patients that exhibit resistance to those derived from dexamethasone 
sensitive patients.
39
  Using this signature to query the Connectivity Map led to the identification 
of the mTOR inhibitor rapamycin as an agent capable of reverting resistance in cell culture 
assays using the dexamethasone-resistant CEM-cl lymphoid cell line.
39
  This sensitization was 
dependent on mTOR inhibition and is thought to be mediated by downregulation of the 
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antiapoptotic protein, MCL1. The Connectivity Map thus helped to identify rapamycin as a 
therapeutic candidate for clinical evaluation in dexamethasone-resistant ALL patients. 
 
1.3.7 Hair growth modulators 
Although the Connectivity Map database has been primarily used in the field of cancer, it 
has also been useful in the identification of compounds that can influence normal physiological 
processes unrelated to cancer. The discovery of novel hair-growth inducers by Ishimatsu-Tsuji 
and coworkers utilized the day 2 and day 4 gene expression signature of mouse dorsal skin cells 
treated topically with cyclosporine A, a known inducer of hair growth.
40
  Using the 2 day 
signature to query the Connectivity Map, fluphenazine was identified as agent that induced hair-
growth upon topical application.  Iloprost, a compound that matched the 4 day signature, was 
discovered to enhance fluphenazine-induced hair growth. This study demonstrated how 
investigating different phases of a physiological process may be used to identify phase-specific 
small molecule modulators. 
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Figure 1.4. The use of the Connectivity Map database has led to the identification of several small 
molecule therapeutic candidates for the treatment of cancers, and compounds that can modulate 
physiological processes such as hair growth. 
 
1.4 The use of RNAi screens to aid the identification of mechanism of action  
One of the fruits of the genomic age has been the development of powerful genetic 
techniques that enable interrogation of protein function. Genome-wide, pathway-focused 
(targeting apoptosis, kinases and phosphatases), and custom made-to-order RNAi libraries are 
commercially available in siRNA and shRNA formats. Whereas siRNA elicits short-term 
knockdown (2-5 days) and delivery is limited to cell types that may be easily transfected, shRNA 
libraries may be transduced (using viral particles) into cell types that are difficult to transfect, 
enabling stable knockdown and facilitating screens of longer duration.  
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Commercial RNAi libraries are available in pooled or well formats. The experimental 
setups for pool- and well-based experiments are illustrated in Figure 1.5; these experiments can 
implicate a protein in mediating the effect of a compound.  For example, the cells 
transfeced/transduced with the interfering RNA can be treated with an anti-cancer compound at a 
concentration know to give quantitative cell death.  Any surviving cells, therefore, must have an 
mRNA knocked down that was important in the cell death induced by the compound.  
Well-based experiments may require high-throughput screening intensive methods 
(depending on the library size), are typically more costly, but allow more freedom in the 
phenotype being investigated and are suited to both positive and negative selection screens. A 
variety of read-outs may be employed, including high-content imaging, flow cytometry, ELISA, 
and cell viability assays (Figure 1.5B). As an alternative to plate based assays, well-format 
libraries may be printed onto microarrays upon which adherent cells may be grown, and results 
observed using high content imaging techniques. In comparison to well-format RNAi, pooled-
libraries are more cost-effective and screens can often be performed by a single researcher; 
however, the phenotypes that may be investigated are limited. In addition, the experimental 
protocol employed in pooled-library toxicity screens may bias them towards positive selection, 
although negative selection screens are possible if conditions are optimized.
41
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Figure 1.5. An overview of the (A) pooled- and (B) well-based format RNAi screen experiments.  
 
Pooled shRNA screens require transduction of cells such that the shRNA multiplicity of 
infection (MOI) is less than 1. The cells are split into two pools and one is treated with vehicle 
while the other is treated with the small molecule (Figure 1.5A). For screens involving toxic 
molecules, selection is typically performed over 2-3 weeks. The total genomic RNA is isolated, 
the shRNA constructs are amplified by PCR, and the half-hairpin sequences are then hybridized 
to complementary DNA microarrays. By comparing the levels of shRNA constructs in treated 
versus non-treated cells, it is possible to identify shRNAs that are enriched (positive selection) or 
depleted (negative selection) as a result of small molecule treatment (Figure 1.5A).  
While genome-wide RNAi libraries may allow a systematic and unbiased approach to 
interrogating cell biology, there are pitfalls associated with RNAi such as lack of target-
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specificity and knock-down efficiency, which ultimately lead to false positives and false 
negatives, respectively. Both pooled and well-based libraries typically contain multiple 
constructs targeting the same gene, increasing the likelihood that a protein will be effectively 
targeted; this redundancy also helps discern likely true-positives from false-positives arising 
from off-target effects. Furthermore, as shRNA/siRNA constructs continue to be validated for 
knockdown efficacy, revised construct design will continue to improve the quality of RNAi 
libraries.  Despite this, it is not always clear if mRNA knockdown is sufficient to modulate the 
cellular level of a protein such that its function is affected. Protein longevity, expression levels, 
and contribution to functional pathways in a particular cell line  are factors that affect the success 
of RNAi-based experiments.  
Despite these limitations, the use of RNAi libraries may significantly aid investigations 
of the mechanism of small molecules. As described below, several proof-of-principle studies 
have investigated compounds with known modes of action using RNAi screens.  A particular 
appeal of this technique is the ability to identify key proteins that are the compound‟s direct 
target, or regulators of the target. Evidence suggests that upstream proteins are more likely to be 
identified, as proteins considerably downstream of the direct target may be unable confer long-
term survival, especially given that selections are performed over 2-3 weeks.  Of course, if a 
protein‟s down-regulation itself induces toxicity, this may preclude its identification as a small 
molecule target.  A list of such proteins that may elude identification may be inferred from the 
study by Luo and coworkers, which identified 268 essential genes common to 12 cell lines.
41
 
These genes were enriched for pathways involving ribosomal proteins, mRNA processing and 
splicing, translation factors and proteasome degradation.
41
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Figure 1.6. Small molecules and proteins that have been investigated in RNAi screens. 
 
1.4.1 Etoposide 
The ability of whole genome pooled shRNA barcode screens to reveal the molecular 
target of the small molecule etoposide (Figure 1.6) was demonstrated by Luo and coworkers 
using a 45,000 shRNA library that targeted 9,500 genes.
41
  H82 small-cell lung cancer cells were 
transduced with the shRNA library and treated with 1.7 μM etoposide for three weeks (10 
independent transductions and treatments). This dose of etoposide was sufficient to kill >99% of 
treated cells within 7 days.  PCR amplification of the shRNA constructs of surviving cells versus 
control untreated cells revealed 3 of the 5 shRNA constructs targeting topoisomerase II, the 
known target of etoposide, with >40 fold enrichment.   
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1.4.2 Gleevec   
A positive selection screen (similar to etoposide) for gleevec-treated K562 cells 
transduced with a shRNA library was performed over 21 days by Luo and coworkers.
41
   A dose 
of 125 nM gleevec (Figure 1.6) was used, which was sufficient to kill >90% of the treated cells 
within the first 7 days of treatment. Bcr-Abl, the known target of gleevec, is essential for the 
survival of K562 cells and thus precluded its identification through this positive selective screen. 
PTPN1 was one of the genes identified to confer resistance. Encouragingly, this gene was also 
identified in a shRNA screen to identify genes that confer survival to Bcr-Abl RNAi in K562 
cells.
41
 PTPN1 is a negative regulator of Bcr-Abl and shRNAs targeted against PTPN1 were able 
to increase phosphorylation of Bcr-Abl thus conferring resistance to gleevec. The shRNA screen 
thus identified a Bcr-Abl negative regulator that is involved in gleevec induced cell death.  
 
1.4.3 Fas-Activating Antibody (Fas-Ab)   
The identification of proteins involved in Fas-Ab induced Jurkat T cell death using a 
pooled whole genome shRNA positive selection screen was also performed by Luo and 
coworkers.
41
  The knockdown of FAS, FADD, and CASP8 genes were found to confer resistance 
to Fas-Ab. Fas, Fadd and caspase 8 form the death-inducing signaling complex (DISC) that is 
critical to initiating the extrinsic apoptotic pathway upon binding of Fas-Ab to the Fas receptor. 
Two novel genes, ARID1A and CBX1, were also identified in this screen whose knockdown 
prevented caspase-8 activation thus identifying their role upstream of caspase-8 activation in 
Fas-Ab induced apoptosis. In a separate study, Tsujji and coworkers identified CASP8, BID and 
FAS as genes whose knockdown prevented Fas-Ab mediated cell death in the D98/AH2 (derived 
 
 
 20 
from HeLa) cell line.
42
 The inability to identify FADD in this study may be due to technical 
differences in the experiment/RNAi library or cell line-specific effects.  
 
1.4.4 Nultin-3  
In order to identify genes that play a role in nutlin-3 mediated cell death, a barcode 
pooled shRNA screen was conducted in MCF-7 (wild-type p53) breast cancer cells.
43
  Nutlin-3 
(Figure 1.6) is a small molecule inhibitor of the MDM2-p53 protein-protein interaction. MDM2 
binding to p53 inhibits p53-dependent apoptosis by suppressing transcriptional activation of p53 
in response to DNA damage, exporting p53 out of the nuclease and targeting p53 for proteasomal 
degradation due to E3 ligase activity of MDM2.  The shRNA screen was performed by treating 
cells with Nutlin-3 for 14 days at a concentration of 4 μM, was sufficient to induce cell cycle 
arrest without inducing apoptosis. Despite the use of non-toxic concentrations of nutlin-3, 
shRNAs that enabled cell proliferation would be amplified under these conditions. Several 
proteins involved in the p53-pathway were identified which included p53 itself, a p53 binding 
protein (53BP1), and a MDM2 target known to be a transcriptional activator of p53 (hnRNPK). 
Further shRNA experiments determined p53BP1 enables p53 transcriptional activity but does not 
affect induction of p53 protein. As 53BP1 is a component of the ATM-CHK-53BP1 pathway 
that induces p53 upon activation by DNA double strand breaks, it may explain why cancer cells 
are more susceptible to nutlin-3 as normal fibroblast cells exhibited considerably less 53BP1-
containing nuclear foci than MCF-7 breast cancer cells. This data suggests that combination of 
nutlin-3 with DNA damaging anti-cancer agents should be avoided as this may result in 
undesired toxicity towards normal cells. 
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1.4.5 Gemcitabine combination therapy   
In addition to mechanism elucidation, RNAi libraries may aid the identification of 
effective combination therapies.  Gemcitabine (Figure 1.6), a nucleoside analog that replaces 
cytidine during DNA replication and prevents the attachment of other nucleosides, is commonly 
used for the treatment of pancreatic cancer. Using the well-format Qiagen kinase siRNA library 
(2 siRNA constructs per kinase targeting 572 kinases), a screen was performed to identify 
kinases whose knockdown would potentiate gemcitabine toxicity in the MIA PaCa-2 pancreatic 
cancer cell line.
44
 Although several kinases were identified that modestly increased toxicity, two 
siRNA constructs targeting CHK1 were identified that were able to sensitize cells to gemcitabine 
by >10 fold.  Using the small molecule inhibitors of CHK-1, SB 218078 and PD 407824, a 2.6 
and 3.5 fold potentiation of gemcitabine was observed, respectively. CHK1, a protein kinase that 
was known to be activated upon DNA damage by gemcitabine, serves to induce cell cycle arrest 
and allow DNA repair and inhibition of CHK1 induces apoptosis by preventing DNA repair.  
The fact that CHK2 did not potentiate gemcitabine suggests that CHK2, unlike CHK1, is not 
involved in gemcitabine-induced DNA damage response and sheds further light on the 
mechanism of gemcitabine and functional differences between CHK kinases.  
 
1.4.6 Carboplatin resistance  
Apart from investigating the mechanism and potential therapeutic combination strategies, 
RNAi screens have aided the identification of mechanisms of resistance to the effects of small 
molecules. The resistance of ovarian cancer cell lines to carboplatin (Figure 1.6) was 
investigated in a siRNA screen targeting 90 genes associated with resistance to 
carboplatin/paclitaxel combination therapy.
45
 The candidate genes comprised of 39 genes 
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enriched (>2 fold) in post-chemotherapy tumors versus primary tumors and 51 genes enriched 
(>2 fold) post-chemotherapy versus primary chemoresistant tumors. The screen identified the 
ENPP2 gene which encodes for autotoxin, a protein with lysophoslipase D activity, as a 
contributor to carboplatin resistance. Autotaxin produces the pro-survival factors, 
lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P). Experiments using siRNA and 
a chemical inhibitor confirmed autotoxin inhibition accelerates carboplatin-induced apoptosis in 
ovarian cancer cells thus supporting the role of autotaxin in conferring resistance to carboplatin. 
 
1.4.7 ABT-737 resistance  
ABT-737 (Figure 1.6), a potent inhibitor of the antiapoptotic proteins Bcl-2, Bcl-XL and 
Bcl-w has demonstrated toxicity against small-cell lung carcinomas (SCLC) in culture and 
preclinical models.
46
 Some SCLC cell lines and cell lines derived from other cancers are, 
however, resistant to the effects of ABT-737.
46
 To identify the mechanism of ABT-737 
resistance Lin and coworkers conducted a well-format siRNA screen against 4000 druggable 
genes using the NCI-H196 SCLC derived cell line.
47
 RNAi against FGFR2, TNFRSF13B, and 
PRDM13 were initially identified to confer sensitivity however testing of multiple constructs 
against these genes revealed the effects to be off-target as no correlation was observed between 
sensitivity to ABT-737 and the level of target gene knockdown.
47
 One of the major contributions 
to off-target effects arises from the complementation of nucleotides 2-8 of the antisense siRNA 
strand, otherwise known as the „seed‟ region, and the 3‟ UTR of unintended targets.48, 49 A 
BLAST analysis of the „seed‟ regions of effective FGFR2, TNFRSF13B, and PRDM13 siRNA 
constructs suggested an overwhelmingly large number (343) of possible off-targets. However 
from this list, a particular Bcl-2 antiapoptotic protein, Mcl-1 was identified which had implicated 
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in conferring resistance to ABT-737 in other studies. Mcl-1 is Bcl-2 family member protein that 
is not susceptible to inhibition by ABT-737. Further experiments confirmed that the effective 
siRNAs of FGFR2, TNFRSF13B, and PRDM13 induced off-target silencing of Mcl-1 and 
siRNAs against Mcl-1 were able to confer sensitivity to ABT-737. This study exemplifies one of 
the pitfalls associated with RNAi-based screening, and emphasizes the necessity of thorough 
experimental validation of candidate „hit‟ genes. 
 
1.5 Outlook 
Pattern matching of small molecule transcript profiles to databases such as the 
Connectivity Map, which contain profiles of biologically characterized small molecules, is a 
powerful tool in mode-of-action studies. In addition to its utility in target identification, the 
Connectivity Map serves as a convenient platform to connect diverse disease or physiological 
processes to small molecules. The examples highlighted in this chapter suggest that a single 
small molecule may be capable of affecting diverse pathways and thus find applications in 
multiple biological contexts.  It is important to note that although the Connectivity Map database 
contains data from a handful of cancer cell lines, it has proven useful in connecting small 
molecules to physiological processes and cancers whose cell types are not present in the 
database. As future versions will incorporate more compounds and transcript profiles obtained 
from RNAi experiments, the database will strengthen our ability to connect small molecules, 
diseases and genes.  The ease of this method, and the vast amount of data generated from each 
experiment, are considerable strengths of this technique.  
While the Connectivity Map may aid mechanism identification when there are 
compounds of similar mechanism in the database, it may not be able to address biologically 
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active molecules with unprecedented mechanisms. Several proof-of-principle studies using 
compounds with known mechanisms have demonstrated that genome-wide shRNA screens are 
capable of identifying direct targets or upstream proteins involved in the mechanism.  Thus, the 
use of this technology holds considerable promise in aiding characterization of novel small 
molecules with unknown mechanisms.  In addition, RNAi screens may aid the identification of 
combination therapeutics and resistance mechanisms.  The use of the genome expression and 
genome-wide shRNA screens compliment traditional target identification techniques, and are 
likely to significantly expedite mechanism elucidation and the applications of small molecules in 
medicinal chemistry and chemical biology. 
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CHAPTER 2. THE IDENTIFICATION AND MECHANISTIC 
CHARACTERIZATION OF 4150: A RAPID INDUCER OF CASPASE-
DEPENDENT APOPTOSIS 
 
The work presented in this chapter could not have been accomplished without Dr. Karson Putt 
who conducted the high-throughput screen that led to the discovery of 4150. In addition, I would 
like to acknowledge Michael Lambrecht and Dr. Seok Ho Kim for contributions to chemical 
synthesis and Laurie Nguyen for assistance with biological testing. Michael Lambrecht also 
characterized the hydrate form of 4150 by NMR and absorbance spectroscopy. I would also like 
to acknowledge Professor Tim Fan for his assistance with the syngeneic tumor models. 
 
2.1 Introduction 
2.1.1 Apoptosis is mediated by caspases 
Apoptosis is a form of programmed-cell death mediated by caspases, a family of cysteine 
proteases that cleave after aspartate residues. Caspases exist in the cell as inactive zymogens 
known as procaspases. During apoptosis procaspases are processed by proteolytic cleavage of 
their inhibitory pro-domains to active caspases. There are 14 members of the caspase family that 
have been identified and not all caspases are involved in apoptosis.
1
 For the caspases that 
participate in cell death, there is a hierarchy within the apoptotic signaling cascade. Caspases -2, 
-8, -9 and -10 are apoptosis initiators whose activation leads to cleavage and activation of the 
apoptosis executioner caspases -3, -6 and -7 (Figure 2.1).
1
 The remaining members of the 
caspase family modulate inflammatory responses.
1
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Upon activation of executioner caspases, cell death is inevitable and apoptosis proceeds 
as a result of the cleavage of various cellular proteins. In fact several hundreds of proteins have 
been identified as substrates of the executioner caspases.
2
 While not all these proteins play a role 
in implementing apoptosis, the cleavage certain executioner caspase targets have been identified 
to enable apoptosis. Depending on the role of the target protein in the cell, cleavage by caspase-3 
may lead to inactivation (loss of function) or activation (gain of function). For example, poly-
ADP-ribose polymerase-1 (PARP-1), a protein involved in the DNA-damage repair response, is 
inactivated by caspase-3 which facilitates apoptosis by blocking energy-depletion induced 
necrosis and inhibiting DNA-repair induced survival.
3
 The caspase-3 mediated cleavage of 
inhibitor of caspase-activated DNase (ICAD) relieves the inhibition of caspase-activated DNase 
(CAD) resulting in DNA cleavage and chromatin condensation, one of the hallmarks of 
apoptosis.
4-6
 Furthermore, cleavage and activation of Rho-associated kinase-1 (ROCK1) results 
in cellular blebbing, eventually leading to membrane encapsulated cytoplasmic particles 
(apoptotic bodies) that separate from the cell.
7
 These apoptotic bodies are cleared by neighboring 
healthy cells or cells of the immune system by phagocytosis, and prevent acute inflammation that 
otherwise results from other non-programmed forms of cell death such as necrosis.
8-10
 The 
activation of caspases also leads to the externalization of phosphatidylserine on the cell 
membrane prior to a loss in cell membrane permeability, another hallmark of apoptosis.
11, 12
 
While the direct dependence on caspase-3 activation remains controversial, the externalization of 
phosphatidylserine is presumably due to indirect activation of scramblases by caspase-3-
mediated cleavage and activation of protein kinase c (PKC) delta.
13
  
There are two pathways of inducing apoptosis depending on the origin of the initiating 
signal either from within or outside the cell: the mitochondrial-mediated intrinsic pathway and 
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the cell membrane receptor-mediated extrinsic pathway (Figure 2.1). The extrinsic pathway 
involves natural ligands such as TNF and FasL binding to cell membrane receptors which result 
in the recruitment of death domain proteins (TRADD or FADD) to proteolytically activate 
procaspase-8 in a multi-protein complex called the death-inducing signaling complex (DISC).
14, 
15
 In type I cells, the initiator caspase-8 directly activates the executioner caspase-3, after which 
apoptosis ensues.
16
 However, in type II cells, caspase-8 activation does not directly lead to 
caspase-3 activation. Rather, the caspase-8 mediated cleavage of Bid, a proapoptotic protein 
residing in the cytosol, to truncated Bid (tBid) is required.
16
 Once cleaved, tBid induces 
mitochondrial cytochrome c release which activates caspase-9 and -3.
16
  
 
Figure 2.1. A schematic of the intrinsic and extrinsic pathways of apoptosis. The extrinsic pathway is 
activated by binding of death ligands to cell membrane receptors and activates caspase-3 through 
caspase-8 activation. The intrinsic pathway, induced by most small molecule apoptotic stimuli, relies on 
mitochondrial cytochrome c release which activates caspase-9 to activate caspase-3.  
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Most small molecules induce apoptosis through the intrinsic pathway. In the intrinsic 
pathway, mitochondrial cytochrome c release in to the cytosol is required to activate the initiator 
caspase-9 through a multi-protein cytosolic complex known as the apoptosome. The apoptosome 
is composed of apoptosis-protease activating factor (APAF1), cytochrome c, and procaspase-9 
and activates caspase-9 in a dATP dependent manner.
17-20
 Once caspase-9 has been activated, it 
cleaves and activates the executioner caspase-3 resulting in apoptosis.  
 
2.1.2 Mechanisms of Cytochrome c release in the intrinsic pathway 
The critical factor in activating the intrinsic pathway is the release of cytochrome c, 
located within the intermembrane space, from the mitochondria. There are two models that have 
been proposed for cytochrome c release: mitochondrial permeability transition pore (MPTP) and 
mitochondrial outer membrane permeability (MOMP). Although MPTP can lead to cytochrome 
c release and apoptosis, it is more commonly associated with necrosis and AIF-dependent cell 
death.
21, 22
 In MPTP, channels that span both the outer and inner mitochondrial membrane form 
to allow transport of molecules smaller than 1.5 kDa across the mitochondrial membranes.
23
 
Cytochrome c release is thought to eventually occur as a result of mitochondrial swelling and 
rupture of the outer membrane due to osmosis.
23
 MPTP occurs through the action of multiple 
mitochondrial proteins that include the voltage-dependent anion channel (VDAC), adenosine 
nucleotide transporter (ANT), cyclophilin D, and mitochondrial transmembrane inner protein 
(TIM).
24, 25
 It has been noted that calcium uptake by mitochondria stimulated by ionophores or 
other small molecules plays a critical role in MPTP induction.
26-31
 The involvement of 
cyclophilin D as a critical component of MPTP is supported by the use of cyclosporine A, a 
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small molecule inhibitor of cyclophilin D that is able to prevent MPTP-dependent cytochrome c 
release.
22, 32-34
  
In MOMP, pores are formed selectively in the outer membrane of the mitochondria 
releasing cytochrome c present in the intermembrane space without disrupting the inner 
mitochondrial membrane.
35
 Whereas MPTP results in the simultaneous loss in mitochondrial 
membrane potential,
36, 37
 MOMP can occur without disrupting mitochondrial membrane 
potential.
38-40
 
MOMP is regulated by various proteins of the B-cell lymphoma (Bcl) family that contain 
BH3 binding domains. Bcl proteins are categorized into three classes based upon their function: 
i) pro-apoptotic proteins; ii) anti-apoptotic proteins; and iii) BH3-only proteins that modulate the 
activity of the other two categories (Table 2.1). 
 
Table 2.1. Members of the Bcl family of proteins fit into three categories: pro-apoptotic, anti-apoptotic and 
BH3-only. 
Pro-apoptotic Anti-apoptotic BH3-only 
BAX BCL-2 BID 
BAK BCL-xL BAD 
BOK BCL-w BIM 
  MCL-1 BMF 
  A1 BIK 
  BOD/DIVA HRK 
    BLK 
    BNIP3 
    BNIP3L 
    PUMA 
    NOXA 
 
The pro-apoptotic Bcl proteins include Bax, Bak and Bok. Bax and Bak, and not Bok, are 
currently viewed as the direct effectors of MOMP.
39, 41
 Bax is cytosol soluble and migrates to the 
mitochondria upon treatment of cells with apoptotic stimuli.
39, 41, 42
 Bak is tethered to the 
mitochondria by its carboxy-terminal region.
39, 41, 42
 Upon activation by apoptotic stimuli, both 
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Bax and Bak insert themselves into the outer mitochondrial membrane and expose their BH3 
domain resulting in the formation of oligomers of various sizes.
41-43
 Cells containing single 
deletions of either Bax or Bak are able to undergo MOMP and apoptosis as normal; however, 
simultaneous deletion of both proteins prevents MOMP and apoptosis, suggesting these proteins 
have some overlapping function but play necessary roles in MOMP.
44-47
 Bok is not currently 
considered as a direct effector of MOMP.
48
 Unlike Bax and Bak, Bok is often deleted in cancer 
cells and only induces apoptosis when overexpressed.
49
 
The anti-apoptotic Bcl membrane proteins include Bcl-2, Bcl-xL, MCL-1 and A1. These 
proteins all contain the BH1, BH2 and BH3 domains which form an α-helix groove (BH groove) 
that can bind to the BH3 domains of pro-apoptotic Bax or Bak, preventing their oligomerization 
and subsequent MOMP.
38, 42
 Bcl-2 is thought to specifically inhibit Bax, MCL-1 inhibits Bak 
specifically, and Bcl-xL is capable of inhibiting both Bax and Bak.
38, 50-52
  
Of the BH3-only Bcl proteins, tBid, Bim and Puma are believed to be capable of directly 
activating Bax and Bak by inducing conformation changes upon binding.
38-40, 42, 45, 53
 The activity 
of BH3-only proteins, tBid, Bak or Puma, may be sequestered by the Bcl-2 antiapoptotic proteins 
and may require intervention of other members of the BH3-only proteins to relieve inhibition.
38-
40
 In another model, it is thought that Bax and Bak, even when conformationally active, are 
sequestered by Bcl-2 antiapoptotic proteins and intervention of BH3 only proteins is required to 
relieve this inhibition and allow active Bax and Bak to induce MOMP through 
oligomerization.
38-40
 As the BH3 domains have little overall consensus, there may be unknown 
BH3-only proteins that have yet to be discovered and functions identified. Overall the regulation 
of MOMP is tightly regulated by the balance between proapoptotic, anti-apoptotic and BH3-only 
Bcl proteins. 
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2.1.3 Cancers are resistant to apoptosis 
Most cancers possess misregulated apoptotic pathways that confer resistance to apoptotic 
stimuli. The most common mechanism of resistance involves mutations in the p53 tumor 
suppressor that functions to recognize DNA damage and induce apoptosis. In fact, almost 50% of 
solid tumors have p53 mutations/deletions.
54
 Additionally, cancers with functional p53 may 
evade apoptosis by upregulating Mdm-2, a protein that facilitates degradation of p53.
55
 The up-
regulation of the anti-apoptotic Bcl-2 protein is another common mechanism of resistance to 
apoptosis in cancers.
56,
 
57
 The apoptotic pathway may also be inhibited by cell growth pathways 
that are constitutively active in cancer. The Akt growth signaling pathway prevents translation of 
pro-apoptotic Bim, inactivates pro-apoptotic Bad, and prevents degradation of anti-apoptotic 
MCL-1 protein.
58
 Activation of MAP kinase ERK targets pro-apoptotic Bim for degradation.
58
 
The apoptotic pathway in cancer may also be deregulated by the up-regulation of X-linked 
inhibitor of apoptosis (XIAP), which inhibits activated caspase-3, -7 and -9.
59, 60
  
 
2.1.4 Small molecule regulators of apoptosis 
Several small molecules have been developed to regulate apoptosis by directly targeting 
components in the apoptotic pathway (Figure 2.2). Small molecule inhibitors of Bcl-2, such as 
HA14-1 or ABT-737, are able to re-sensitize cancer cells that express Bcl-2 to various apoptotic 
stimuli.
61-63
 SM164, a small molecule inhibitor of XIAP modeled on the endogenous XIAP 
inhibitor SMAC, is able to sensitize XIAP expressing cancer cells to apoptosis.
60, 64, 65
 A small 
molecule activator (AA2) of the apoptosome facilitates caspase-9 activation.
66
 Small molecules 
such as PAC-1 and 1541 bypass the apoptotic machinery and directly activate the executioner 
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caspase, caspase-3.
67, 68
 As certain cancers have elevated levels of procaspase-3, these direct 
activators of caspase-3 may be able to overcome Bcl-2 mediated resistance mechanisms.
67
 
1541
PAC-1
SM-164
HA14-1
ABT-737
AA2
 
Figure 2.2. Small molecules have been developed to directly target components of the apoptotic 
pathway. These molecules include Bcl-2 inhibitors (HA14-1, and ABT-737), XIAP inhibitor (SM-164), 
apoptosome facilitator (AA2) and caspase-3 activators (1541 and PAC-1). 
 
 
2.1.5  Rapid apoptosis induction by small molecules 
While the field of apoptosis is almost 40 years old and our knowledge of the mechanisms 
involved is quite extensive there still remains opportunities to uncover novel aspects of this type 
of programmed cell death. In general, it has been considered that apoptosis requires significant 
amounts of time to fully manifest after exposure of cells to apoptotic stimuli such as small 
molecule toxins or death ligands. Although the times to cell death may differ from cell line to 
cell line and may depend upon the concentration or type of apoptotic stimuli, it is interesting to 
consider the prospect of whether a small molecule can induce apoptosis in an unprecedented 
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rapid manner relative to other small molecule apoptotic stimuli. Such a molecule may have a 
novel mechanism of activating apoptosis and may provide therapeutic benefits. In this chapter 
we describe the discovery and characterization of a bis-aldehyde small molecule, named 4150, 
that induces rapid apoptosis across multiple cell lines. 
 
2.2 High-throughput toxicity screen identifies 4150    
In an effort to identify novel small molecules with anti-cancer activity, a collection of 
approximately 5000 small molecules from the UIUC heritage library was screened for activity 
against the human leukemia HL-60 cell line.
69
 The compounds were screened at 20 μM in a 384 
well plate format and cell viability was assessed by the MTS assay after a 24 hour incubation of 
cells in the presence of compound. The high throughput screen identified compound 4150 to 
have potent cytotoxic properties (Figure 2.3).  The synthesis of compound 4150 was first 
reported in 1911,
70
 and the batch that led to its discovery was synthesized in the laboratory of 
Professor David Y. Curtin in the 1960s.
71
 Other than the severe skin-irritant properties of 4150, 
no other biological activities regarding this small molecule have been reported in the literature.
71
 
Given the unusual structure of the molecule and its potential as an anticancer agent, we set out to 
characterize its mechanism of cytotoxicity.  
 
 
Figure 2.3. Structure of 4150, a small molecule identified to be a potent inducer of cell death. 
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2.3 Evaluation against cancer cell lines and structure-activity relationship    
In order to determine the general anti-cancer properties of 4150, cytotoxicity against 
multiple cancer cell lines from different tissue origins was determined. As shown in Table 2.2, 
4150 exhibited potent death induction against the normal (i.e. fibroblasts) and cancer cell lines 
after 24 hour incubation with IC50 values in the 0.5-3.4 µM range. 4150 was active against the 
HL-60 vincrinstine-resistant cell line which exhibits P-glycoprotein-mediated resistance to 
several clinically-used cancer therapeutics.
72-74
 MCF-7, a cell line that lacks functional caspase-
3, and relies on an alternate executioner caspase, caspase-7 to induce apoptosis, was the most 
resistant of the cell lines with an IC50 of 3.4 µM. 
 
Table 2.2. The average IC50 values of 4150 against normal and cancer cell lines assessed after 24 hour 
incubation.  
 
Cell Line Cell Type Average IC50 (μM) 
3T3 Mouse Embryonic Fibroblast 1.0 ± 0.2 
Hs888Lu Human Lung Fibroblast 1.7 ± 0.1 
SKW 6.4 Human B Lymphoblast 1.1 ± 0.1 
U937 Human Lymphoma 0.7 ± 0.3 
HL-60 Human Leukemia 2.1 ± 1.4 
HL-60 VCR Human Leukemia Vincristine Resistant 1.6 ± 0.5 
HeLa Human Cervical Cancer 0.6 ± 0.4 
MCF-7 Human Breast Cancer 3.4 ± 0.1 
SK-MEL-5 Human Melanoma 0.7 ± 0.1 
 
Errors represent the standard deviation of the IC50 values obtained from three independent experiments. 
Cell viability for adherent cells was measured by the sulforhodamine B assay while the MTS assay was 
used to assess suspension cells. 
 
We also submitted the 4150 for assessment in the NCI 60 cancer cell line panel. The 
NCI-60 results revealed 4150 has an average 50% growth inhibition (GI50) of 0.33 μM and an 
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average 50% lethal concentration (LC50) of 6.5 μM (see Figure 2.4). Interestingly, the patter of 
activity in this cell line panel did not strongly correlate with other agents in the NCI database.   
 
 
 
Figure 2.4. Growth inhibition (GI50), total growth inhibition (TGI) and lethal concentration (LC50) results for 
4150 against the National Cancer Institute 60 cancer cell line panel (NCI60). 
 
 
 In order to investigate the structure-activity relationship of 4150, various derivatives of 
this compound (shown in Figure 2.5) were synthesized and evaluated for their ability to affect 
U937 human lymphoma cell viability after 24 hours. Cell viability was assessed using a soluble 
tetrazolium salt assay ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS) which measures dehydrogenase enzyme activity 
found in metabolically active cells.
75
 Dose response curves were generated and the IC50 values 
obtained are shown in Figure 2.5. 
GI50 0.330 μM TGI 1.2 μM LC50 6.45 μM Average 
Min 
Max 
0.148 μM 
2.09 μM 
0.327 μ M 
4.33 μM 
0.724 μM 
>100 μM 
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Figure 2.5. Structural derivatives of 4150 and their IC50 values against U937 lymphoma cells after 24 
hour incubation. Cell viability was measured by the MTS assay.  
 
 
The evaluation of the compounds revealed that 4150 was toxic to U937 cells with an IC50 
value of 0.9 µM.  Interestingly, both aldehyde groups were essential for full activity, as removal 
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of one aldehyde (F6), or replacement of one or both aldehydes with alcohol functionality (F4 and 
F5) resulted in over 30-fold loss in potency. The bifluorene ethane (F1) and bifluorenyl ethene 
(F7) derivatives lacking aldehyde functionality were completely inactive (IC50 values > 100 
μM). Replacement of the aldehydes with carboxylic acids (F3), methyl esters (F17), oximes 
(F21), acetyls (F22), trifluoroacetyl (F18) or N-acyl hydrazones (F20) moieties resulted in 
complete loss in activity (IC50 > 100 µM). The cyclic anhydride (F8) and 
dimethoxytetrahydrofuran (F7) forms were also inactive. The t-butyl imine derivative (F19) 
exhibited similar activity to 4150. Other dialdehyde derivatives bearing bromo (F12), azido 
(F15) or alkyne (F16) functionality at the 2-positions of the fluorine moieties exhibited a slight 
reduction (approximately 2-3 fold) in activity. Tetrasubstituted bromo (F13) or chloro (F14) 
derivatives were even less active than disubstituted derivatives with approximately a 4 fold loss 
in activity. The carboxylic acid (F23) or methyl alcohol (F24) fluorene monomers were inactive 
while an aldehyde fluorine monomer (F25) with alkyne functionality was 21 fold less active than 
4150 and 9 fold less active than its corresponding dimer (F16). Conjugation of biotin to the 
fluorine monomer (F26) or dimer (F27) resulted in compounds that lack activity. 
 
2.4  Global transcriptional profiling 
To gain further information about the mechanism by which 4150 exerts it cytotoxic 
effect, we performed whole genome transcriptional profiling in U937 cells. Treatment of cells 
with 700 nM of 4150 for 6 hours resulted in the up- and down-regulation of 987 and 825 probes 
respectively (p values < 0.05). The top 20 transcripts that were up- or down-regulated are listed 
in Table 2.3.  
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Table 2.3. The top 20 up- and down-regulated transcripts as revealed by whole genome transcript 
profiling of U937 cells treated with 4150 (700 nM) for 6 hours. The data shown is derived from three 
independent experiments. The Symbol gene ID, the known protein designation/function, p values and fold 
change are listed.  
 
SYMBOL Protein & Function p value Fold Change 
DDIT3 DNA-damage-inducible transcript 3 Inhibits the DNA-binding activity of C/EBP and LAP 0 5.2 
CTH Cysteine desulfhydrase converts cystathione derived from methionine into cysteine 0 4.5 
HMOX1 heme oxygenase cleaves heme to form biliverdin, potent anti-oxidant 0.0000061 3.4 
NLRP12 NLR family, pyrin domain containing 12:attenuating factor of inflammation by suppressing 
inflammatory responses in activated monocytes 
0 3.3 
TNFAIP6 TNF-stimulated gene 6 protein: involved in extracellular matrix stability and cell migration 0 3.2 
ASNS Cell cycle control protein TS11: blocks progression through the G1 phase of the cell cycle 0 3.1 
TRIB3 p65-interacting inhibitor of NF-kappa-B negative regulator of NF-kappa, sensitizes cells to 
TNF/TRAIL-induced apoptosis 
0 3.1 
CTH Cysteine desulfhydrase converts cystathione derived from methionine into cysteine 0 3.0 
CTH Cysteine desulfhydrase converts cystathione derived from methionine into cysteine 0 2.9 
TSC22D3 TSC-22 related protein:  transcriptional regulator plays a role in anti-inflammatory and 
immunosuppressive effects of glucocorticoids and IL-10 
0 2.9 
LY96 lymphocyte antigen 96: confers responsiveness to lipopolysaccyaride  0 2.7 
TSC22D3 TSC-22 related protein:  transcriptional regulator plays a role in anti-inflammatory and 
immunosuppressive effects of glucocorticoids and IL-10 
0 2.7 
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 0 2.7 
FAM129A cell growth inhibiting protein 39: Regulates phosphorylation of EIF2A, EIF4EBP1 and 
RPS6KB1. May be involved in ER stress 
0 2.7 
TUBE1 tubulin, epsilon 1 0 2.6 
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A: response is correlated with 
apoptosis 
0 2.6 
ADM2 adrenomedullin 2: Activates the cAMP-dependent pathway 0 2.6 
FBXL13 F-box and leucine-rich repeat protein 13: protein-ubiquitin ligase 0 2.6 
C1orf24 cell growth inhibiting protein 39: Regulates phosphorylation of EIF2A, EIF4EBP1 and 
RPS6KB1. May be involved in ER stress 
0 2.5 
PCK2 phosphopyruvate carboxylase: conversion of oxaloacetate to phosphoenolpyruvate 0 2.5 
HSPA8 Heat shock 70kDa protein 8: stabilize preexistent proteins against aggregation, fold newly 
translated polypeptides, anti-apoptotic 
0 -3.5 
INSIG1 insulin induced gene 1: endoplasmic reticulum (ER) membrane protein that plays a critical 
role in regulating cholesterol concentrations in cells 
0 -3.2 
HSPA1B Heat shock 70kDa protein 1B: stabilize preexistent proteins against aggregation, fold newly 
translated polypeptides, anti-apoptotic 
0.0000076 -3.2 
HSPA8 Heat shock 70kDa protein 8: stabilize preexistent proteins against aggregation, fold newly 
translated polypeptides, anti-apoptotic 
0 -3.1 
HSPA1A Heat shock 70kDa protein 1A: stabilize preexistent proteins against aggregation, fold newly 
translated polypeptides, anti-apoptotic 
0.0000048 -2.8 
SC4MOL sterol-C4-methyl oxidase-like localized to the endoplasmic reticulum membrane and is 
believed to function in cholesterol biosynthesis 
0 -2.2 
SBF1 SET-binding factor 1: Inhibits myoblast differentiation in vitro and induces oncogenic 
transformation in fibroblasts 
0 -2.1 
MAT2A Methionine adenosyltransferase 2 Catalyzes the formation of S-adenosylmethionine from 
methionine and ATP 
0.0000091 -2.1 
CBX6 chromobox homolog 6:Involved in maintaining the transcriptionally repressive state of genes 0 -2.1 
TFRC transferrin receptor: Cellular uptake of iron occurs via receptor-mediated endocytosis of 
ligand-occupied transferrin receptor into specialized endosomes 
0.0000095 -2.0 
B4GALT5 Beta-1,4-GalTase: plays a role in glycolipid biosynthesis 0 -2.0 
TMEM158 transmembrane protein 158: Constitutive activation of the Ras pathway triggers an 
irreversible proliferation arrest 
0.0000002 -2.0 
NP purine nucleoside phosphorylase 0 -1.9 
GEMIN6 gemin 6: plays a role in the cytoplasmic assembly of small nuclear ribonucleoproteins 
(snRNPs).  
0 -1.9 
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Table 2.3 (continued) 
 
SYMBOL Protein & Function p value Fold Change 
ISG20L2 interferon stimulated exonuclease gene 20kDa-like 2:xoribonuclease involved in ribosome 
biogenesis in the processing of the 12S pre-rRNA 
0 -1.8 
ATP5G1 ATPase subunit 9 0.0000006 -1.8 
TUBB2C tubulin, beta 2C 0.0000001 -1.8 
RPL29 60S ribosomal protein L29 0.0000307 -1.8 
SLC39A10 solute carrier family 39 (zinc transporter), member 10 0.0000152 -1.8 
RPL29 60S ribosomal protein L29 0.000008 -1.8 
 
 
One of the characteristic markers of ER-stress is the induction of CHOP (DDIT3), a 
DNA damage-induced transcription factor that is not present under normal conditions.
76
 As 
shown in Table 2.3, cells treated with 4150 exhibited a 5.2 fold up-regulation of CHOP.  As the 
expression of CHOP is tightly regulated at the transcriptional level, the transcript profile suggests 
CHOP may play a role in 4150-induced cell death. CHOP is known to down-regulate the 
transcription of the anti-apoptotic protein Bcl-2,
77
 and its expression induces cell death.
78
  Other 
ER-stress associated transcripts affected include the up-regulation of cell growth inhibiting 
protein 39 (C1ort24 and FAM129A) that regulates translation by affecting the phosphorylation 
of eukaryotic translation initiation factor 2 alpha (EIF2A), eukaryotic translation initiation factor 
4E binding protein 1 (EIF4EBP1) and ribosomal protein S6 kinase (RPS6KB1), which are part 
of the mTOR/Akt cell proliferation pathway.  The down-regulation of 60S Ribosomal protein 
L29 (RPL29) was also induced. Down-regulation of cholesterol and lipid synthesis is also 
commonly observed in ER-stress response
79
 and free cholesterol is known to induce the ER-
stress response in macrophages.
80
 Cells treated with 4150 showed reduced levels of several 
transcripts involved in cholesterol and lipid synthesis such as INSIG1, B4GALT5 and ER-
associated sterol-C4-methyl oxidase (SC4MOL). Ingenuity pathway analysis (IPA) of the 
transcript profile revealed fatty acid biosynthesis as a major pathway affected by 4150 (p value = 
1.44 x 10
-4
, Table 2.4). The endoplasmic reticulum stress pathway was also implicated (p value 
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3.04 x 10
-4
, Table 2.4) with a large fraction of genes affected (0.333) which included up-
regulation of ATF4, IRE1, XBP1 and P58IPK transcripts, which serve to induce CHOP 
transcription. Other notable transcripts affected included down-regulation of heat shock protein 
70, a protein folding chaperone protein that has antiapoptotic activity, and up-regulation of anti-
inflammatory transcripts (NLRP12, TSC22D3, LY96). 
 
Table 2.4. The most significant canonical pathways affected by treatment of U937 cells with 4150 as 
determined by Ingenuity Pathway Analysis (IPA). 
 
 
Canonical Pathway p value Fraction of Genes affected 
Aminoacyl-tRNA Biosynthesis  4.95E-09  12/83 (0.145) 
Pyrimidine Metabolism 4.54E-08  25/232 (0.108) 
Glycine, Serine and Threonine Metabolism 1.03E-06  15/150 (0.1) 
Fatty Acid Biosynthesis 1.44E-04  5/51 (0.098) 
Endoplasmic Reticulum Stress Pathway 3.04E-04  6/18 (0.333) 
 
 The expression data was used to query the connectivity map database which consists of 
whole genome transcriptional profile of over 1300 biologically active molecules against multiple 
cancer cell lines.
81, 82
  As the biological mechanisms of many of these compounds are known, the 
connectivity map database can aid in the identification of the mode of action of novel small 
molecules.
83-85
  According to the database the transcriptional profile of 4150 is very similar to the 
transcriptional changes induced by thapsigargin (match = 0.801 where 1 is 100% positive 
correlation and -1 is perfect anti-correlation, Table 2.4.3).  Thapsigargin, an inhibitor of sarco 
endoplasmic reticulum calcium ATPase (SERCA), prevents calcium uptake by the endoplasmic 
reticulum (ER) from the cytosol resulting in depletion of ER intracellular calcium stores and 
induction of the ER stress response.
76
 
 
 
 47 
2.5 4150 generates reactive oxygen species and induces the up-regulation of 
HO-1 
 Prolonged calcium release from intracellular stores, such as the ER, serves as a stress 
signal to initiate cell death. The calcium released by the ER into the cytosol accumulates in 
mitochondria, resulting in inhibition of the electron transport chain and the generation of reactive 
oxygen species (ROS).
76
 ROS produced by the mitochondria can further abrogate ER stress 
resulting in more calcium release.
76
 If sufficient ROS is generated, mitochondrial dysfunction 
occurs resulting in the release of cytochrome c and initiation of caspase, CHOP or JNK-mediated 
cell death pathways.
76
 
To determine if ROS is produced upon treatment of cells with 4150, U937 cells were 
incubated in the presence of dihydroethidium (DHE), a dye that is sensitive to oxidation by 
superoxide anion radicals, to produce ethidium which intercalates DNA and exhibits an increase 
in fluorescence. As shown in Figure 2.6, a 20 minute treatment of U937 cells with 4150 (2 and 
10 μM) resulted in rapid accumulation of superoxide anion radical anions. Thapsigargin (10 μM), 
an inducer of calcium release from intracellular stores induced a similar response whereas high 
concentrations of etoposide, a topoisomerase II inhibitor, did not induce ROS.   
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Figure 2.6.  U937 cells exhibit a rapid accumulation of superoxide anion radicals upon treatment with 
4150 and thapsigargin.  Cells were treated with compound or vehicle control for 20 minutes, and 
superoxide anion radicals were assessed by ethidium staining and flow cytometry. Etoposide, a 
topoisomerase II inhibitor did not elicit ROS production even at a high concentration (100 μM).  Error bars 
represent the standard deviation from 3 independent experiments.  
 
The acute amount of ROS produced by 4150 likely results in the activation of oxidative 
stress response pathways.  This notion is consistent with the transcript profile of cells treated 
with 4150, which showed a 3.4 fold up-regulation of the oxidative stress-response transcript of 
heme monooxygenase 1 (HMOX-1).  Heme monooxygenase is responsible for the biosynthesis 
of heme, a potent antioxidant, and it is induced under oxidative stress via the NRF-2 mediated 
oxidative stress pathway.
86-88
 The expression of heme monooxygenase 1 protein (HO-1) was 
confirmed (by Western blot) in U937 cells treated with 4150 (1 μM) for 6 hours (Figure 2.7).  
Hemin, an activator of NRF2-mediated transcription was used as a positive control for HO-1 
induction.
87
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Figure 2.7. U937 cells treated with 4150 (1 μM for 6 hours) showed elevated levels of heme mono-
oxygenase 1 (HO-1), an oxidative stress associated protein, as determined by western blot. Hemin, an 
inducer of NRF-2 mediated transcription served as positive control for HO-1 induction.  
 
2.6  4150 induces rapid apoptosis 
 Treatment of U937 cells with 10 μM of 4150 resulted in extensive blebbing of the cell 
membrane within just one hour of treatment as visualized by light microscopy (Figure 2.8A) and 
scanning electron microscopy (Figure 2.8B). Cell blebbing is a hallmark of apoptosis that results 
from the activation of RHO kinase 1 (ROCK1) by caspase-3.
7
 The co-treatment of cells with 
4150 and a pan-caspase inhibitor, Q-VD-OPh, was able to prevent cell blebbing, suggesting the 
cellular blebbing is a result of caspase activation and ROCK1 activity. 
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Figure 2.8. A) Light microscopy images of U937 cells treated with DMSO, 4150 (10 µM) or 4150 in the 
presence of caspase inhibitor Q-VD-OPh (10 µM) for 1 hour. Cells treated with 4150 show cellular 
blebbing that is inhibited by the pan-caspase inhibitor. B) Scanning electron micrographs of U937 cells 
show pronounced apoptotic blebbing after 1 hour of treatment with 10 µM 4150 (right) versus DMSO 
vehicle control treated cells (left). 
 
Another hallmark of apoptosis is the externalization of phosphatidylserine on the cell 
membrane prior to loss of cell membrane integrity.
11, 12
 These events can be monitored by cell 
flow cytometry where phosphatidylserine exposure is assessed by the binding of FITC-
conjugated annexin V and cell membrane integrity is assessed by the exclusion of propidium 
iodide. Viable cells exclude propidium iodide and do not bind FITC-annexin V. Apoptotic cells 
show externalization of phosphatidylserine prior to loss of membrane integrity; this is shown by 
the transition of cells from the viable (lower left) quadrant to the early apoptotic (lower right) 
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quadrant. The FITC-annexin V vs propidium iodide (AV/PI) plot in Figure 2.9 for both U937 
and HL-60 cells shows a rapid externalization of phosphatidylserine following treatment with 
4150. In U937 cells this shift was observed after 2 hours of treatment with 10 µM 4150 while in 
HL-60 cells the shift occurred after 3 hours. To confirm that the phosphatidylserine 
externalization is caspase-dependent, we used the pan-caspase inhibitor Q-VD-OPh which 
covalently inhibits activated caspases to inhibit downstream caspase activity (such as 
phosphatidylserine exposure) and halt the induction of apoptosis. As shown in Figure 2.9, 
pretreatment of cells with Q-VD-OPh, resulted in quantitative protection consistent with caspase-
mediated induction of cell death.  
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Figure 2.9. A) AV/PI graphs of A) U937 cells treated with 10 µM 4150 for 2 hours and B) HL-60 cells 
treated with 10 µM 4150 for 3 hours show transition of cells through the early apoptotic AV+/PI- quadrant. 
This transition is prevented by the pan-caspase inhibitor Q-VD-OPh. 
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Using the AV/PI method to quantitate cell viability, we performed a time course analysis 
of cell death induction in U937 cells treated with 2, 5 or 10 µM 4150. As shown in Figure 2.10, 2 
µM of 4150 induces 50% cell death by 9 hours. However, consistent with the rapid blebbing 
observed at higher concentrations of 4150, treatment of the cells with 5 or 10 µM 4150 resulted 
in more rapid loss in viability with 50% cell death occurring in just 2.5 or 1.5 hours, respectively. 
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Figure 2.10.  Time course analysis of U937 cells reveals that 4150 induces cell death in a time- and 
concentration-dependent manner. Cell viability was assessed by AV/PI staining where AV-/PI- cells were 
considered viable. 
 
2.7 4150 converts to hydrate in aqueous solutions 
 As aldehydes may exist in aqueous solution as the hydrate we sought to determine 
whether hydration occurs upon addition of 4150 to aqueous solutions. When 4150 was added to 
an 80/20 mixture of DMSO/water to a final concentration of 5 mM, the aldehyde NMR signals 
disappeared within 24 hours and the NMR spectra was consistent with the cyclic hemiactal 
hydrate in a 3:1 ratio of diastereomers (Figure 2.11). The hydrate also has a different HPLC 
retention time than the parent 4150.  
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Figure 2.11.  Time course NMR analysis of 4150 at 5 mM reveals 4150 converts to hydrated form in 24 
hours in a 80/20 mixture of DMSO/water.  
 
To observe how rapid this process is at a biologically relevant concentration of 10 µM, 
we used absorbance spectroscopy at 253 nm. As shown in Figure 2.12, 4150 rapidly hydrates 
with a half-life of 8.3 minutes when at a concentration of 10 µM.  
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Figure 2.12.  Time course analysis of 4150 to hydrate conversion by absorbance spectroscopy at 253 nm 
reveals 4150 has a half-life of approximately 8.3 minutes in water.  
 
In order to determine whether the hydration affects biological activity, we assessed the 
ability of 4150 or pre-made hydrate to induce rapid cell death against U937 in 2 hours assessed 
by AV/PI. As shown in Figure 2.13, both forms of 4150 are similar in activity. Furthermore the 
two forms of 4150 are equally active in 24 hour cell viability assays as assessed using the MTS 
assay. 
 
 
 55 
FITC-A
P
I-
A
10
0
10
1
10
2
10
3
10
0
10
1
10
2
10
3
0.01% 1.15%
95.61%
3.23%
4150 Hydrate
24 hour MTS IC50 (μM) 0.86 0.86
A)
B)
FITC-A
P
I-
A
10
0
10
1
10
2
10
3
10
0
10
1
10
2
10
3
0.00% 9.00%
5.12%
85.88%
FITC-A
P
I-
A
10
0
10
1
10
2
10
3
10
0
10
1
10
2
10
3
0.04% 7.14%
14.08%
78.74%
10 μM Hydrate10 μM 4150DMSO
 
Figure 2.13.  Comparison of the biological activity of 4150 and pre-formed hydrate in affecting A) rapid 
cell death induction in U937 cells in 2 hours at 10 µM, and B) 24 hour IC50 values (determined by MTS 
assay). 
 
2.8 Rate of 4150-induced apoptosis is more rapid than other toxins 
Compared to necrosis or non-programmed cell death, apoptosis typically requires more 
time to culminate in cell death, due to the numerous translocation and proteolytic events 
involved. The time required to observe phenotypic changes, such as cell blebbing and 
phosphatidylserine exposure, due to apoptosis induction by small molecules varies depending on 
the mechanism of action. We sought to determine if induction of early apoptotic events by 60-90 
minutes, as observed for 10 μM 4150, was unique. To do so we investigated a collection of 25 
other small molecules that consisted of clinically used anticancer agents and biological tool 
molecules that directly target components of the apoptotic cascade further downstream of typical 
toxins. The molecules in this collection were chosen in order to encompass diversity in 
mechanism and biological targets. We included inhibitors of kinases (staurosporine and 
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rapamycin), tubulin dynamics (paclitaxel, vincristine and colchicine), topoisomerases 
(camptothecin, etoposide and doxorubicin), DNA alkylators (mitomycin C, cisplatin, MNNG), 
endoplasmic reticulum/proteasome inhibitors (geldanamycin, thapsigargin and tunicamycin), 
ROS inducing agents (DNQ, elesclomol, rotenone and antimycin A) and agents that target 
components of the apoptotic pathway such as Bcl-2 inhibitors (gossypol and HA14-1), XIAP 
inhibitor (SM-164), apoptosome promoter (AA2) and caspase-3 activators (PAC-1 and 1541). As 
caspases can also be activated by chelation of inhibitory zinc,
89, 90
 we also included TPEN, a 
potent zinc chelator known to induce apoptosis in cancer cells.
91-93
 As most of these molecules 
are potent inducers of cell death with IC50 values typically ranging from the nM to low µM 
range, we expected a concentration of 10 µM would enable cell death to proceed at the maximal 
rate associated with each toxin. Time course analysis revealed that the time required for most 
compounds to induce a 50% loss in viability was greater than 5 hours with the exception of the 
caspase-3 activator 1541, which requires 2 hours (Figure 2.14 and 2.8.2). In fact compounds with 
similar mechanisms of action shared similar times to death. For example, the topoisomerase 
inhibitors doxorubicin, etoposide and camptothecin required 5-6 hours to induce 50% cell death 
(Figure 2.15). Agents that stabilize or destabilize tubulin polymerization (taxol, colchicine, 
vincristine) required 14-18 hours (Figure 2.15). However, in the case of 4150, only 90 minutes 
was required for 50% loss in cell viability.  
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Figure 2.14. Time course analysis of U937 cell viability upon treatment with 10 μM of various anticancer 
agents and biological tool molecules. Cell viability was assessed by AV/PI analysis.  
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Figure 2.15. Time to 50% U937 cell death for various anticancer agents and biological tool molecules as 
determined by time course analysis of cell viability (AV/PI analysis). Compound 4150 has the shortest 
time to 50% death when compared to 25 other toxins.   
 
Assessing the loss of cell viability at 2 hours by AV/PI illustrates the uniqueness of the 
rapid cell death induced by 4150 (Figure 2.16). 4150 induced 85% loss in cell viability, 1541 
reduced viability by 50%, and the 24 other compounds were unable to affect cell viability.  
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Figure 2.16. Cell viability of U937 cells assessed by AV/PI after 2 hour treatment with 10 µM 4150 and 25 
other small molecules. Asterisks denote molecules in clinical use or trials.  
 
In order to further support apoptosis as the mode of cell death we performed western blot 
analysis for the cell lines monitoring the cleavage of 32 kDa procaspase-3 to the active 17 kDa 
caspase-3 form. As shown in Figure 2.17A, just one hour of treatment of U937 cells with 10 µM 
4150 was sufficient to induce complete cleavage and activation of caspase-3, whereas the 
caspase-3 activator shows partial cleavage and the other agents show no cleavage at this early 
time point. In addition, significant cleavage of PARP-1 (from 116 to 89 kDa form), a substrate of 
active caspase-3, is observed in 4150 treated cells versus the other toxins. The rapid effects of 
4150 were not cell line specific as a similar effect was observed in SKW 6.4 cells (Figure 
2.17B). 
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Figure 2.17. Immunoblots of A) U937 and B) SKW 6.4 cells treated with various toxins for 1 hour show 
prominent activation of caspase 3 by 4150 (10 µM)versus 25 other toxins (all tested at 10 µM). The 
cleavage of PARP-1 by caspase-3 is shown in A). 
 
The rapid activation of executioner caspases is further supported by assessing the 
caspase3/7-like substrate cleavage activity in cells using AcDEVD-pNA as the substrate. As 
shown in Figure 2.18, the cleavage activity of the executioner caspases 3 and 7 occurs much 
earlier for 4150 than for staurosporine (10 µM), thapsigargin (10 µM) or etoposide (50 µM) in 
A) 
B) 
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both U937 and HL-60 cells. It was also noted that the maximal DEVD-ase cleavage rate 
achieved is higher for 4150 than other toxins. During apoptosis, active caspases are partially 
inactivated by the proteasome limiting the maximal caspase activity.
94
 However, in the case of 
4150 it is conceivable the higher maximal rate of caspase activity may be due to a lack of 
proteasome-mediated inactivation due to the unusually rapid phenotype.  
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Figure 2.18. DEVD-ase activity of caspase 3/7 measured in A) U937 cells and B) HL-60 cells upon time 
course treatment with 4150 (10 µM), etoposide (50 µM), thapsigargin (10 µM) and staurosporine (10 µM). 
Errors represent standard deviation of 3 replicates. 
 
 
2.9 4150-induces apoptosis through the intrinsic pathway 
The unusually rapid induction of apoptosis by 4150 challenges the notion that apoptosis 
necessarily requires a long period of time to fully manifest itself. To identify the underlying 
processes and events that lead to this rapid phenotype, we investigated the apoptotic cascade in 
more detail. A time course western blot analysis in U937 and SKW 6.4 cells for the activation of 
the initiator caspases -8, -9 and the executioner caspase-3 was performed to help determine 
whether the caspase-8 dependent extrinsic pathway or caspase-9 dependent intrinsic pathway 
was responsible for rapid apoptosis induction by 4150. As shown in Figure 2.19, all three 
caspases were activated in cells as early as 20 minutes with complete activation occurring in 45-
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60 minutes of exposure. In contrast, 50 µM etoposide required at least 4 hours and > 8 hours to 
activate caspases in U937 and SKW 6.4 cells, respectively.  
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Figure 2.19. Time course immunoblot analysis of caspase 9, 3, and 8 activation and Bid cleavage in 
U937 and SKW 6.4 cells treated with 4150 (10 µM) or etoposide (50 µM). 
 
 
Previous studies involving single cells have noted that once the initiator caspases have 
been activated, complete activation of downstream caspases including the executioner caspases 
can proceed rapidly in 10-20 minutes. Consistent with these observations, the activation of all 
three caspases (8, 9 and 3) occurred too rapidly to easily distinguish between the intrinsic or 
extrinsic pathways. In order to elucidate which particular apoptotic pathway was at play, we used 
the pan-caspase inhibitor Q-VD-OPh. As shown in Figure 2.19 the presence of Q-VD-OPh 
resulted in a very similar pattern of caspase activation to that observed with the intrinsic pathway 
inducer etoposide. While caspase-9 was partially inhibited, caspase-3 cleavage to the 17 kDa 
form was prevented and instead the semi-processed 19 kDa form was observed indicating an 
intact 2 kDa pro-domain representing inhibited caspase-3. The activation of caspase-8, a known 
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substrate of caspase-3, was completely prevented in the presence of Q-VD-OPh, consistent with 
an intrinsic pathway mechanism where caspase-8 activation is downstream of caspase-3.  
Furthermore we employed isogenic Jurkat cell lines that lack functional Fas-associated 
death domain (FADD) or caspase-8 (C8), both critical components of the death inducing 
signaling complex (DISC) involved in the extrinsic pathway. These cell lines have been noted 
for their resistance to the extrinsic pathway stimuli Fas-L and TNF.
95-97
 However, in the case of 
4150, these cell lines were similarly susceptible as wild-type cells in both the 2 hour AV/PI rapid 
cell death and 24 hour assays, consistent with the notion that the extrinsic pathway is not 
involved in 4150-induced apoptosis (Figure 2.20).  
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Figure 2.20. Treatment of Jurkat C8-/- or FADD-/- cells reveal they are equally susceptible as wild type in 
A) rapid cell viability AV/PI assay (10 µM 4150) and B) 24 hour IC50 assays to the effects of 4150. Data 
represents average of 3 independent experiments and error bars are the standard deviation. 
 
2.10 4150 induces rapid cytochrome c release  
As the intrinsic pathway requires the release of cytochrome c release to activate caspase-
9, we expected a rapid release of cytochrome c in 4150 treated cells. Consistent with this 
hypothesis, cell flow cytometry confirmed that cytochrome c release occurs as early as 10 
minutes and is complete in 20 minutes (no further changes are observed at later time points) in 
both U937 and SKW 6.4 cells (Figure 2.21).  
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Figure 2.21. Time course analysis of cytochrome c in A) U937 and B) SKW 6.4 cells by flow cytometry 
shows cytochrome c release is partial at 10 minutes and complete by 20 minutes of treatment with 10 µM 
of 4150.  
 
Consistent with the flow cytometry results, immunoblots of the mitochondrial and 
cytosolic fractions of U937 cells revealed cytochrome c release from the mitochondria and 
caspase 9 activation in the cytosol after 20 minutes of exposure to 10 µM 4150 (Figure 2.22A). 
In contrast, etoposide (50 µM) required 3 hours to induce cytochrome c release in U937 cells 
(Figure 2.22B). 
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Figure 2.22. Time course immunoblots of mitochondrial and cytosolic fractions of U937 cells treated with 
A) 10 µM 4150 and B) 50 µM etoposide show cytochrome c release and subsequent caspase 9 activation 
occur after 20 min of treatment with 4150 but require 3 hours of treatment with etoposide. 
 
One possibility is that 4150 directly acts on the mitochondria to induce cytochrome c 
release. As agents that directly act on the mitochondria to induce cytochrome c release are able 
to do so in vitro using isolated intact mitiochondria we investigated whether this was the case for 
4150. Intact mitochondria isolated from U937 cells were placed under both respiring and non-
respiring conditions in the presence of 4150. As a positive control, we used the pro-apoptotic 
Bcl-2 protein Bid which is known to induce cytochrome c release in vitro. As shown in Figure 
2.23, mitochondria under non-respiring conditions are more sensitive to Bid-mediated 
mitochondrial release than respiring mitochondria. While Bid was able to induce cytochrome c 
release under both conditions, a high concentration of 4150 (up to 100 µM) did not release any 
detectable cytochrome c release in this in vitro system. Based upon this result we reasoned that 
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4150 does not simply act directly on mitochondria to release cytochrome c. Rather other cellular 
events are likely to precede cytochrome c release. 
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Figure 2.23. 4150 does not induce cytochrome c release from the mitochondrial pellet into the 
supernatant of isolated mitochondria treated with 4150 in vitro under respiring or non-respiring conditions. 
The positive control, pro-apoptotic full length recombinant Bid protein (FL-Bid) is able to induce 
cytochrome c release. 
 
2.11 Transmission Electron Microscopy 
In order to further identify morphological changes occurring within the cell during the 
rapid induction of apoptosis, we conducted transmission electron microscopy on U937 cells 
treated with 10 µM of 4150 for 5, 30 or 60 minutes. The 5 minute treatment of cells with 4150 
induced substantial changes in mitochondrial morphology where the organelles became more 
translucent with the cristae being clearly visible in contrast to vehicle treated control cells where 
mitochondria were much darker and opaque (Figure 2.24). At 30 minutes, the mitochondria have 
undergone further changes with predominantly translucent structures remaining without cristae. 
This time point coincides with caspase activation (Figure 2.19). At 60 minutes, with fully active 
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caspase-3 (Figure 2.19), the nuclei exhibit stage II chromatin condensation (peripheral nuclear 
condensation) consistent with caspase-activated DNAse (CAD) activity.
98 
 
A) B)
C) D)
 
Figure 2.24. Transmission electron micrographs of U937 cells treated with A) vehicle, or 10 µM 4150 for 
B) 5 min, C) 30 min and D) 60 min. The images show rapid changes in mitochondrial morphology 
(arrows) after 5 min of treatment with 4150. At 30 min, mitochondria are largely devoid of cristae and at 
60 min, peripheral nuclear condensation is apparent.  
 
2.12 Use of small molecule cytoprotectants to investigate 4150’s mechanism 
In order to identify possible mechanisms that may be involved in the rapid apoptosis 
induction by 4150 we investigated a panel of small molecules that are known to inhibit various 
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processes in the cell. The panel included the pan-caspase inhibitor Q-VD-OPh as a positive 
control for protection. We also included the small molecule inhibitor of Bid and tBid 
translocation (BI6C9) given tBid translocation can mediate amplification and acceleration of the 
apoptotic cascade.
99-101
 Agents that target the mitochondria were included. DIDS is proposed to 
be a covalent inhibitor of the voltage-dependent anion channel (VDAC).
102, 103
 FCCP is known to 
dissipate the mitochondrial membrane potential and halt mitochondrial respiration.
104
 We also 
investigated the mitochondrial electron transport chain inhibitors of complex I and complex III 
(rotenone and antimycin A, respectively). Cyclosporine A, the inhibitor of cyclophilin D is 
known to prevent mitochondrial permeability transition pore (MPTP) formation and subsequent 
cytochrome c release.
32-34
 To rule out the involvement of glycolysis we employed sodium 
fluoride.
105
 We also investigated various antioxidants to rule out the involvement of a reactive 
oxygen species (ROS) based mechanism of cell death. Calcium dependent pathways were 
investigated using Ru360, an inhibitor of mitochondrial calcium transporter
106
 and covalent 
calpain/cathepsin inhibitors. As granzyme B is a known endogenous activator of caspases, we 
also investigated a covalent inhibitor of granzyme B. Finally we incorporated inhibitors of 
transcription and translation (actinomycin D and cycloheximide). Cells were pretreated with 
these protective agents for 2 hours after which 4150 (10 µM) was added and cell viability was 
assessed by annexin V/PI after a 2 hour incubation to identify agents that can inhibit the rapid 
(~85%) in cell viability.  
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Figure 2.25. U937 cells pre-treated with various potential cytoprotective agents and inhibitors of various 
cellular pathways were treated with 10 µM 4150 for 2 hours and protection from the effects of 4150 was 
assessed by AV/PI. The average percentage protection and standard deviations were determined from 3 
independent experiments.  
 
As shown in Figure 2.25, the pan-caspase inhibitor afforded quantitative protection 
consistent with caspase-dependent apoptosis. The complete protection afforded by BI6C9 
suggested the involvement of Bid in 4150-mediated cell death. Agents that inhibit mitochondrial 
function such as rotenone, antimycin A and FCCP, all provided significant protection as did the 
VDAC inhibitor, DIDS. This suggested the necessity of mitochondrial respiration and implicated 
the involvement of VDAC. MPTP formation however does not appear to be involved as 
suggested by the lack of protection in the presence of cyclosporine A. Additionally, inhibition of 
glycolysis or the use of antioxidants were unable to afford significant protection. Inhibition of 
calcium-, Granzyme B-, transcription- or translation-mediated pathways did not afford protection 
from the rapid cell death phenotype. 
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To further investigate how the inhibition of Bid/tBid translocation, VDAC and 
mitochondrial respiration may be able to afford protection to 4150-treated cells, immunoblots 
were performed on mitochondrial and cytosolic fractions. As shown in Figure 2.26, Q-VD-OPh 
is unable to inhibit cytochrome c release consistent with the intrinsic pathway where cytohrome c 
release precedes caspase activation. The bid inhibitor (BI6C9), VDAC inhibitor (DIDS) and 
complex I inhibitor (rotenone), however, were all able to prevent cytochrome c release and 
subsequent caspase-9 activation. This data suggested mitochondrial respiration and VDAC 
function as critical requirements for cytochrome c release upon 4150 treatment. 
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Figure 2.26. A) The cytoprotective agents DIDS, BI6C9 and rotenone prevent mitochondrial cytochrome 
c release and caspase 9 activation in U937 cells treated with 10 µM 4150 for 30 minutes. B) Schematic of 
the prevention of cytochrome c release by cytoprotective agents. 
 
2.13 Mitochondrial Outer Membrane Permeability 
As the presence of cyclosporine A, a small-molecule inhibitor of cyclophilin D, was 
unable to mitigate the rapid cell death induced by 4150 (Figure 2.25), this suggested cytochrome 
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c release does not occur by MPTP. To confirm this, we employed a cell flow cytometry assay to 
directly monitor MPTP in whole cells. In this experiment U937 cells were loaded with 
fluorescent calcein in the presence of cobalt. Cobalt, a quencher of calcein fluorescence, is 
unable to enter intact mitochondria. However if MPTP occurs, the calcein fluorescence is 
quenched by cobalt entry into the mitochondria. As shown in Figure 2.27, treatment of U937 
cells with 10 µM of 4150 did not result in a loss of fluorescence calcein signal over a time course 
of 90 minutes, considerably longer than the 20 minutes required for cytochrome c release to 
occur. In contrast, the positive control for MPTP, ionomycin in the presence of calcium, was able 
to completely abolish calcein fluorescence after 10 minutes incubation with cells. This data, 
together with the lack of protection by cyclosporin A suggests that 4150 does not induce 
cytochrome c release through a MPTP mechanism. Unfortunately, no simple assay exists for 
assessing mitochondrial outer membrane permeability (MOMP). While the role of the voltage 
dependent anion channel (VDAC) in MOMP is controversial, several studies have implicated an 
essential role of VDAC in apoptosis induced by Bax, Bim, Bak and small molecule apoptotic 
stimuli.
102, 103, 107-109
 The significant protection afforded by DIDS, a proposed covalent inhibitor 
of VDAC, and its ability to prevent cytochrome c release (Figures 2.29 and 2.30) implicate 
VDAC-dependent release of cytochrome c, presumably through a MOMP mechanism.  
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Figure 2.27. The assessment of mitochondrial permeability transition pore (MPTP) formation in U937 
cells was determined using a calcein + cobalt assay using cell flow cytometry. Ionomycin in the presence 
of calcium is able to induce MPTP whereas 10 µM 4150 does not induce MPTP over 90 minutes of 
treatment.  
 
 
2.14 The role of Bcl proteins 
 The near quantitative protection afforded by the small molecule inhibitor of Bid (BI6C9) 
suggested Bid or tBid protein may be involved in 4150-induced rapid apoptosis (Figure 2.25). 
Immunoblots of the mitochondrial fraction of U937 cells demonstrated an increased presence of 
full-length Bid protein at the mitochondria simultaneous with cytochrome c release (Figure 
2.22A). This accumulation of Bid at the mitochondria was not observed for etoposide treated 
cells (Figure 2.22B). The protection afforded by BI6C9 appears to occur through the prevention 
of cytochrome c release and subsequent caspase-9 activation as determined by immunoblots of 
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the mitochondrial fraction of U937 cells (Figure 2.26). The involvement of full length Bid in 
glutamate exitotoxicity in neurons has been proposed based on cytoprotection afforded by 
BI6C9.
110
  
We considered the possibility 4150 cooperates with full-length Bid to induce cytochrome 
c release. Using isolated mitochondria we investigated whether 4150 can potentiate full-length 
Bid-induced cytochrome c release in vitro. As shown in Figure 2.28, 4150 was unable to 
potentiate Bid-induced cytochrome c release.  
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Figure 2.28. The combination of 4150 and full length Bid protein does not result in an increase in 
cytochrome c release from isolated mitochondria in vitro.  
  
The proteolytic cleavage of Bid to tBid is known to accelerate the induction of apoptosis 
in response to apoptotic stimuli.
99-101
 It is conceivable that the protection observed by BI6C9 is 
 
 
 75 
due to inhibition of tBid-accelerated apoptosis. In addition to a possible unusual involvement of 
Bid, other Bcl proteins are expected to be involved in 4150-induced apoptosis. As the data 
obtained thus far supports VDAC-mediated MOMP, Bax and Bak, are expected to play a role in 
cytochrome c release. As mentioned previously, simultaneous deletion of Bax and Bak is known 
to prevent MOMP and apoptosis.
39, 41
 To verify whether Bid, Bax or Bak are involved in 4150-
induced cell death we tested mouse embryonic fibroblast (MEF) cell lines that lack Bid or 
simultaneously lack Bax and Bak. As shown in Figure 2.29, Bid
-/-
 MEFs and Bax
-/-
Bak
-/-
 double 
knockout MEFs were equally sensitive as wild type cells to 4150 in a rapid 4 hour assessment of 
cell viability by AV/PI (10 µM 4150) and in 24 hour IC50 dose response assays. The Bax-/-Bak-
/- MEFs were resistant to etoposide with a 6 fold reduction in the 24 hour IC50 value (Figure 
2.29B). The MEF cell lines were confirmed to possess the expected deletions by immunoblotting 
(Figure 2.29C).  
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Figure 2.29. 4150 is equally efficacious against wild type MEFs, Bid
-/-
 MEFs and Bax
-/-
Bak
-/-
 MEFs as 
assessed in A) 4 hour AV/PI assay (10 µM 4150) and B) 24 hour IC50 assays. Bax
-/-
Bak
-/-
 MEF are 
resistant to etoposide. C) The cell lines were confirmed to possess deletions of the respective proteins by 
immunoblotting. 
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Despite the protection afforded by BI6C9 in U937 cells, the conserved sensitivity of Bid
-
/-
 MEFs versus wild type cells indicate Bid is not involved in 4150-induced apoptosis. BI6C9 
was developed by NMR structure-based ligand design to fit a binding pocket in tBid protein.
111, 
112
 The exclusive selectivity of BI6C9 for Bid or tBid has not been demonstrated by experiments 
involving Bid knockout cells.
111, 112
 Binding pockets similar to tBid‟s may be present in other 
BH3-only proteins. The protection afforded by BI6C9, in 4150-induced cell death, may therefore 
be due to off-target inhibition of these proteins. 
The data also suggests 4150-induced cytochrome c is not mediated by Bax or Bak. As 
Bax
-/-
Bak
-/-
 double knockout cells are resistant to diverse apoptotic stimuli,
45
 this result is 
surprising and implicates an alternate mechanism of MOMP induction may be at play in 4150-
treated cells. 
 
 
2.15  Whole genome shRNA screen 
Whole genome shRNA screens in a pooled format have been able to identify the protein 
targets and critical proteins in the mechanism of action of several small molecules, which include 
etoposide, gleevec, nutlin-3 and Fas receptor antibody.
113-115
 While this method has not been 
used in discovery mode for the investigation of molecules with unknown mechanisms, we were 
hopeful this unbiased genome-wide technique may aid the identification of critical proteins 
involved in 4150 induced apoptosis. The screen was performed with the GeneNet shRNA human 
50K shRNA library, which consists of approximately 200,000 constructs targeting 47,500 
transcripts. The library was packaged into FIV pseudoviral particles and transduced into MIA 
PaCa-2 pancreatic cells at a MOI of 0.7 (quantitated by number of GFP positive cells) and a 100 
fold theoretical representation of the shRNA library. Four to seven days after transduction we 
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commenced 2-3 day treatment of cells with 4150 (1.25-1.8 µM) followed by several days of 
recovery in drug free media after which the treatment and recovery processes were repeated two 
more times over a period spanning 20 days. The shRNA constructs were amplified by PCR 
amplification of total RNA isolated from the cells and the levels of half-hairpin constructs 
present in control and 4150-treated cells were quantitated using HG Affymetrix U133 Plus 2 
microarrays. A graphical representation of the results are shown in Figure 2.30. While most 
shRNA constructs are equally represented among 4150 and control samples, there are several 
that are enriched or depleted in the 4150 sample versus the control. 
 
Figure 2.30. Plot of shRNA construct levels in 4150 versus control sample after 20 days of selection in a 
whole genome pooled shRNA screen. Constructs enriched or depleted by over 40 fold are represented 
on the graph. 
  
As we had simultaneously performed the shRNA screen with DNQ, a molecule that 
induces programmed necrosis, we were able to garner information about the uniqueness of the 
4150 vs DNQ affected shRNA constructs. There was considerable overlap in the shRNA 
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constructs depleted in both 4150 and DNQ treatments suggesting these shRNAs likely contribute 
to general sensitization of cells to toxic stimuli. The enriched shRNA constructs for the two 
compounds, however, were very dissimilar suggesting compound specific effects. As shRNA 
constructs enriched in 4150 versus control likely confer resistance of cells to 4150-induced 
toxicity, the targets likely play a role in inducing toxicity or activating apoptosis. We identified 
32 genes that were targeted with 2 or more shRNA constructs showing a > 5 fold enrichment. 
Also identified, were 140 genes whose constructs were enriched >40 fold. The top 50 shRNA 
constructs enriched in the screen are listed in Table 2.5. Of particular note was the 572 fold 
enrichment of glutathione s-transferase zeta 1 (GSTZ1), a protein that is typically associated with 
the detoxification of electrophilic molecules.
116
 Given GSTZ1‟s pro-survival function, one would 
expect depletion of the shRNA targeting GSTZ1 in 4150-treated cells. However the enrichment 
of GSTZ1 shRNA, suggests it plays a pro-apoptotic role in 4150-induced cell death. Another 
candidate of interest is Bcl2-rambo (MIL1 protein) whose shRNA construct was enriched 120 
fold. Bcl2-rambo, when ectopically expressed, induces apoptosis in cell culture.
117
 While Bcl-
rambo belongs to the BH3 only category of Bcl proteins, it does not interact with Bcl-2, Bax or 
Bak.
117
 Another candidate of interest is rho-related GTP-binding protein (RhoB) which was 
enriched 39 fold. RhoB protein is a GTPase that regulates actin binding and vesicle transport and 
is known to mediate apoptosis in neoplastically transformed cells in response to DNA alkylators 
but not UV- or doxorubicin-induced DNA damage.
118-120
 In order to validate the hits we will 
assess siRNA of 172 genes in a single-well per siRNA experiment in order to identify proteins 
that play a role in rapid caspase activation. We will also assess 58 known apoptosis genes to fully 
characterize the role of known players in the apoptotic cascade. 
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Table 2.5. The top 50 enriched shRNA constructs with the fold change for 4150 treated cells (average of 
two experiments) versus untreated cells compared to the fold change observed for DNQ treated cells. 
 
GeneBank# Gene name AVG 4150 FC DNQ 
g12655190 Homo sapiens, glutathione transferase zeta 1 (maleylacetoacetate isomerase), 
clone MGC:2029, mRNA, complete cds.  
571.9 1.2 
BE551347 hypothetical protein FLJ1305 354.4 1.0 
g7662081 Homo sapiens syntaphilin (KIAA0374), mRNA.  265.1 10.9 
AF043899 Homo sapiens amphiphysin IIc1 mRNA, complete cds.  220.5 0.7 
g4558755 Homo sapiens testis-specific chromodomain Y-like protein (CDYL) mRNA, 
alternatively processed, complete cds.  
213.8 2.4 
BG034080 bridging integrator 1  213.7 0.8 
g4757747 Homo sapiens bridging integrator 1 (BIN1), mRNA.  198.4 0.6 
AI927368 ESTs, Weakly similar to A46010 X-linked retinopathy protein (H.sapiens 194.8 0.8 
AF036973 HCGIV-6 protei 162.2 0.8 
g2199534 Homo sapiens amphiphysin II mRNA, complete cds.  143.2 0.5 
BF339860 Homo sapiens, clone IMAGE:5304059, mRN 142.1 0.9 
g10938012 Homo sapiens E4F transcription factor 1 (E4F1), mRNA.  139.9 0.3 
AW241715 ubiquitination factor E4B (homologous to yeast UFD2)  136.7 0.7 
g12653432 Homo sapiens, Similar to POM (POM121 rat homolog) and ZP3 fusion protein, 
clone MGC:8359, mRNA, complete cds.  
130.1 6.5 
AI803525 protein phosphatase 2, regulatory subunit B (B56), alpha isoform  121.8 0.7 
AF229115 Homo sapiens PAVL1 mRNA, 3 untranslated region 121.4 1.0 
g13183304 Homo sapiens MIL1 protein isoform 1 (MIL1) mRNA, complete cds.  120.0 0.5 
AL133618 Homo sapiens mRNA; cDNA DKFZp434C2021 (from clone DKFZp434C2021) 106.5 0.6 
g5326761 Homo sapiens calciumcalmodulin-dependent protein kinase II beta 6 subunit 
(CAMKB) mRNA, complete cds.  
106.4 0.7 
g8923776 Homo sapiens p65 protein (HSAJ2425), mRNA.  103.0 0.7 
g8923447 Homo sapiens hypothetical protein FLJ20484 (FLJ20484), mRNA.  91.9 0.8 
U85978 Human chloride channel protein (p64) pseudogene, partial cd 91.0 1.0 
g5305404 Homo sapiens Na+H+ exchanger isoform 2 (NHE2) mRNA, complete cds.  88.0 1.0 
g12005666 Homo sapiens NPD015 mRNA, complete cds.  85.5 0.6 
g7662487 Homo sapiens KIAA1104 protein (KIAA1104), mRNA.  81.7 0.9 
BE670928 KIAA0301 protei 79.1 0.7 
g4557454 Homo sapiens choline kinase (CHK), mRNA.  76.8 0.7 
g4757761 Homo sapiens ring finger protein 14 (RNF14), mRNA.  75.3 0.3 
AK026829 Homo sapiens cDNA: FLJ23176 fis, clone LNG10452 71.8 0.3 
g7657185 Homo sapiens hypothetical protein (HS322B1A), mRNA.  71.8 1.0 
g5032006 Homo sapiens purine-rich element binding protein A (PURA), mRNA.  71.3 0.6 
g6563227 Homo sapiens rap2 interacting protein x mRNA, complete cds.  71.1 1.2 
AA740186 Biliverdin reductase A  71.1 1.4 
BF593650 sin3-associated polypeptide, 18kD  70.4 0.6 
AI825302 EST 69.9 1.0 
AL558479 Thy-1 cell surface antigen  69.5 1.3 
 
 
 
 
 80 
Table 2.5 (continued) 
 
GeneBank# Gene name AVG 4150 FC DNQ 
g6841507 Homo sapiens HSPC143 mRNA, complete cds.  69.5 0.6 
g2055231 Homo sapiens mRNA for prepro cortistatin like peptide, complete cds.  69.1 0.4 
AU152635 ferrochelatase (protoporphyria)  69.0 4.3 
BE567813 ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome)  68.4 0.7 
g5803130 Homo sapiens RAB31, member RAS oncogene family (RAB31), mRNA.  68.2 0.9 
AL050002 Homo sapiens mRNA; cDNA DKFZp564O222 (from clone DKFZp564O222) 66.4 1.1 
R64130 pro-platelet basic protein (includes platelet basic protein, beta-thromboglobulin, 
connective tissue-activating peptide III, neutrophil-activating peptide-2 
66.1 0.4 
g13124753 Homo sapiens KIAA0595 protein (KIAA0595), mRNA.  65.5 0.7 
g4885570 Homo sapiens RAN binding protein 9 (RANBP9), mRNA.  65.3 0.8 
g13375728 Homo sapiens hypothetical protein FLJ22054 (FLJ22054), mRNA.  64.6 1.2 
BC034417 Homo sapiens, hypothetical protein FLJ23074, clone MGC:34146 
IMAGE:5164977, mRNA, complete cds.  
64.3 0.9 
AW071239 DnaJ (Hsp40) homolog, subfamily C, member  63.7 0.9 
g8051612 Homo sapiens KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention 
receptor 3 (KDELR3), transcript variant 1, mRNA.  
62.8 1.0 
g8922933 Homo sapiens hypothetical protein FLJ11196 (FLJ11196), mRNA.  62.6 1.1 
 
 
2.16 4150 can covalently modify proteins 
As aldehyde groups are electrophilic and may react with sulfur or amine nucleophiles 
present in biological systems, we assessed whether 4150 is capable of covalently modifying a 
protein in vitro. We incubated myoglobin protein, which has 17 lysines, with 4150 in a 1:1 molar 
ratio to protein. The sample was then subjected to reduction using sodium cyanoborohydride to 
irreversibly trap any imines. As shown in Figure 2.31, the sodium cyanoborohydride treated 
sample exhibited an increase in mass (by 354 Da) consistent with a covalent modification of the 
protein with 4150 according to the scheme in Figure 2.31B. If sodium cyanoborohydride is not 
added, then the covalent adduct is not observed suggesting it is readily reversible under non-
reductive conditions. The pre-formed hydrate is also able to modify myoglobin under reductive 
conditions (data not shown). Whether the covalent modifications of proteins plays a role in 
4150‟s mechanism of action remains to be determined. Preliminary experiments using azido or 
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alkyne derivatives of 4150 (F15 and F16, repectively) fail to indicate covalent labeling that can 
be competed with parent 4150 as assessed by click reaction of cell lysate with fluorescent 
reporter click reaction partners. 
DMSO 4150 4150 + NaCNBH3
B)
A)
 
Figure 2.31. 4150 is capable of modifying proteins in vitro as A) treatment of myoglobin with 4150 in 
presence of sodium cyanoborohydride shows a covalent adduct that is not present in the absence of 
reducing agent. A schematic of the modification suggested by mass spectrometry is shown in B).   
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In order to identify components of the cellular proteome that may be covalently modified 
upon treatment of cells with 4150 or may be involved in the mechanism of the rapid phenotype 
we employed 2D DIGE analysis which can potentially detect post-translational modifications, 
cleavage events or 4150-labelled proteins based upon changes in electrophoretic motility. In 
order to identify early events independent of caspase-mediated cleavage U937 cells were 
pretreated with 50 µM Q-VD-OPh, the pan-caspase inhibitor, for an hour and a half followed by 
a short treatment with 4150 (10 µM, 15 minutes). The cells were then pelleted and lysed in 
buffer containing sodium borohydride. Additionally we also performed a similar experiment 
where the cells were washed with PBS and lysed with buffer containing sodium 
cyanoborohydride. Both these reductive agents were investigated in order to account for changes 
in equilibrium of 4150 labeling that may occur under the different experimental conditions. 
These results are in the process of being obtained and their implications for the mechanism of 
4150 have yet to be determined. 
 
2.17 4150 inhibits tumor growth in vivo 
The rapid induction of apoptosis by 4150 may be advantageous for anticancer effects in a 
clinical setting. Several obstacles challenge the translation of small molecules from cell culture 
experiments to clinical use. While mechanism and potency influence success in cell culture, 
pharmacokinetics, bioavailability and off-target toxicity all present significant challenges in 
achieving success in vivo. The unique ability of 4150 to induce rapid apoptosis may be desirable 
from a pharmacokinetic viewpoint. We therefore investigated whether this molecule was capable 
of eliciting an antitumor response in vivo. We used two syngeneic subcutaneous models of 
aggressive and metastatic cancer in mice: B16F10 melanoma and 4T1 breast cancer. We found 
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that 4150 administered in corn oil intraperitoneally was well tolerated at 20 mg/kg daily with 
temporary weight loss occurring after 4 days. Daily injections of 25 mg/kg resulted in more 
severe weight loss at day 3 with some cases of lethality at day 4. Therefore we performed the 
study at the maximal tolerated dose of 20 mg/kg. As shown in Figure 2.32, administration of 
4150 (4 days of dosing) resulted in approximately 50% inhibition of tumor volume and tumor 
weight in the 4T1 model. In the B16F10 model, which progressed more rapidly than the 4T1 
model, administration of 4150 during the first three days was sufficient to decrease tumor 
volume and tumor mass by 60% (Figure 2.33). The anticancer effect of 4150 in vivo in these 
rapidly growing aggressive models is promising and will be the subject of further investigation 
and optimization.  
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Figure 2.32. 4150 inhibits 4T1 subcutaneous tumor growth in vivo as measured by A) tumor volume (p 
value = 0.0325) and B) tumor mass after tumor excision on day 7 (p value = 0.0496). Arrows in A) 
indicate 4150 administration at 20 mg/kg once a day for 4 days. 
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Figure 2.33. 4150 inhibits subcutaneous B16F10 tumor growth in vivo as measured by A) tumor volume 
(p value = 0.0026) and B) tumor mass after tumor excision on day 6 (p value = 0.0220). Arrows in A) 
indicate 4150 administration at 20 mg/kg once a day for three days. 
 
2.18 Conclusions and outlook 
We have serendipitously discovered the molecule, 4150, to be an unusually rapid inducer 
of caspase-dependent apoptosis. This agent at a modest concentration of 10 µM is able to induce 
apoptosis much more rapidly than 25 other small molecule anticancer agents and biological tool 
molecules tested at the same concentration. The involvement of caspases in the rapid death 
induction is supported by immunoblotting, caspase-3/7 substrate cleavage activity assays and by 
the quantitative protection afforded by the pan-caspase inhibitor Q-VD-OPh. 4150-induced cell 
death features several phenotypic hallmarks of apoptosis such as cellular blebbing (30 minutes 
after stimuli), peripheral nuclear condensation (60 minutes after stimuli), and exposure of 
phosphatidylserine prior to cell membrane permeability (90 minutes after stimuli).  
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The induction of apoptosis by 4150 occurs through the intrinsic pathway as supported by 
the rapid cytochrome c release (within 20 minutes), the inability of Q-VD-OPh to prevent 
cytochrome c release, and the sensitivity of cell lines devoid of functional extrinsic pathway 
signaling (Jurkat FADD
-/-
 and Casp8
-/-
). Using a panel of small molecules as potential 
cytoprotective agents we were able to identify the requirement for VDAC and mitochondrial 
respiration in order to induce cytochrome c release. Dissipation of the mitochondrial proton 
gradient has been observed to inhibit Bax-induced apoptosis.
121
 In addition, inhibition of 
complex III by antimycin A offers protection to nitric oxide-induced apoptosis.
122
 
The transcript profile of 4150 at low concentrations matched the transcript profile of 
thapsigargin, suggesting ER-stress as a contributor to cell death. Despite this match, it is unlikely 
that the compounds share a similar mode of action. Thapsigargin, a very potent inhibitor of 
SERCA, induces instantaneous calcium release from intracellular calcium stores such as the 
endoplasmic reticulum.
76
 Unlike 4150, treatment of U937 with 10 µM thapsigargin was unable 
to elicit a rapid loss of cell viability or caspase activation. Thapsigargin and tunicamycin, another 
potent inducer of ER-stress,
76
 required at 14-24 hours to induce 50% cell death. In addition, ER-
stress induced death requires a transcriptional and translational response to manifest.
76
 4150-
induced rapid apoptosis, however, is transcription- and translation-independent as assessed by 
the lack of protection by actinomycin D and cycloheximide, respectively. 
The role of ROS in 4150-induced cell death is also ambiguous. Despite rapid ROS 
production in U937 cells by 10 µM 4150, several antioxidants were unable to prevent cell death. 
In addition, very potent inducers of ROS such as DNQ and elesclomol were unable to affect 
U937 cell viability in less than 6 hours.  
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In vitro studies using isolated mitochondria suggest that 4150 does not directly act upon 
the mitochondria to induce cytochrome c release. Furthermore, the mechanism of cytochrome c 
release in whole cells appears to be mediated by VDAC-dependent MOMP rather than MPTP. 
Surprisingly, Bax and Bak do not appear to be involved in MOMP induction as suggested by the 
similar sensitivity of Bax
-/-
Bak
-/-
 double knockout MEFs to wild type MEFs. As low expression 
of Bax or Bak is observed with poor patient survival in cancers such as melanoma, the ability to 
induce apoptosis in a Bax and Bak independent manner may be beneficial.
123
 
The ability to induce very rapid apoptosis by 4150 challenges the notion that apoptosis 
necessarily requires a significant amount of time to occur. This result is exceptional considering 
the field of apoptosis is over 40 years old and the mechanisms of hundreds of apoptosis-inducing 
small molecules have been investigated to this date. Using a pooled shRNA genome wide screen 
we hope to identify critical proteins involved in the rapid induction of apoptosis. 
A rapid-inducer of apoptosis would not only be a powerful tool in uncovering novel 
aspects of the apoptotic machinery, but it may possess therapeutic advantages in tackling cancer 
in patients. The rapid induction of cell death may elicit more rapid responses with the potential to 
alleviate undesirable toxicity which often results due to the necessary prolonged exposure to 
chemotherapeutics required to elicit a therapeutic response. The therapeutic potential of 4150 is 
promising given its activity against aggressive breast cancer and melanoma in animal models of 
cancer. In addition, there have been significant efforts in nanoparticle-based strategies to 
selectively deliver drugs to tumors and 4150, undoubtedly, will be an interesting candidate for 
such approaches given the ease with which it may be reversibly conjugated to nanoparticle 
through its aldehyde groups.  
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2.19 Materials and methods 
General 
Anti-HMOX-1 rabbit polyclonal antibody (SPA-896) was purchased from Stressgen. 
Antibodies for PARP-1, caspase-3, caspase-8, caspase-9, Bid, Bax, Bak, cytochrome c, actin and 
CoxIV were purchased from Cell Signaling Technologies. Full-length recombinant Bid was 
purchased from R&D Systems. Annexin V-FITC conjugate was obtained from SouthernBiotech. 
Propidium iodide, sulforhodamine B, staurosporine, rapamycin, colchicine, vincristine, 
paclitaxel, camptothecin, etoposide, doxorubicin, mitomycin C, cisplatin, MNNG, thapsigargin, 
tunicamycin, rotenone, antimycin A, gossypol, HA14-1, TPEN, BI6C9, FCCP, DIDS, 
cyclosporine A, sodium fluoride, tempol, dicoumarol, tiron, diphenyleneiodonium chloride 
(DPI), allopurinol, N-acetyl-L-cysteine (NAC), calpain inhibitor I, actinomycin D, 
cycloheximide and cobalt (II) chloride were obtained from Sigma Aldrich. Ru360, Q-VD-OPh 
and granzyme B inhibitor I were obtained from Calbiochem. MnTBAP hydrochloride was 
purchased from Santa Cruz Biotechnology. Apoptosis activator 2 (AA2) was purchased from 
Tocris Biosciences. Calcein-AM was purchased from Invitrogen. MTS was obtained from 
Promega Inc. RNA isolation was conducted using the Qiagen mini-prep RNeasy kit (Qiagen) 
with on-column DNase digest performed using RNase-free DNase (Qiagen). Illumina 
HumanHT-12 bread array was purchased from Illumina. The GeneNet human 50K plasmid 
siRNA Library in pSIF1-H1-copGFP was purchased from System Biosciences Inc. Human U133 
plus 2.0 microarrays were purchased from Affymetrix Inc. Balb/c and C57Bl/6 female mice (6-8 
weeks old) were purchased from Charles River. 
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Cell culture conditions 
All cells were grown in RPMI 1640 or DMEM media supplemented with 10% FBS, 1% 
penicillin-streptomycin and incubated at 37 ºC in 5% CO2, 95% humidity incubator. 
 
High-throughput cell death screen
69
 
HL-60 cells were plated into 384 well plates (50 μL of 2 x 106 cells/mL per well) in 
RPMI cell culture media. Library compounds were transferred using a 384-pin transfer apparatus 
(V & P Scientific, San Deigo) which transferred 0.1 μL from 10 mM DMSO stock solutions to 
achieve a final concentration of 20 μM. Controls containing DMSO only and 10 μM etoposide 
were used to serve as live and dead controls respectively. The cells were incubated for 24 hours. 
A solution containing the soluble tetrazolium salt ((3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) and the electron 
coupling reagent, phenazine methosulfate (PMS) was prepared according to the manufacturer‟s 
instructions (Promega, Madison WI) and 10 μL added to each well. The plates were incubated at 
37 ºC for approximately an hour after which the formation of the reduced formazan product by 
viable cells was assessed at 490 nm using a SpectraMax Plus 384 well plate reader (Molecular 
Devices, Sunnyvale CA). The top 220 toxic compounds were selected and re-tested at 1 μM. 
Compound 4150 induced quantitative cell death under these conditions. 
 
MTS assay for suspension cells 
Serial dilutions of compound in 100% DMSO were added in triplicate (2 μL to each well) 
to empty wells of a 96-well plate. Suspension cells (HL-60, U937, SKW 6.4, Jurkat WT, Jurkat 
CASP8
-/-
, Jurkat FADD
-/-
) cells in RPMI 1640 media were added to 96-well plates (198 μL 
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containing 4 x 10
4 
cells) and the cells incubated for 24 hours. A solution containing the soluble 
tetrazolium salt ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt; MTS) and the electron coupling reagent, phenazine methosulfate 
(PMS) was prepared according to the manufacturer‟s instructions (Promega) and 20 μL added to 
each well. The plates were incubated at 37 ºC for 15-45 min and the absorbance at 490 nm was 
measured using a SpectraMax Plus 384 well plate reader (Molecular Devices, Sunnyvale CA). 
The average IC50 and standard deviation determined from three independent experiments. 
 
Sulforhodamine B assay for adherent cells 
Serial dilutions of compound in 100% DMSO were added in triplicate (2 μL to each well) 
to empty wells of a 96-well plate. Adherent cells (3T3, Hs888Lu, MCF-7, HeLa, WT-MEF, 
MEF Bax
-/-
Bak
-/-
, MEF Bid
-/-
, 4T1, B16F10) cells were added to each well (5 x 10
3
 cells in 198 
μL of RPMI 1640 or DMEM media). The plates were incubated for 24 hours. The media was 
removed from the plate and ice-cold trichloroacetic acid (100 μL of 10% w/v trichloroacetic 
acid) was added to the plates which were then incubated at 4 ºC overnight to fix the cells. The 
trichloroacetic acid was removed and the wells washed with 200 μL of de-ionized water 5 times. 
Sulforhodamine B (200 μL of 0.04 % sodium salt dissolved in 1% acetic acid) was added to each 
well and the plates incubated at room temperature for 30 min. Excess sulfrorhodamine B was 
removed by washing the plates 5 times with 1% acetic acid. The bound dye was released by the 
addition of unbuffered Tris-base (200 μL of 10 mM solution) and after a 30 min incubation at 
room temperature the absorbance at 510 nm was measured (Molecular Devices SpectraMax Plus 
384 plate reader). The average IC50 and standard deviation determined from three independent 
experiments. 
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Gene expression analysis 
U937 cells (3 x 10
6
 cells in 6 mL RPMI 1640 with 10% FBS) were incubated in the 
presence of 700 nM 4150 or DMSO vehicle (0.2% final DMSO v/v) for 6 hours in a 12-well 
plate. Aliquots (500 μL) were taken at 6 and 24 hours to assess viability (by annexin V/PI 
staining and flow cytometry) in order to ensure no toxicity occurred at 6 hours but toxicity was 
observed at 24 hours. After 6 hours of incubation, 5 mL of cells were pelleted (500 x g, 5 min) 
and RNA isolated with on-column DNase digestion. RNA integrity was assessed using an 
Agilent Bioanalyzer. Whole genome transcript profiling was performed on the Illumina 
HumanHT-12 bread array for seven compounds and DMSO control from three independent 
experiments. The raw bead-level files were processed with Illumina® BeadStudio 3.1, Gene 
Expression Module v3.2.6 
124
, without background correction or normalization, to get one value 
per beadtype for each array. These 48,803 beadtype values were then input into R 
125
 using the 
beadarray package 
126
 from the Bioconductor Project 
127
. The vsn algorithm 
128
 was used for 
background correction, normalization and transformation of the beadtype values to the glog2 
scale. Differential expression was assessed using a mixed linear model using the Limma package 
129
, which uses an empirical Bayes correction 
130 
that helps to improve power by borrowing 
information across beadtypes. All the desired pair-wise comparisons between the 8 treatment 
groups (control + 4150 + 6 unrelated compounds) were pulled as contrasts from the model and 
the p-values were corrected for multiple hypothesis testing using the False Discovery Rate 
method 
131
 separately for each contrast. In order to facilitate comparisons of our results with 
those of Connectivity Map database we used Illumina‟s probe mapping file that matched probes 
from Illumina‟s HumanWG-6v3 array (same probes as the HumanHT-12 array) to Affymetrix‟s  
U133Plus2.0 array
132
. The top 50 up- and down-regulated probe set IDs ordered according to 
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fold change were used to create the seed for the connectivity map (CMAP) database matching. 
Analysis of the canonical pathways was performed using Ingenuity Pathway Analysis (IPA, 
Ingenuity Systems) software using a p-value cutoff of 0.05 to define the network eligible genes. 
 
Measurement of ROS production 
U937 cells (1 mL of 5 x 10
5
 cells/mL) in Hank‟s buffered salt solution (HBSS) 
containing 5 mM glucose were treated with DMSO, 2 or 10 μM 4150, 10 μM thapsigargin, 100 
μM etoposide (1% DMSO final) and incubated in the presence of 5 μM dihydroethidium a 37 ºC, 
5% CO2 incubator for 20 minutes. Dihydroethidium is oxidized in the presence of superoxide 
anion radicals to ethidium, which intercalates DNA and experiences a 24 fold increase in 
fluorescence. The levels of ethidium were assessed by flow cytometry. Live cells were analyzed 
based on gating on the forward and side scatter properties and the geometric mean of ethidium 
staining was determined using the software FCS Express.  
 
Immunoblotting 
U937 cells (3 x 10
6
 cells in 2 mL RPMI) or SKW 6.4 cells (5 x 10
6
 cells in 2 mL RPMI) 
were treated with compound (1% final DMSO v/v) for the appropriate period of time. After 
centrifugation and washing with PBS, cells were lysed with RIPA lysis buffer containing 
protease cocktail inhibitor and cell debris removed by centrifugation (16000 x g. 5 min). The 
lysate concentrations were normalized after determination of protein concentration by the 
Bradford assay and whole cell lysate (40-60 μg) was resolved by 4-20% gradient SDS-PAGE gel 
electrophoresis at 120 V for 70 min after which proteins were transferred onto PVDF membranes 
(60 V for 2 hours) and blocked in 5% BSA or fat-free milk in TBST (as per primary antibody 
manufacturer‟s instructions) overnight at 4 ºC. The membranes were blotted for molecules of 
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interest with primary antibody (1:1000 in 5% BSA or milk in TBST) overnight at 4 ºC. The 
bound primary antibodies were detected using appropriate secondary HRP conjugated antibodies 
(1:5000 in TBST) for 1 hour at room temperature and visualized by ECL autoradiography. The 
membranes were stripped in acidic methanol, blocked and re-probed as necessary.  
 
Scanning electron microscopy 
 U937 cells (4 x 10
6
 cells in 8 mL 0.45 micron-filtered cell culture media) were treated 
with 1% DMSO) or 10 µM 4150 in 10 cm culture dishes for 60 minutes . The cells were 
centrifuged (250 x g, 5 min) and the media aspirated. Ice-cold Karnovsky‟s fixative (1 mL of 
0.45 micron filtered) was added to the cell pellet which was resuspended by gently agitation. The 
cells were fixed overnight at 4 ºC and submitted for scanning electron microscopy (SEM) sample 
processing. The cells were stained with OsO4, placed on filter paper and dehydrated. After 
mounting, the cells were coated with Pd/Au and scanning electron microscopy was performed. 
 
Annexin V analysis of suspension cells, protection assays, time course 
Suspension cells were plated into a 24 well plate (5 x 10
5 
cells in 0.99 mL cell culture 
media). Adherent cells (MEFs) were plated at into 12 well plates (2 x 10
5
 cells in 0.99 mL cell 
culture media). The drug of interest was added from DMSO stocks such that the final 
concentration of DMSO was 1% v/v. The cells were incubated for the appropriate time after 
which they were centrifuged (400 g for 5 min) and resuspended in annexin V binding buffer (0.5 
mL) containing 1 μg/mL Propidium iodide and 100X dilution of FITC-Anexin V (Southern 
Biotechnology). The samples were analyzed immediately by cell flow cytometry on a Benton 
Dickinson LSRII flow cytometer. For protection assays, U937 cells were pretreated with the 
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prospective protective agents for 2 hours at the following concentrations: NaF (1 mM), 
cyclosporine A (10 μM), FCCP (10 μM), cycloheximide (10 μM), actinomycin D (2 μM), 
rotenone (100 μM), antimycin A (100 μM), sodium pyruvate (5 mM), tempol (400 μM), 
granzyme B inhibitor I (50 μM), calpain inhibitor I (50 μM), MnTBAP (20 μM), DPI (10 μM), 
allopurinol (1 mM), dicoumarol (50 μM), tiron (10 mM), Ru360 (10 μM), BI6C9 (100 μM), 
NAC (10 mM), DIDS (2 mM), and Q-VD-OPh (50 μM). The cells were then co-treated with 
4150 at 10 μM for 2 hours prior to analysis. For the 36 hour time course analysis of various 
toxins at 10 μM, cells were plated (1 x 106 U937 cells in 1.98 mL RPMI) into 24 well plates in 
the presence of drug and 200 μL aliquots were removed during the time course and analyzed by 
propidium iodide/FITC-Anexin V staining. 
 
Caspase 3/7-like protease activity   
HL-60 cells (4 x 10
5
 cells in 99 µL) or U937 cells (2.5 x 10
5
 cells in 99 µL) were plated 
in 96-well plate and treated with 4150 (10 µM), thapsigargin (10 µM), staurosporine (10 µM), 
etoposide (50 µM) for various times (1% DMSO final v/v). The plate was centrifuged (1000 x g, 
5 min) and the media removed. The cells were washed with PBS (200 µL) and resuspended in 
caspase-3 activity buffer (80 µL). The cells were lysed in the wells using a probe-tip sonicator 
and 45 µL of the lysate was transferred into a 384-well plate. Caspase 3/7 substrate, AcDEVD-
pNA was added (5 µL of 2 mM DMSO stock) such that the final concentration was 200 µM. A 
kinetic read was performed monitoring the absorbance at 405 nm every 45 seconds with 5 
seconds agitation between reads for 2 hours using a Molecular Devices Spectramax 384 plus 
plate reader. The rates of substrate cleavage were determined from the slopes of the linear 
portion of the kinetic curves (t = 50 to 6000 seconds). 
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Cytochrome c release by flow cytometry 
Suspension cells (2.5 x 10
6
 SKW 6.4 cells or 1.5 x 10
6
 U937 cells in 1 mL RPMI) were 
treated with 10 μM 4150 in a 24 well plate for 10, 20, 30, 45 and 60 min. The cells were 
centrifuged (1000 x g, 2 min), washed with cold PBS and resuspended in cold permeabilization 
buffer (PBS containing 50 μg/mL digitonin and 100 mM KCl) and placed on ice for 5 min after 
which > 95% of cells were permeabilized as determined by trypan blue. The cells were fixed by 
addition of paraformaldehyde (0.5 mL of 8% solution in PBS) by incubating at room temperature 
for 20 min. The fixed cells were washed three times with 1 mL PBS and blocked in 200 μL 
blocking buffer (3% BSA, 0.05% saponin in PBS) for 1 h at room temperature. Anti-cytochrome 
c monoclonal antibody (Clone 6H2.B4, BD Pharmingen, San Diego, CA) was added (200 μL of 
1:100 dilution in blocking buffer) to achieve a final antibody dilution of 1:200 and the cells 
incubated at 4 ºC overnight. The cells were pelleted and washed with PBS (1 mL) and secondary 
antibody added (200 μL of 1:200 dilution of AlexaFluor 488 antimouse antibody in blocking 
buffer) and the cells incubated at room temperature in the dark. The cells were pelleted and 
washed with PBS (3 mL) and resuspended in PBS (1 mL) and analyzed by flow cytometry. 
During acquisition whole intact cells were gated for analysis based on side scatter and forward 
scatter characteristics. 
 
Cytochrome c release by immunoblot 
U937 cells (3 x 10
6
 cells in 2 mL RPMI) or SKW 6.4 cells (5 x 10
6
 cells in 2 mL RPMI) 
were treated with 10 μM 4150 for 10, 20, 30, 45 or 60 minutes in a 12-well plate. Cells were 
centrifuged (1000 x g. 2 min), washed with ice-cold PBS and resuspended in cold 200 μL 
digitonin permeabilization buffer (75 mM NaCl, 1 mM Sodium phosphate monobasic, 8 mM 
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sodium phosphate dibasic, 250 mM sucrose, 190 μg/mL digitonin, protease cocktail inhibitor, pH 
7.5) and placed on ice for 5 min. Cell permeability (> 95%) was confirmed by trypan blue. The 
permeabilized cells were centrifuged (14000 x g, 5 min) and 150 μL of supernatant (cytosolic 
fraction) was saved. The pellet (mitochondrial fraction) was washed in 200 μL digitonin 
permeabilization buffer and lysed in 25 μL RIPA lysis buffer. After normalizing samples for 
protein concentration, 40 µg cytosolic fraction and 50 µg mitochondrial fraction were resolved 
by electrophoresis on 4-20% SDS-Page gels and immunoblotted for Caspase-9 and cytochrome c 
respectively.  Cytosolic immunoblots were re-probed for actin while mitochondrial immunoblots 
were re-probed with CoxIV to confirm equal loading. For protection assays against cytochrome c 
release, cells were pre-treated with protective agents for 90 minutes and co-treated with 10 μM 
4150 for 30 minutes. The protective agents were used at the same concentration as listed in the 
annexin V/propidium iodide assays. 
 
In vitro cytochrome c release from isolated mitochondria 
U937 cells (120 x 10
6
) were washed twice in PBS and resuspended in 800 μL ice-cold 
lysis buffer (50 mM HEPES, 5 mM DTT, 5 mM PMSF, 25 mM MgCl2, protease cocktail 
inhibitor, pH 7.5) and the cells were passed through a 26 gauge needle 26 times using a 1mL 
syringe until >95% cells were lysed as determined by trypan blue. Isolation buffer (0.25 M 
sucrose in lysis buffer pH 7.5) was added to the lysed cells (2.4 mL) and mixed by inversion. 
Debris was removed by centrifugation (500 x g. 10 min at 4 ºC) and the mitochondria in the 
supernatant were pelleted by centrifugation (10000 x g, 5 min at 4 ºC). The mitochondrial pellet 
was resuspended in washing buffer (2 mL of 50 mM HEPES, 250 mM KCl, 25 mM EDTA, pH 
7.5) and incubated on ice for 2 min and centrifuged (12500 x g, 5 min). The mitochondrial pellet 
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was resupended in either non-respiration (300 μL of 50 mM HEPES, 5 mM DTT, 5 mM PMSF, 
25 mM MgCl2, protease inhibitor, 250 mM KCl, 25 mM EDTA, pH 7.5) or respiration buffer 
(300 μL of 50 mM HEPES, 1250 mM sucrose, 5 mM ATP, 0.4 mM ADP, 25 mM sodium 
succinate, 10 mM potassium phosphate dibasic, pH 7.5). The mitochondria were aliquoted into 
18 μL aliquots and 4150 or full length recombinant Bid protein (R&D systems) added to achieve 
a final volume of 20 μL. The samples were incubated in a 37 ºC water bath for 30 min and then 
the mitochondria were pelleted (16500 x g, 5 min at 4 ºC. The supernatant was saved (15 μL) 
and the pellet washed with washing buffer (100 μL), and finally lysed in RIPA lysis buffer (20 
μL) and debris removed by centrifugation. Supernatant and pellet lysates were loaded and run on 
SDS-PAGE gels and processed for immunoblotting of cytochrome c and CoxIV (loading 
control). Potentiation of Bid induced release was investigated by performing the experiment 
under non-respiring conditions and co-addition of 4150 and Bid to isolated mitochondria. 
 
MPTP calcein-cobalt assay 
U937 cells (1 x 10
6
 cells/mL in HBSS) were loaded with calcein-AM (20 nM final 
concentration) for 45 minutes at 37 ºC. The cells were washed with HBSS and resuspended in 
RPMI and plated into a 24-well plate (1 x 10
6
 cells in 1mL). The cells were treated with 4150 (10 
μM) for 15, 30, 45, 60 and 90 minutes. Cobalt(II) chloride was added (10 μL of 80 mM stock in 
HBSS) to the cells 10 minutes prior to the end of the time points. The cells were pelleted and 
resuspended in HBSS (0.5 mL) and calcein fluorescence was measured by flow cytometry. As a 
positive control for MPTP, ionomycin and calcium were added to calcein-labelled cells in HBSS 
10 minutes prior to analysis by flow cytometry.   
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Transmission electron microscopy 
U937 cells (4 mL of 5 x 10
5
 cells/ml) were treated with DMSO or 10 μM of 4150 for 5, 
30 and 60 minutes. The cells were centrifuged 400xg for 5 min and the media aspirated. The 
cells were fixed by the addition of Karnovsky‟s fixing solution (0.5 mL) and placed in a 4 ºC 
fridge overnight. The next day, the cells were microwave fixed, stained with 2% OsO4, washed 
with 3% KCN and enbloc stained with uranyl acetate. The samples were dehydrated with 
acetonitrile and ethanol, suspended in pure epoxy, and embedded overnight at 85 ºC. The 
embedded samples were cut into thick and then thin sections and these were mounted and 
viewed.  
 
Whole genome shRNA screen 
The GeneNet Human 50K Plasmid siRNA Library in pSIF1-H1-copGFP vector (200,000 
shRNA constructs targeting 47,400 transcripts) were packaged into pseudoviral FIV particles by 
transfecting HEK-293TN cells with the library and packaging vectors as per the manufacturer‟s 
instructions. The viral particles were isolated from the culture medium at 48 and 72 h by 
precipitation with PEG-IT as per the manufacturer‟s instructions. The viral pellet was 
resuspended in HBSS and stored at -80 ºC until further use. The amount of virus required to 
transduce MIA PaCa-2 cells at an appropriate multiplicity of infection (MOI). Once the 
conditions required to transduce cells at an MOI of 0.5-0.7 (40-50% GFP positive) were 
identified, the transduction was scaled up such that the library would be represented 100 fold. A 
total of 37.5 million MIA PaCa-2 cells were plated into 15 cm cell culture dishes (9.4 x10
6
 
cells/plate in 20 mL DMEM) 24 h prior to transdcution. Cells were transduced at 90% 
confluency with viral particles in DMEM containing 10 µg/mL polybrene. After 24 h of 
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incubation, the media was replaced and the cells expanded in culture for another 72 h and the % 
GFP-positive cells quantitated by flow cytotmetry. The cells were then pooled and 40 million 
cells in 160 mL DMEM were treated with 4150 (1.5 µM) or left untreated in 15 cm dishes. After 
2-3 days of drug treatment, cells were allowed to recover in drug-free medium. Three rounds of 
treatment (1.25-1.8 µM 4150) were performed over 20 days with at least 40 million cells being 
passaged after each round of treatment to maintain 100-fold library representation. At the end of 
the experiment, the cells were pooled and total RNA was isolated from 8 million cells using the 
Qiagen RNeasy kit without on-column DNAse digest. The RNA samples were submitted for 
Agilent Bioanalyzer quality control. After cDNA synthesis, the shRNA constructs were PCR 
amplified, biotinylated, lambda exonuclease treated (as per manufacturer‟s instructions) and 
hybridized to Affymetrix Human HG 133 Plus 2 microarrays.  
 
Covalent modification of proteins in vitro 
Horse heart myoglobin (from Sigma Aldrich, MO) was dissolved in 50 mM Tris buffer 
(pH 7.5) to a concentration of 3.3 mg/mL. For each sample, 20 µL of the myoglobin solution (80 
µg protein) was added to 0.5 µL of DMSO or 10 mM 4150. The samples were incubated at room 
temperature for 30 minutes and 1 µL of 25 mg/mL NaCNBH3 in DMSO was added (1 mg/mL 
final). After incubating overnight at room temperature, the protein was cleaned by TCA 
precipitation and subjected to ESI mass spectrometry. 
 
B16F10 tumor model 
B16F10 cells in HBSS (100 μL of 1 x 107 cells/mL) were injected subcutaneously into 
the right flank of shaved and sedated C57BL/6 female mice (6-8 weeks old). Seven days after 
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inoculation, the mice were randomized based upon tumor size with 7 mice per group. Vehicle or 
compound (20 mg/kg) was administered intraperitoneally as a corn oil DMSO suspension (300 
μL of 10% DMSO in trans fat-free corn oil) once daily for 3 consecutive days. Tumor 
measurements were performed every other day using a caliper and tumor volume was calculated 
using the equation (0.5 x l x w
2
).  On day 6 after the commencement of treatment, the mice were 
sacrificed as the average tumor volume in the control group had reached 1800 mm
3
. The tumors 
were then surgically removed and their mass measured.  
 
4T1 tumor model 
4T1 murine breast cancer cells in HBSS (100 μL of 1 x 107 cells/mL) were injected 
subcutaneously into the right flank of shaved and sedated Balb/c female mice (6-8 weeks old). 
Six days after inoculation, the mice were randomized based upon tumor size with 7 mice per 
group. Vehicle or compound (20 mg/kg ) was administered intraperitoneally as a corn oil DMSO 
suspension (300 μL of 10% DMSO in trans fat-free corn oil) once daily for 4 consecutive days. 
Tumor measurements were performed every other day using a caliper and tumor volume was 
calculated using the equation (0.5 x l x w
2
).  On day 7 after the commencement of treatment, the 
mice were sacrificed as the average tumor volume in the control group had reached 1000 mm
3
. 
The tumors were then surgically removed and their mass measured.  
 
Synthesis 
General 
Dry benzene, tetrahydrofuran and diethyl ether were obtained by passing over activated 
alumina columns or molecular sieves in a commercial solvent purification system (Innovative 
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Technologies). Tetraphenylethylene (F2), 9-fluorenemethanol (F11), fluorene-9-carboxylic acid 
(F10), 9-aminoacridine, acridine orange free base, cycloheximde, actinomycin D, antimycin A, 
rotenone, etoposide, daunorubicin, doxorubcin, cis-diammineplatinum(II) dichloride, 
sulforhodamine B sodium salt, 2,7-dichlorodihydrofluorescein diacetate, dihydroethidium, 
propidium iodide, pyridinium chlorochromate (PCC), trimethylbenzylammonium hydroxide 
(Triton B) were obtained from Sigma Aldrich. Compound F1, 9,9‟-difluorenyl, was obtained 
from City Chemicals. Compound F2, 9,9‟-bifluorene, was obtained from Matheson Coleman & 
Bell. 
 
Compound analysis 
All NMR experiments were recorded in CD2Cl2 (Sigma), CDCl3 (Sigma), DMSO-d6 
(Cambridge Isotope Laboratories) on a Varian Unity 400 MHz or 500 MHz spectrometer with 
residual undeuterated solvent as the internal reference. Chemical shift, δ (ppm); coupling 
constants, J (Hz); multiplicity (s = singlet, d = doublet, t = triplet, q = quintet, m = multiplet); 
and integration are reported. High-resolution mass spectral data was recorded on a Micromass Q-
Tof Ultima hybrid quadrupole/time-of-flight ESI mass spectrometer at the University of Illinois 
Mass Spectrometry Laboratory.  
 
Synthesis of 4150 
1 eq. KOt-Bu
1 eq. Ethyl Formate
CHO
CHO
OHC
Diethyl Ether
4 h reflux
25 %
Diethyl Ether
2 h reflux
50 %
SOCl2
4150  
Scheme 2.1. 
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Synthesis of 4150 was achieved by formylation of fluorene to yield 9-formylfluorene 
which was then refluxed in ether in the presence of SOCl2 yielding the dimer, 4150, according to 
the procedure described in the literature.
133
  
 
Synthesis of F4 and F5 
OHOH
HO
+
Triton B
6 eq. Paraformaldehyde
F5
8 %
F4
63 %
Pyridine
2 h 25 oC
F1
 
Scheme 2.2. 
Treatment of F1 with trimethylbenzylammonium hydroxide (Triton B) and excess 
paraformalydehyde in pyridine yielded F4 and F5 by the procedure described in the literature.
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Synthesis of F6 
OH
F5
1.5 equiv. PCC
CHO
F6
CH2Cl2, reflux 3h
95 %
 
Scheme 2.3. 
The compound F5 (100 mg, 0.277 mmol) was dissolved in CH2Cl2 (10 ml) in a 40 ml 
reaction vessel. Pyridinium chlorochromate (PCC) was added (119.6 mg, 0.555 mmol, 2 equiv.) 
and the reaction heated at reflux for 1.5 h. Diethyl ether (20 ml) was added and the organic layer 
separated from the PCC tar. This extraction was repeated 3 times. The combined organic layers 
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were run through a florisil column (pre-conditioned with hexanes) using ethyl acetate as the 
eluent. The solvent was removed in vacuo to yield F6 as a yellow oil (94.5 mg, 95 % yield). 
 
Synthesis of F3 
Na (s), CO2 (g)
CO2HHO2C52 %
F3F2  
Scheme 2.4. 
The compound F3 was synthesized according to the procedure described in the literature.
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Synthesis of F7 
Na (s), CO2 (g) CO2HHO2C
41 %
F7 F9  
Scheme 2.5. 
Tetraphenylsuccinic acid, F7, was prepared according to the procedure described in the 
literature.
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CHAPTER 3. TRIPHENYLMETHYLAMIDES: STRUCTURE-ACTIVITY-
RELATIONSHIP OF COMPOUNDS THAT INDUCE APOPTOSIS IN 
MELANOMA 
 
The information and contents for this chapter were reproduced in part with permission from 
Palchaudhuri, R.; Hergenrother, P. J. "Structure-Activity-Relationship of 
Triphenylmethylamides, Compounds that Potently Induce Apoptosis in Melanoma Cell Lines" 
Bioorg. Med. Chem. Lett. 2008, 18, 5888-5891. 
 
3.1 Introduction 
Metastatic melanoma is a particularly aggressive form of cancer that is resistant to 
standard anti-cancer therapies.  If identified early, melanoma (Stage I/II) primary tumors can be 
surgically resected with a > 95% success rate.
1
  In contrast, late-stage (Stage IV) metastatic 
melanoma is one of the most deadly forms of cancer, with the median survival of patients with 
distant metastases being 7-8 months.
2
  The current standard of care for patients with late-stage 
melanoma is dacarbazine/temozolomide chemotherapy or immunotherapy involving interleukin-
2/interferon-α.3-5 Few patients respond positively to these treatments; sometimes tumor shrinkage 
is observed for a few months, after which tumor growth typically resumes.
5, 6
 Drugs that target 
rapidly dividing cells by interfering with DNA synthesis (S-phase arrest) or mitosis (M-phase 
arrest) such as taxol, etoposide, cisplatin, and doxorubicin have failed to demonstrate efficacy in 
large randomized trials with melanoma patients.
7
 The resistance to DNA-targeted therapy may 
be due to down regulation of DNA mismatch repair enzymes in melanoma.
8
 Additionally, 
elevated levels of survivin, a protein that assists mitotic spindle formation permitting the evasion 
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of the G2/M checkpoint, may allow melanoma to resist the effects anti-mitotics.
9, 10
  Given these 
characteristics, we hypothesized that compounds inducing arrest in the G1-phase of the cell cycle 
might prove to be effective for the treatment of certain melanomas (and other cancers).
11, 12
  
Towards this end, we recently identified the triphenylmethylamides (TPMAs) as a novel class of 
molecules that induce G1-phase arrest and apoptosis in several human melanoma cell lines in 
culture.
11
 Two representative TPMAs, 4A and 4BI, are shown in Figure 3.1.  These compounds 
also reduce cellular levels of the transcription factor NFκB in melanoma cell lines in culture.11, 12  
In addition, the compound 4BI is relatively non-toxic against bone marrow cells from healthy 
human donors,
11
 and [
11
C]labeled TPMAs have been synthesized for positron emission 
tomography (PET) imaging.
13
 While the functionality on the nitrogen side of the amide has little 
influence on the potency of the TPMAs (amides based on phenethylamine, 4-methoxy-
phenylamine, and 2-(3-methoxy-phenyl)-ethylamine are all potent inducers of apoptosis), the 
triphenylmethyl moiety is critical to activity as the diphenylmethylamides are largely inactive.
11
  
In order to further optimize the antiproliferative properties of this class of compounds, we 
investigated modifications on the triphenylmethyl portion of the molecule. 
 
Figure 3.1. The TPMAs 4A and 4BI were previously identified as potent inducers of cell death in human 
melanoma cell lines in cell culture. 
 
3.2 Library synthesis and evaluation in cell culture 
The study was performed through synthesis of derivatives with functionalized 
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triphenylmethyl moieties and extensions of the carbon chain between the triphenylmethyl moiety 
and the amide.  Various triphenylmethyl-containing carboxylic acids were prepared (as described 
in the materials and methods) and coupled with phenethylamine or D-phenylalanine methyl ester 
using benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP)-mediated 
coupling reactions (Chart 3.1).  
 
Chart 3.1. Synthesis and biological evaluation of TPMA phenethylamine (A) and D-phenylalanine (BI) 
derivatives with functionalized triphenylmethyl groups and varying carbon chain lengths between the 
triphenylmethyl motif and amide. The values for phenethylamine derivatives are italicized while those for 
D-phenylalanine derivatives are in parenthesis.  Compounds 4A and 4BI were synthesized as previously 
reported.
11
  Biomass was assessed by the sulforhodamine B assay after 72 h incubation in the presence 
of compound.  Average IC50 values and standard deviations were determined from three independent 
experiments.
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The desired TPMA derivatives were obtained in moderate to excellent yields (72% average 
yield).  The compounds were named based on the triphenylmethyl (first number), the number of 
methylenes between the triphenylmethyl and the amide (second number), and whether they were 
derivatives of phenethylamine or D-phenylalanine (A or BI).  The TPMA derivatives were 
evaluated against two human melanoma cell lines, SK-MEL-5 and UACC-62 in cell culture 
assays that involved co-incubation of cells with various doses of compound for 72 hours, at 
which time growth inhibition was assessed by quantification of biomass using the 
sulforhodamine B assay.
14
 To obtain the IC50 values, the compounds were assessed by three 
independent experiments and the average IC50 values and standard deviations were determined.  
The results obtained (Chart 3.1) demonstrate that introduction of functional diversity in 
the triphenylmethyl group considerably affects the cell culture potency of the TPMAs.  With the 
exception of 5-0-A, the more hydrophilic hydroxyl-bearing TPMAs (such as 4-0-A, 4-0-BI, 6-0-
A, 6-0-BI, 7-0-A and 7-0-BI) were less potent than the parent unfunctionalized TPMAs 4A and 
4BI.  
It was also noted that methyl ether substituted TPMAs, 1-0-A and 1-0-BI, were slightly 
less potent than the parent TPMAs 4A and 4BI that do not possess methyl-ether functionality.  
Systematically increasing the number of methyl ether substitutions resulted in a progressive 
reduction in potency as evidenced by 2-0-A, 2-0-BI, 3-0-A and 3-0-BI.  TPMAs 9-0-A and 9-0-
BI which bear conformationally rigid triphenylmethyl motifs were as much as 4-fold less active 
than parent compounds 4A and 4BI, highlighting the requirement for flexibility in the 
triphenylmethyl motif.  Replacement of one of the phenyls of the triphenyl with a 2-thiophene 
(8-0-BI and 8-0-A) modestly decreased the potency.  Surprisingly, increasing the length of the 
carbon chain between the triphenylmethyl and the amide group (10-1-BI, 10-2-A, 10-2-BI, 10-3-
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A and 10-3-BI) selectively reduced potency against UACC-62 cells whereas activity against SK-
MEL-5 cells remained unaltered.  
 
3.3 TPMA derivatives induce G1-phase cell cycle arrest 
In order to determine whether the novel TPMA derivatives share a similar mode of action 
to the parent TPMAs 4A and 4BI we assessed the most potent compounds for their ability to 
induce cell cycle arrest.  Rapidly dividing HL-60 cell line (human leukemia) were treated with 
20 μM compound for 6 hours, after which the cells were fixed, RNase treated and stained with 
propidium iodide to assess DNA content. The cells were analyzed by cell flow cytometry to 
determine the percentage of the cell population in various phases of the cell cycle. As shown in 
Figure 3.2, the TPMAs 1-0-A, 2-0-A, 5-0-A and 10-3-A all induce G0/G1-phase arrest, similar 
to the parent TPMAs 4A and 4BI with as much as a 10% increase in G0/G1-phase being induced 
.  
0
10
20
30
40
50
60
70
Control 4A 4BI 1-0-A 2-0-A 5-0-A 10-3-A
%
 o
f 
C
e
ll
 P
o
p
u
la
ti
o
n
G0/G1
S
G2/M
Figure 3.2. Cell cycle analysis of HL-60 cells treated with various TPMAs. Cells were incubated for 6 h 
incubation in the presence of 20 μM compound, and then analyzed by propidium iodide staining and cell 
flow cytometry. Control indicates cells treated with vehicle only. 
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3.4 TPMAs induce apoptosis 
The most potent TPMA 5-0-A identified from the library was evaluated for its ability to 
induce apoptosis. A hallmark of apoptosis is the externalization of phosphatidylserine prior to the 
disruption of cell membrane integrity. Using cell flow cytometry, phosphatidylserine 
externalization and cell membrane integrity were simultaneously assessed by the binding of 
FITC-conjugated Annexin V to phosphatidylserine and exclusion of propidium iodide 
respectively. As shown in Figure 3.3, U-937 human lymphoma cells treated for 48 hours with 
100 μM of TPMA 5-0-A show a large number of cells in the early apoptotic quadrant (lower 
right; Annexin V positive/propidium iodide negative) which are diagnostic of cells with 
phosphatidyl serine exposure without compromised cell membranes. This data demonstrates 
TPMA 5-0-A-induces apoptosis which likely results after the induction of G0/G1-phase arrest. 
  
 
Figure 3.3.  The TPMA 5-0-A induces cell death via apoptosis. U-937 cells were treated with vehicle (left) 
or 100 μM 5-0-A (right) for 48 h, and the cell populations were quantified using FITC-conjugated Annexin 
V and propidium iodide staining together with cell flow cytometry. 
 
 
3.5 TPMAs demonstrate broad spectrum anti-cancer activity 
The ability of TPMAs 4A, 4BI, 5-0-A and 10-2-BI to induce anti-cancer effects against 
cancers other than melanoma were assessed in cell culture using leukemia, lymphoma, breast and 
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adrenal cancer cell lines. As shown in Table 3.1, the TPMAs exhibited potent anti-proliferative 
activity against leukemia, lymphoma, and breast cancer cell lines in addition to melanoma 
demonstrating their broad spectrum efficacy. In comparison, the PC-12 rat adrenal cancer cell 
line was found to be fairly resistant to the general effects of the TPMAs with the TPMA 5-0-A 
however, being the most potent (IC50 = 16   4 μM). 
Table 3.1. Evaluation of TPMAs 4A, 4BI, 5-0-A and 10-2-BI against various cancer cell lines in culture. 
Cells were incubated in the presence of compound for 72 h and cell growth/viability was assessed as 
described in the materials and methods. Average IC50 values and standard deviations were determined 
from 3 independent experiments. 
 
 
 
3.6 Conclusions and outlook 
Triphenylmethylamides (TPMAs) show promise as anti-cancer agents against human 
melanoma and other cancer cell lines in culture.  Introduction of 3,4-dihydroxy functionality on 
the triphenylmethyl moiety modestly increased the potency but also increased the aqueous 
solubility; the solubility of compound 5-0-A in phosphate-buffered saline (PBS, pH 7.4) is 
approximately 80 μM, compared to approximately 20 μM for 4BI.  Compounds having an 
extension of the carbon chain length between the triphenylmethyl motif and the amide, such as 
10-2-BI, showed similar abilities in inducing cell death in SK-MEL-5 cells as 4A and 4BI.  This 
work adds to a growing body of literature showing that a variety of compounds possessing the 
triphenylmethyl group induce death in cancer cells, albeit by diverse mechanisms.
11, 12, 15-23
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While the biological target of the TPMAs remains unknown, the structure-activity-relationship 
described herein may prove useful for further optimization and development of triphenylmethyl-
containing anti-cancer agents. 
 
3.7 Materials and methods 
General  
Dry dichloromethane was obtained by distillation over P2O5 under a dry nitrogen 
atmosphere. PyBOP was purchased from Novabiochem. Di-isopropylethylamine (DIPEA), 1 M 
BBr3 in CH2Cl2, triphenylacetic acid, triphenylpropionic acid, D-phenylalanine methyl ester 
hydrochloride, p-anisylchlorodiphenylmethane, phenazine methosulfate and sulforhodamine B 
sodium salt were obtained from Sigma Aldrich. Phenethylamine was purchased from Acros 
Organic. FITC-conjugated Annexin V was obtained from SouthernBiotech and 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt was 
obtained from Promega Incorporated. 
 
Compound Analysis.  
All NMR experiments were recorded in CD2Cl2 (Sigma), CDCl3 (Sigma), or Acetone-d6 
(Sigma) on a Varian Unity 400 MHz or 500 MHz spectrometer with residual undeuterated 
solvent as the internal reference. Chemical shift, δ (ppm); coupling constants, J (Hz); multiplicity 
(s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet); and integration are reported. 
High-resolution mass spectral data was recorded on a Micromass Q-Tof Ultima hybrid 
quadrupole/time-of-flight ESI mass spectrometer at the University of Illinois Mass Spectrometry 
Laboratory.  
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Synthesis of Acids 
The acids 4,4’-dimethoxytriphenylacetic acid (2-0-Ac), 4,4’,4’’-
trimethoxytriphenylacetic acid (3-0-Ac), 3,4-dihydroxytriphenylacetic acid (5-0-Ac) and 
4,4’-dihydroxytriphenylacetic acid (6-0-Ac) were prepared as previously described.24 
 
Diphenyl-2-thiophenyl acetic acid (8-0-Ac) was prepared as previously described.
25
  
 
9-Phenyl-fluorene-9-carboxylic acid (9-0-Ac) was prepared as previously described.
26
 
 
Synthesis of 4-methoxytriphenylacetic acid (1-0-Ac).  
To a 25 mL 3-neck flask containing dry THF under argon was added lithium metal (104 
mg, 14.98 mmol, 9.25 equiv.) cut into small pieces and p-anisylchlorodiphenylmethane (500 mg, 
1.62 mmol). A spatula was used to scrape a new surface on the lithium to initiate the reaction 
which was then allowed to proceed protected from light with vigorous stirring for 18 h at 25 ºC. 
The deep red solution was transferred via canula to a dry 50 mL round bottom flask under argon 
and dry CO2 gas (Matheson Tri-Gas) was bubbled through the solution for a period of 15 min. 
Dichloromethane (20 mL) was added and the product was extracted into 5% Na2CO3 solution (4 
x 50 mL). The basic extracts were combined, filtered and acidified with conc. HCl. The 
precipitate thus obtained was filtered, washed with water, and dried in vacuo to yield the desired 
product 4-methoxytriphenylacetic acid (327 mg, 1.03 mmol, 64% yield) as a white solid. The 
product was identical to that described previously.
24
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Synthesis of 4-hydroxytriphenylacetic acid (4-0-Ac).  
To 1 M BBr3 in CH2Cl2 (2.9 ml, 2.9 mmol, 2.3 equiv.) cooled to -78 ºC in a 25 mL 3-
neck flask under argon was added 4-methoxytriphenylacetic acid (400 mg, 1.256 mmol 
dissolved in 10 mL CH2Cl2) drop wise over a period of 5 min. The flask was allowed to warm to 
room temperature over a period of 3.5 h and stirred at ambient temperature for 20 h. Water (25 
mL) was added and resulting yellow precipitate was filtered, dissolved in diethyl ether (50 mL) 
and then extracted into 10% NaOH (5 x 10 mL). The basic extracts were combined, acidified 
with HCl, and the isolated yellow precipitate was dried in vacuo to yield 4-
hydroxytriphenylacetic acid (212 mg, 0.697 mmol, 55% yield). The product was identical to 
that described previously.
24
 
 
Synthesis of 4,4’,4’’-trihydroxytriphenylacetic acid (7-0-Ac).  
To a 1 M BBr3 solution in CH2Cl2 (4.8 mL, 4.8 mmol, 4.54 equiv.) cooled to -78 ºC in a 
50 mL 3-neck flask under argon was added 4,4’,4’’-trimethoxytriphenylacetic acid24 (400 mg, 
1.057 mmol dissolved in 6 mL dry CH2Cl2) over a period of 5 min. The reaction was warmed to 
room temperature over a period of 4 h and stirred for 20 h at 25 ºC, after which the product was 
isolated in a manner analogous to that described for 4-hydroxytriphenylacetic acid. This 
method yielded 4,4’,4’’-trihydroxytriphenylacetic acid (216.7 mg, 0.644 mmol, 61%) as an 
orange solid.  
NMR 
1
H (500 MHz, Acetone-d6) δ ppm: 11.22 (s, 1H); 8.29 (s, 3H); 7.02 (d, 6H, J=8.8Hz); 
6.74 (d, 6H, J=8.9Hz). 
NMR 
13
C (126 MHz, Acetone-d6) δ ppm: 176.706; 157.761; 136.979; 133.195; 115.947; 
66.888. 
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Synthesis of triphenylpentanoic acid (10-3-Ac).  
In a 100 mL 3-neck flask charged with 1.26 ml (3.792 mmol) of a 3 M solution of CrO3 
in H2SO4 was added a solution of 5,5,5-triphenylpentanol
27
 (300 mg, 0.948 mmol in 30 mL 
acetone) drop wise over a period of 2 h. After 12 h of stirring at room temperature, 100 mL of 
diethyl ether was added and the solution was washed with water (3 x 50mL) and brine (50 mL). 
The acid was then extracted with 10% NaOH (3 x 20 mL) and the basic extracts were combined 
and acidified with HCl. The resulting precipitate was filtered and dried in vacuo to yield 
triphenylpentanoic acid (299 mg, 0.904 mmol, 95% yield) as a white solid. 
NMR 
1
H (500 MHz, CD2Cl2) δ ppm: 7.28-7.17 (m, 15H) 2.61 (m, 2H) 2.34 (t, 2H, J=7.3Hz) 
1.37 (m, 2H)  
 
Synthesis of triphenylbutanoic acid (10-2-Ac).  
The alcohol, triphenylbutanol
28
 (133.7 mg, 0.442 mmol) was oxidized using a method 
analogous to the preparation of R3Ac to yield 4,4,4-triphenylbutanoic acid (120.3 mg, 0.380 
mmol, 86% yield) as a white solid. The product obtained was identical to that previously 
reported.
29
  
 
Synthesis of the Triphenylmethylamide (TPMA) Library.   
A library of 24 amides was generated in parallel by coupling 1-0-Ac, 2-0-Ac, 3-0-Ac, 4-
0-Ac, 5-0-Ac, 6-0-Ac, 7-0-Ac, 8-0-Ac, 9-0-Ac, 10-1-Ac, 10-2-Ac and 10-3-Ac with either 
phenethylamine or D-phenylalanine methyl ester. In each case, into a 5 mL scintillation vial was 
placed 0.1 mmol carboxylic acid and 0.12 mmol PyBOP (1.2 equiv.). A stock solution 
containing 0.07 M amine and 0.11 M di-isopropylethyl amine (DIPEA) in dry CH2Cl2 was 
prepared and 2 mL (1.4 equiv. amine and 2.2 equiv. DIPEA) was added to each scintillation vial. 
 
 
129 
 
The reactions were stirred at 25 ºC for 12 h under a N2 atmosphere. The coupling products of 1-
0-Ac, 2-0-Ac, 3-0-Ac, 4-0-Ac, 8-0-Ac, 9-0-Ac, 10-1-Ac, 10-2-Ac and 10-3-Ac were purified by 
column chromatography on silica using 50:50 ethyl acetate/hexanes as the eluent. The coupling 
products of  5-0-Ac, 6-0-Ac and 7-0-Ac were purified by column chromatography on silica using 
ethyl acetate as the eluent. The compounds were synthesized in 72% average yield with the 4-0-
A/BI, 7-0-A/BI and 5-0-A TPMAs being low yielding (20 to 61%). No coupling product (5-0-
BI) could be obtained for the reaction between 5-0-Ac and D-phenylalanine methyl ester. The 
compounds 4A and 4BI were synthesized as previously described.
11
 
 
Triphenylmethylamide 1-0-A 
NMR 
1
H (126 MHz, Acetone-d6) δ ppm: 7.28-7.23 (m, 9H); 7.22-7.17 (m, 5H); 7.13 (d, 1H, 
J=6.9Hz); 6.81 (d, 1H, J=9.0Hz); 3.78 (s, 3H); 3.56 (dd, 2H, J=7.0Hz, J=12.9Hz); 2.80 (t, 2H, 
J=7.1Hz). 
NMR 
13
C (126 MHz, Acetone-d6) δ ppm: 174.413; 160.224; 146.174; 141.301; 137.599; 
133.505; 132.312; 130.587; 130.239; 129.413; 128.384; 127.976; 114.757; 68.694; 56.438; 
43.086; 36.983. 
HRMS (ESI): found: 422.2123 (M+H); calculated for C29H28NO2: 422.2120. 
Yield: 81% 
 
Triphenylmethylamide 1-0-BI 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.22 (m, 9H); 7.14 (m, 4H); 7.05 (d, 2H, J=9.0Hz); 6.90 
(dd, 2H, J=1.4Hz, J=7.7Hz); 6.76 (d, 2H, J=9.0Hz); 6.16 (d, 1H, J=7.4Hz); 4.95 (dt, 1H, 
J=5.2Hz, J=7.7Hz); 3.79 (s, 3H); 3.72 (s, 3H)‟ 3.02 (ddd, 2H, J=6.5Hz, J=14.0Hz, J=21.9Hz). 
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NMR 
13
C (126 MHz, CDCl3) δ ppm: 173.390; 171.924; 158.272; 143.279; 135.691; 135.005; 
131.616; 130.385; 128.955; 128.674; 127.835; 127.030; 126.876; 113.144; 66.830; 55.180; 
53.768; 52.295; 37.558. 
HRMS (ESI): found: 480.2166 (M+H); calculated for C31H30NO4: 480.2175. 
Yield: 68% 
 
Triphenylmethylamide 2-0-A 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.24 (m, 6H); 7.17 (m, 2H); 7.07 (d, 4H, J=8.3Hz); 7.04 (d, 
2H, J=7.2Hz); 6.78 (d, 4H, J=8.3Hz); 5.887 (s, 1H) 3.79 (s, 6H); 3.61 (dd, 2H, J=6.3Hz, 
J=12.8Hz); 2.78 (t, 2H, J=6.8Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 173.775; 158.170; 143.750; 138.534; 135.461; 131.409; 
130.170; 128.592; 128.511; 127.761; 126.733; 126.326; 113.068; 66.285; 55.122; 41.154; 
35.245. 
HRMS (ESI): found: 452.2223 (M+H); calculated for C30H30NO3: 452.2226. 
Yield: 100% 
 
Triphenylmethylamide 2-0-BI 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.22 (m, 6H); 7.15 (m, 2H); 7.06 (d, 4H, J=8.9Hz); 6.92 (d, 
2H, J=7.2Hz); 6.77 (d, 4H, J=8.9Hz); 6.18 (d, 1H, J=7.5Hz); 4.95 (dt, 1H, J=5.3Hz, J=7.7Hz); 
3.79 (s, 6H); 3.73 (s, 3H); 3.14 (dd, 1H, J=5.1Hz, J=14.1Hz); 2.93 (dd, 1H, J=7.9Hz, J=14.1Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 173.645; 171.912; 158.199; 143.549; 135.661; 135.266; 
131.484; 130.247; 128.918; 128.622; 127.760; 126.981; 126.767; 113.074; 66.101; 55.131; 
53.706; 52.245; 37.507. 
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HRMS (ESI): found: 510.2285 (M+H); calculated for C32H32NO5: 510.2280. 
Yield: 75% 
 
Triphenylmethylamide 3-0-A 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.23 (m, 3H); 7.07 (m, 8H); 6.78 (d, 6H, J=8.6Hz); 5.86 (t, 
1H, J=5.3Hz); 3.79 (s, 9H); 3.61 (dd, 2H, J=6.3Hz, J=12.8Hz); 2.79 (t, 1H, J=6.8Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 173.867; 158.101; 138.596; 135.841; 131.315; 128.595; 
128.478; 126.288; 113.004; 65.545; 55.109; 41.089; 35.283. 
HRMS (ESI): found: 482.2333 (M+H); calculated for C31H32NO4: 482.2331. 
Yield: 98% 
 
Triphenylmethylamide 3-0-BI 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.22 (m, 3H); 7.05 (dd, 6H, J=1.2Hz, J=8.6Hz); 6.93 (d, 
2H, J=7.5Hz); 6.76 (dd, 6H, J=1.2Hz, J=8.7Hz); 6.17 (d, 1H, J=7.4Hz); 4.94 (m, 1H); 3.79 (m, 
9H); 3.73 (m, 3H); 3.13 (dd, 1H, J=5.1Hz, J=14.0Hz); 2.93 (dd, 1H, J=8.0Hz, J=14.0Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 174.228; 172.259; 158.465; 135.982; 135.885; 131.695; 
129.231; 128.923; 127.283; 113.344; 65.706; 55.436; 53.984; 52.547; 37.806. 
HRMS (ESI): found: 540.2382 (M+H); calculated for C33H34NO6: 540.2386. 
Yield: 83% 
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Triphenylmethylamide 4-0-A 
NMR 
1
H (500 MHz, Acetone-d6) δ ppm: 1H-NMR (499 MHz) 8.48 (s, 1H); 7.23 (m, 15H); 6.96 
(d, 2H, J=8.8Hz); 6.72 (d, 2H, J=8.8Hz); 3.56 (dd, 2H, J=7.0Hz, J=12.9Hz); 2.81 (t, 2H, 
J=7.1Hz). 
NMR 
13
C (126 MHz, Acetone-d6) δ ppm: 174.603; 157.981; 146.314; 141.304; 136.331; 
133.555; 132.324; 130.585; 130.231; 129.342; 128.302; 127.965; 116.317; 68.682; 43.110; 
36.994. 
HRMS (ESI): found: 408.1975 (M+H); calculated for C28H26NO2: 408.1964. 
Yield: 57% 
 
Triphenylmethylamide 4-0-BI 
NMR 
1
H (500 MHz, CD2Cl2) δ ppm: 7.23 (m, 9H); 7.11 (m, 4H); 6.95 (d, 2H, J=8.9Hz); 6.91 
(dd, 2H, J=2.0Hz, J=7.4Hz); 6.66 (d, 2H, J=9.0Hz); 6.19 (d, 1H, J=7.6Hz); 4.88 (dt, 1H, 
J=5.1Hz, J=7.7Hz); 3.71 (s, 3H); 3.13 (dd, 1H, J=5.1Hz, J=14.0Hz); 2.93 (dd, 1H, J=7.8Hz, 
J=14.1Hz). 
NMR 
13
C (126 MHz, CD2Cl2) δ ppm: 173.782; 172.354; 155.317; 143.909; 136.422; 135.416; 
132.310; 130.906; 129.542; 129.198; 128.376; 127.571; 127.435; 115.165; 67.453; 54.392; 
52.804; 37.951. 
HRMS (ESI): found: 466.2022 (M+H); calculated for C30H28NO4: 466.2018. 
Yield: 20% 
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Triphenylmethylamide 5-0-A 
NMR 
1
H (500 MHz, Acetone-d6) δ ppm 7.91 (m, 1H); 7.87 (s, 1H); 7.20 (m, 15H); 6.71 (d, 1H, 
J=8.4Hz); 6.66 (d, 1H, J=2.3Hz); 6.52 (s, 1H); 6.45 (dd, 1H, J=2.4Hz, J=8.4Hz); 3.55 (dd, 2H, 
J=7.1Hz, J=12.9Hz); 2.81 (t, 2H, J=7.1Hz). 
NMR 
13
C (126 MHz, Acetone-d6) δ ppm: 174.537; 165.094; 146.362; 145.819; 141.350; 
137.161; 132.383; 130.580; 130.248; 129.259; 128.257; 127.970; 124.110; 120.050; 116.292; 
68.759; 43.177; 37.100. 
HRMS (ESI): found: 424.1929 (M+H); calculated for C28H26NO3: 424.1913. 
Yield: 45% 
 
Triphenylmethylamide 6-0-A 
NMR 
1
H (500 MHz, Acetone-d6) δ ppm 8.40 (s, 1H); 7.22 (m, 8H); 7.14 (m, 2H); 6.98 (d, 4H, 
J=8.8Hz); 6.72 (d, 4H, J=8.9Hz); 6.47 (m, 1H); 3.56 (dd, 2H, J=7.1Hz, J=12.9Hz); 2.81 (t, 2H, 
J=7.1Hz). 
NMR 
13
C (126 MHz, Acetone-d6) δ ppm: 175.089; 157.830; 146.770; 141.284; 136.818; 
133.466; 132.235; 130.577; 130.212; 129.214; 128.126; 127.945; 116.186; 67.951; 43.095; 
37.010. 
HRMS (ESI): found: 424.1927 (M+H); calculated for C28H26NO3: 424.1913. 
Yield: 73% 
 
Triphenylmethylamide 6-0-BI 
NMR 
1
H (500 MHz, Acetone-d6) δ ppm 8.37 (s, 2H); 7.24 (m, 6H); 7.16 (m, 2H); 7.05 (dd, 2H, 
J=1.9Hz, J=7.4Hz); 6.93 (dd, 4H, J=7.6Hz, J=8.8Hz); 6.70 (dd, 4H, J=2.5Hz, J=8.9Hz); 6.51 (d, 
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1H, J=7.6Hz); 4.84 (dt, 1H, J=5.0Hz, J=8.2Hz); 3.70 (s, 3H); 3.16 (dd, 1H, J=5.0Hz, J=14.0Hz); 
3.01 (dd, 1H, J=8.4Hz, J=14.0Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 174.812; 172.164; 154.849; 143.241; 135.214; 134.328; 
131.448; 130.189; 128.859; 128.777; 127.910; 127.181; 126.889; 114.914; 66.409; 53.952; 
52.590; 37.393. 
HRMS (ESI): found: 482.1984 (M+H); calculated for C30H28NO5: 482.1967. 
Yield: 71% 
 
Triphenylmethylamide 7-0-A 
NMR 
1
H (500 MHz, Acetone-d6) δ ppm:  8.35 (s, 3H); 7.19 (m, 5H); 6.98 (d, 6H, J=8.7Hz); 
6.70 (d, 6H, J=8.7Hz); 6.44 (d, 1H, J=5.1Hz); 3.54 (dd, 2H, J=6.9Hz, J=13.0Hz); 2.80 (t, 2H, 
J=7.1Hz). 
NMR 
13
C (126 MHz, Acetone-d6) δ ppm: 175.454; 157.702; 141.331; 137.352; 133.391; 
130.585; 130.208; 127.935; 116.050; 67.215; 43.077; 37.054. 
HRMS (ESI): found: 440.1876 (M+H); calculated for C28H26NO4: 440.1862. 
Yield: 61% 
 
Triphenylmethylamide 7-0-BI 
NMR 
1
H (500 MHz, Acetone-d6) δ ppm:  8.34 (s, 3H); 7.25 (s, 3H); 7.05 (dd, 2H, J=1.7Hz, 
J=7.5Hz); 6.94 (d, 6H, J=8.8Hz); 6.69 (d, 1H, J=8.8Hz); 6.49 (d, 1H, J=7.5Hz); 4.83 (dt, 1H, 
J=5.0Hz, J=8.1Hz); 3.69 (s, 3H); 3.15 (dd, 1H, J=5.0Hz, J=13.9Hz); 3.01 (dd, 1H, J=8.4Hz, 
J=14.0Hz). 
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NMR 
13
C (126 MHz, Acetone-d6) δ ppm: 175.474; 173.558; 157.792; 138.565; 137.025; 
133.438; 131.012; 130.316; 128.586; 116.084; 67.074; 55.784; 53.322; 38.684. 
HRMS (ESI): found: 498.1922 (M+H); calculated for C30H28NO6: 498.1917. 
Yield: 42% 
 
Triphenylmethylamide 8-0-A 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.27 (m, 10H); 7.07 (m, 6H); 6.93 (dd, 1H, J=3.7Hz, 
J=5.2Hz); 6.62 (dd, 1H, J=1.2Hz, J=3.6Hz); 5.90 (t, 1H, J=4.6Hz); 3.66 (dd, 2H, J=6.8Hz, 
J=12.6Hz); 2.83 (t, 2H, J=6.8Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 173.211; 147.207; 143.201; 138.414; 129.455; 129.045; 
128.598; 128.071; 127.474; 126.991; 126.428; 125.196; 65.252; 41.303; 35.190. 
HRMS (ESI): found: 398.1582 (M+H); calculated for C26H24NOS: 398.1579. 
Yield: 89% 
 
Triphenylmethylamide 8-0-BI 
NMR 
1
H (500 MHz, CD2Cl2) δ ppm: 7.27 (m, 10H); 7.13 (m, 2H); 6.95 (m, 5H); 6.62 (dd, 1H, 
J=1.3Hz, J=3.7Hz); 6.22 (d, 1H, J=7.3Hz); 4.92 (dt, 1H, J=5.2Hz, J=7.6Hz); 3.73 (m, 3H); 3.08 
(ddd, 2H, J=6.4Hz, J=14.0Hz, J=21.7Hz). 
NMR 
13
C (126 MHz, CD2Cl2) δ ppm: 173.483; 172.184; 147.644; 143.715; 136.350; 130.223; 
130.082; 129.583; 129.261; 128.652; 128.155; 127.650; 127.484; 125.952; 65.667; 54.434; 
52.838; 37.886;  
HRMS (ESI): found: 456.1643 (M+H); calculated for C28H26NO3S: 456.1633. 
Yield: 74% 
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Triphenylmethylamide 9-0-A 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.78 (d, 2H, J=7.6Hz); 7.49 (d, 2H, J=7.6Hz); 7.42 (dt, 2H, 
J=1.0Hz, J=7.5Hz); 7.29 (m, 2H); 7.22 (m, 5H); 7.06 (m, 2H); 6.97 (m, 2H); 5.71 (m, 1H). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 171.717; 146.585; 142.107; 140.574; 138.534; 128.714; 
128.536; 128.419; 128.400; 128.154; 127.254; 126.948; 126.364; 126.118; 120.249; 68.225; 
40.827; 35.329. 
HRMS (ESI): found: 390.1852 (M+H); calculated for C28H24NO: 390.1858. 
Yield: 99% 
 
Triphenylmethylamide 9-0-BI 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.78 (dd, 1H, J=7.5Hz, J=15.1Hz); 7.55 (d, 1H, J=7.6Hz); 
7.45 (m, 2H); 7.39 (dt, 1H, J=1.1Hz, J=7.5Hz); 7.33 (dt, 1H, J=1.1Hz, J=7.5Hz); 7.19 (m, 5H); 
7.09 (m, 4H); 6.69 (d, 2H, J=6.9Hz); 6.14 (d, 1H, J=7.7Hz); 4.82 (td, 1H, J=5.8Hz, J=7.8Hz); 
3.67 (s, 3H); 2.95 (dq, 1H, J=5.8Hz, J=13.9Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 171.583; 171.547; 146.234; 141.794; 140.649; 135.287; 
128.971; 128.498; 128.168; 127.311; 127.046; 126.900; 126.375; 125.809; 120.423; 120.191; 
68.075; 53.139; 52.315; 37.227. 
HRMS (ESI): found: 448.1911 (M+H); calculated for C30H26NO3: 448.1913. 
Yield: 86% 
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Triphenylmethylamide 10-1-A 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.27 (m, 13H); 7.22 (m, 5H); 6.98 (m, 2H); 4.84 (m, 1H); 
3.56 (m, 2H); 3.20 (dd, 2H, J=7.1Hz, J=12.8Hz); 2.45 (t, 1H, J=7.1Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 170.420; 146.187; 138.656; 129.106; 128.520; 128.431; 
128.035; 126.373; 126.265; 56.092; 48.662; 40.479; 35.034. 
HRMS (ESI): found: 406.2168 (M+H); calculated for C29H28NO: 406.2171. 
Yield: 75% 
 
Triphenylmethylamide 10-1-BI 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.24 (m, 18H); 6.86 (m, 2H); 5.42 (d, 1H, J=7.3Hz); 4.61 
(dd, 1H, J=6.3Hz, J=13.3Hz); 3.61 (dd, 2H, J=15.1Hz, J=58.2Hz); 3.58 (s, 3H); 2.78 (dq, 2H, 
J=6.1Hz, J=13.9Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 171.564; 170.028; 146.123; 135.811; 129.126; 129.075; 
128.414; 128.049; 126.876; 126.399; 55.938; 53.272; 52.027; 48.393; 37.691. 
HRMS (ESI): found: 464.2216 (M+H); calculated for C31H30NO3: 464.2226. 
Yield: 37% 
 
Triphenylmethylamide 10-2-A 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.28 (m, 16H); 7.18 (m, 4H); 5.19 (s, 1H); 3.45 (dd, 2H, 
J=6.9Hz, J=13.0Hz); 2.95 (m, 2H); 2.76 (t, 2H, J=7.0Hz); 1.88 (m, 2H). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 172.758; 146.695; 138.790; 129.046; 128.690; 128.575; 
127.920; 126.451; 125.947; 64.045; 56.026; 40.505; 35.562; 33.204.  
HRMS (ESI): found: 420.2325 (M+H); calculated for C30H30NO: 420.2327.  
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Yield: 70% 
 
Triphenylmethylamide 10-2-BI 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.27 (m, 15H); 7.19 (m, 3H); 7.06 (m, 2H); 5.68 (d, 1H, 
J=7.7Hz); 4.86 (td, 1H, J=5.9Hz, J=7.6Hz); 3.71 (s, 3H); 3.10 (ddd, 1H, J=5.9Hz, J=13.9Hz, 
J=42.6Hz); 2.92 (m, 2H); 1.94 (m, 2H). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 172.317; 172.021; 146.616; 135.779; 129.183; 129.023; 
128.524; 127.957; 127.079; 125.988; 55.948; 52.960; 52.292; 37.860; 35.336; 32.984. 
HRMS (ESI): found: 478.2380 (M+H); calculated for C32H32NO3: 478.2382.  
Yield: 92% 
 
Triphenylmethylamide 10-3-A 
NMR 
1
H (500 MHz, CD2Cl2) δ ppm: 7.29-7.17 (m, 20H); 5.48 (s, 1H); 3.45 (dd, 2H, J=6.9Hz, 
J=12.9Hz); 2.77 (t, 2H, J=7.0Hz); 2.57 (m, 2H); 2.06 (t, 2H, J=7.4Hz); 1.34 (dtd, 2H, J=4.5Hz, 
J=7.5Hz, J=11.8Hz). 
NMR 
13
C (126 MHz, CD2Cl2) δ ppm: 172.769; 147.910; 139.757; 129.717; 129.287; 129.060; 
128.375; 126.891; 126.409; 57.139; 40.999; 40.051; 37.246; 36.210; 22.423. 
HRMS (ESI): found: 434.2491 (M+H); calculated for C31H32NO: 434.2484. 
Yield: 83% 
 
Triphenylmethylamide 10-3-BI 
NMR 
1
H (500 MHz, CD2Cl2) δ ppm: 7.28 (m, 1H); 7.31-7.06 (m, 15); 5.85 (d, 1H, J=7.5Hz);  
4.82 (td, 1H, J=5.9Hz, J=7.8Hz); 3.70 (s, 3H); 3.13 (dd, 1H, J=5.6Hz, J=13.9Hz); 3.04 (dd, 1H, 
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J=6.2Hz, J=13.9Hz); 2.57 (dt, 2H, J=2.3Hz, J=6.5Hz); 2.11 (dt, 2H, J=4.1Hz, J=7.3Hz); 1.34 (dt, 
2H, J=7.1Hz, J=13.4Hz). 
NMR 
13
C (126 MHz, CD2Cl2) δ ppm: 172.616; 172.459; 147.886; 136.748; 129.803; 129.715; 
129.036; 128.377; 127.524; 126.412; 57.131; 53.565; 52.711; 39.955; 38.300; 37.000; 22.266. 
HRMS (ESI): found: 492.2543 (M+H); calculated for C33H34NO3: 492.2539. 
Yield: 75% 
 
Solubility approximations 
 The approximate solubility of 4BI and 5-0-A in phosphate-buffered saline (PBS) was 
determined by the incremental addition of compound from a 10 mM ethanol stock to a PBS 
solution until the solution‟s opacity increased in comparison to PBS alone. 
 
Cell culture  
All cell lines were maintained in RPMI 1640 media supplemented with 10% FBS 
(Gemini Bioproducts) with the exception of PC-12 cells which were grown in RPMI 1640 media 
supplemented with 10% horse serum and 5% FBS. The cell lines were cultured in a 5% CO2, 37 
ºC incubator.  
 
Sulforhodamine B cell proliferation assay 
The sulforhodamine protocol
14
 was used to assess the growth inhibition effects of the 
TPMAs on adherent cell lines. Briefly, UACC-62 or SKMEL-5 (3,000 cells in 198 μL of RPMI 
1640 media) were added to a 96-well plate. Compound (2 μL of ethanol stocks) was added in 
triplicate to achieve concentrations of compound ranging from 0.005 μM to 100 μM. The plates 
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were incubated in a 37 ºC, 5% CO2 incubator for 72 h. The media was removed from the plate 
and ice-cold trichloroacetic acid (200 μL of 10% w/v trichloroacetic acid) was added and the 
plates kept at 4 ºC for 1 h. The trichloroacetic acid was removed and the plates washed with 200 
μL of de-ionized water 5 times. Sulforhodamine B (200 μL of 0.04% sodium salt dissolved in 
1% acetic acid) was added and the plates incubated at room temperature for 30 min. The plates 
were washed 5 times with 1% acetic acid. The dye was released by the addition of tris-base (200 
μL of 10 mM solution) and absorbance of each well was measured at 530 nm after 30 min on a 
Molecular Devices Spectramax plate reader. A similar procedure was used to assess growth 
inhibition of MCF-7 and PC-12 cells which were plated at 5,000 and 20,000 cells/well 
respectively at the beginning of the experiment. Dose response curves were generated and IC50 
values were calculated by fitting the data to a logistic dose response function using the software 
TableCurve 2D. The average IC50 values and standard deviations were determined based on three 
independent experiments. 
 
MTS assay 
The growth inhibition by the triphenylmethylamides on HL-60 and U-937 suspension cell 
lines was assessed by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium salt-based (MTS) assay. Briefly, HL-60 and U-937 cells were 
plated at 10,000 cells/well in a 96-well plate and incubated for 72 h in the presence of varying 
concentrations of compound. After the 72 h incubation the MTS reagent was added per the 
manufacturer‟s instructions (Promega) and after 30 min at 37 ºC the absorbance at 490 nm was 
recorded on a Molecular Devices Spectramax plate reader. Dose response curves were generated 
and IC50 values were calculated by fitting the data to a logistic dose response function using the 
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software TableCurve 2D. The average IC50 values and standard deviations were determined 
based on three independent experiments. 
 
Cell cycle arrest  
HL-60 cells (1.98 mL of 1 x 10
6
 cells/mL) were treated with 20 μL ethanol stocks of the 
various compounds at 20 μM. The cells were incubated at 37 ºC for 6 h. The cells were 
centrifuged (400 x g for 5 min), washed with PBS (2 mL), and fixed by the addition of ice cold 
70% ethanol (1 mL) with gentle vortexing. The samples were placed in a 4 ºC refrigerator 
overnight. The fixed cells were centrifuged (1000 x g for 5 min), washed with PBS (1 mL), and 
RNAse treated (50 μL of 0.14 mg/ml RNAse in PBS) for 2 h at 4 ºC. Propidium iodide (400 μL 
of 50 μg/ml in PBS) was added to the samples and the DNA content was measured using a 
Benton Dickinson cell flow cytometer. Percentage population distribution in the various phases 
of the cell cycle was calculated using the software FCS Express 3. 
 
Assessment of apoptosis by annexin V/propidium iodide staining 
U-937 cells (0.99 mL of 1 x 10
6
 cells/mL) were incubated with either 10 μL ethanol 
vehicle or 100 μM 5-0-A (from 10mM ethanol stock) for 48 h at 37 ºC. The cells were 
centrifuged (400 x g for 5 min) and washed twice with 1 mL Annexin V binding buffer (10 mM 
HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4). The cells were resuspended in 100 μL Annexin 
V binding buffer and 10 μL of FITC-conjugated Annexin V solution (SouthernBiotech) was 
added and the cells placed on ice for 30 min. Prior to cytometry measurements, 400 μL of 
Annexin V buffer was added to the sample, followed by 1 μL of propidium iodide (1 mg/mL in 
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PBS) and the sample was then analyzed on a Benton Dickinson cell flow cytometer. Appropriate 
FITC and propidium iodide channel compensation adjustments for U-937 cells were conducted. 
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CHAPTER 4.  THE COMPLEX ROLE OF THE TRIPHENYLMETHYL 
MOTIF IN ANTI-CANCER AGENTS 
 
The information and contents for this chapter were reproduced in part with permission from 
Palchaudhuri, R.; Nesterenko, V.; Hergenrother, P. J. "The Complex Role of the 
Triphenylmethyl Motif in Anti-Cancer Compounds" J. Am. Chem. Soc. 2008, 130, 10274-10274. 
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4.1 Introduction 
Approximately 1 in 4 deaths in the U.S. are caused by cancer, and in 2005 cancer 
overtook heart disease as the top killer of Americans under age 85.
1
  Despite dramatic advances 
in our understanding of the underlying biology of this disease, cancer death rates have remained 
constant (at roughly 200 deaths for every 100,000 people) over the last 30 years,
1
 highlighting 
the need for new therapeutic agents.  We recently identified a family of compounds, the 
triphenylmethylamides (TPMAs), which induce apoptotic death in multiple melanoma cell lines.
2
  
Two representative TPMAs, 4BI and 4A, are shown in Figure 4.1.  The TPMAs arrest growth of 
melanoma cells in the G1-phase of the cell cycle, substantially reduce cellular levels of active 
NFB, and induce apoptosis.  In addition, the TPMAs have reduced toxicity to normal cells 
derived from the bone marrow of healthy human donors, and high doses of these compounds are 
well tolerated by mice.
2
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Figure 4.1. Triphenylmethyl-containing compounds with anti-cancer properties. 
 
Other compounds containing this functional group also possess anti-cancer properties 
(Figure 4.1).  Notably, the anti-fungal agent clotrimazole inhibits the growth of cancer cells in 
culture,
3
 and has shown efficacy in various mouse models of cancer.
3, 4
  Further studies indicate 
that clotrimazole arrests cells in the G1-phase of the cell cycle.
5
  The anti-cancer properties of 
clotrimazole have been linked to its ability to affect intracellular Ca
2+
 levels thereby inhibiting 
translation, in addition to inhibition of glycolysis by inducing the detachment of mitochondrial-
bound hexokinase.
3, 6
  Other studies have shown that 3,3-diaryl-1,3-dihyroindoles also have anti-
proliferative activity against cancer cell lines in cell culture,
7-9
 and this effect may also be a result 
of the inhibition of translation mediated by depletion of intracellular Ca
2+
 stores.
8, 9
  A 
clotrimazole derivative lacking imidazole functionality has also been shown to induce G1-phase 
cell cycle arrest and inhibit tumor growth in mouse xenograft models,
10
 and even simple 
triphenylmethane derivatives potently induce death of cultured cancer cells.
5
  Finally, a recent 
publication highlighted the activity of S-trityl-L-cysteine (STLC, Figure 4.1), a compound that 
showed potent anti-tumor activity in a screen against the NCI-60 cell line panel.
11
  S-trityl-L-
cysteine induces M-phase arrest by targeting the Eg5 kinesin spindle motor protein involved in 
bipolar spindle formation and maintenance.
11
  As evaluated by the NCI, STLC has shown anti-
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cancer activity in over 20 mouse xenograft models, and is one of the 171 compounds in the NCI 
standard agent database that are of “special interest”.12 
The combined data indicates that triphenylmethyl-containing compounds have 
considerable potential as anti-cancer agents.  However, the precise manner by which some 
compounds of this class exert their anti-cancer effect remains unknown.  The goal of our current 
study was to build a unified picture of the anti-cancer mode of action of compounds containing 
this functional motif.  Interestingly, although the triphenylmethyl moiety dominates the steric 
and conformation properties of the compounds described herein, our work shows that 
compounds containing this functional group can be placed into at least four distinct classes based 
on their mechanism of action and intracellular targets.   
Two of the most potent triphenylmethyl-containing anti-cancer compounds described in 
the literature are STLC and the TPMAs.  Interestingly, these compounds appear to have very 
different modes of action.  STLC induces M-phase cell cycle arrest, through the inhibition of the 
kinesin Eg5.
11
  The TPMAs, conversely, induce G1-phase cell cycle arrest;
2
 the biological target 
of the TPMAs is unknown.  For this study we have designed several novel classes and subclasses 
of triphenylmethyl-containing compounds, and have categorized them according to their cell 
cycle-arresting properties.   Compounds that arrested cellular growth in a discrete phase of the 
cell cycle and that were also potent death inducers were then evaluated in further biological 
assays. 
 
4.2 Design and synthesis of novel triphenylmethyl-containing compounds 
The triphenylmethyl functional group is critical for biological activity of both the TPMAs 
and STLC, as diphenylmethyl-containing derivatives are largely inactive against cultured cancer 
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cells.
2,13
  The substituent projecting off of the amide nitrogen appears to have little influence on 
the anti-cancer properties of the TPMAs.  For example, TPMAs synthesized from 
phenethylamine, 4-methyoxy-phenylamine, and 2-(3-methyoxy-phenyl)-ethylamine are all 
similarly potent inducers of apoptosis in cancer cells in culture.
2
  While modifications of the 
triphenylmethyl motif led to the discovery of 5-0-A, a TPMA, with slightly improved potency 
and aqueous solubility versus the unfunctionalized parent TPMAs (4BI and 4A) we felt we may 
be able to improve the efficacy of these agents by replacing the amide moiety with phosphorous-
containing functional groups such as phosphonate or phosphonochloridate. These compounds are 
collectively known as triphenylmethylphosphonates/phosphonochloridates or TPMPs. The 
phosphorus-containing moieties are significantly more polar than the amide motif and increase 
the overall polarity of triphenylmethyl-containing compounds from cLogP values of 5 for the 
TPMAs to 3.5 for the TPMPs. This increase in polarity would be expected to improve the 
aqueous solubility and may be more suitable for drug development as it has been observed that 
compounds with ClogP > 5 tend to hit multiple drug targets and are more likely to be 
promiscuous aggregators than compounds with ClogP values < 5. In contrast to the amide, the 
phosphorus-containing motif permits the projection of an additional substituent and may provide 
additional opportunities for the development of more potent anti-cancer agents.   
The TPMPs can be placed into three structural classes: phosphonates (Figure 4.2, class I), 
phosphonochloridates (Figure 4.2, class II), and triphenylmethyl ring substituted derivatives of 
class I and II (Figure 4.2, class III).  The TPMPs synthesized are listed in Tables 4.1-3. 
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Figure 4.2.  The three new classes of triphenylmethyl phosphorus-containing derivatives, called TPMPs.  
Class I compounds are phosphonates without ring substitution on the triphenylmethyl moiety.  Class II 
compounds are phosphonochloridates without ring substitutions on the triphenylmethyl moiety.  Class III 
compounds are phosphonates or phosphonochloridates with substituents on the triphenylmethyl moiety. 
 
The synthetic routes to these compounds are outlined in Schemes 4.1-6.  Phosphonates 
bearing dimethyl, diethyl, or dibutyl groups were synthesized in moderate to good yields (25-
98%, average of 79%) via the Arbuzov reaction between triphenylmethyl chlorides and 
commercially available trimethyl-, triethyl- or tributyl- phosphite (compounds 1-9, Scheme 4.1).  
The reactions were complete after refluxing in benzene for two hours.  Compound TPMP-III-7 
was synthesized as previously described,
14
 and TPMP-III-8 was created through the boron 
tribromide mediated demethylation of the para-methoxy triphenylmethyl phosphonate TPMP-
III-4 (Scheme 4.2).   
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Scheme 4.1.  Synthesis of triphenylmethyl phosphonates of Class I and III by the Arbuzov reaction. 
 
OMe
MeO
OMe
P
O
OMe
OMe
OH
HO
OH
P
O
OMe
OMe
BBr3
CH2Cl2
44 %
TPMP-III-4 TPMP-III-8
-78 to 25 C
 
Scheme 4.2.  Synthesis of para-hydroxy substituted triphenylmethyl phosphonate TPMP-III-8. 
 
The limited availability of various trialkylphosphites constrained the number of TPMPs 
that could be synthesized via the Arbuzov reaction. In order to expand the variety of derivatives 
that can be obtained, an alternate strategy was employed that involved the displacement of the 
chlorines of triphenylmethylphosphonyl dichloride TPMP-II-1 by treatment with alkoxides 
(Scheme 3).  By controlling the equivalents of alkoxide, phosphonate as well as 
phosphonochloridates could be synthesized. Six phosphonates of Class I were obtained by 
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treatment of the phosphonyl dichloride TPMP-II-1 with 2.2 equivalents of alkoxide (Scheme 
4.3), with yields ranging from 14-87% (Avg. 59%).  Four phosphonochloridates of Class II and 
III (Scheme 4.4, Avg. 51%) were synthesized using 1.3 equivalents of alkoxide.  Two other 
reactions were used to produce TPMP-I-12 and TPMP-I-11.  Reaction of TPMP-II-1 with the 
alkoxide 1,2-ethanediol yielded the ring closed phosphonate TPMP-I-12 (Scheme 4.5), and 
dihydroxylation of TPMP-I-10 catalyzed by osmium tetroxide afforded the phosphonate TPMP-
I-11 bearing alkyl groups with hydroxyl functionality (Scheme 4.6). 
OH
PCl3
AcCN
TPMP-II-1
2.2 equiv. ROH
2.2 equiv. NaH
P
O
Cl
Cl
P
O
OR
OR
THF, reflux
ROH
2,2,2-Trifluoroethanol
1-Propanol
3-Methyl-3-buten-1-ol
2-Propyn-1-ol
2-Butyn-1-ol
2-Propen-1-ol
TPMP-I-4
TPMP-I-5
TPMP-I-7
TPMP-I-8
TPMP-I-9
TPMP-I-10
85%
87%
38%
75%
67%
14%
YieldTPMP
10
95%
TPMP-I-4, -5, -7, -8, -9, -10
 
Scheme 4.3.  Synthesis of phosphonates of Class I by treatment of the phosphonyldichloride TPMP-II-1 
with 2.2 equivalents of alkoxide. 
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TPMP-II-1 R1, R2, R3 = H
13. R1 = OMe; R2, R3 = H
14.  R1, R2, R3 = Me
2-Propyn-1-ol
2-Butyn-1-ol
2-Propyn-1-ol
2-Propyn-1-ol
TPMP-II-2
TPMP-II-3
TPMP-III-9
TPMP-III-10
64%
52%
41%
45%
ROH TPMP YieldPhosphonyl dichloride
R1
R3
R2 R2
R1
R3
P
O
OR
Cl
R2
R1
R3
90-97%
10. R1, R2, R3 = H
10. R1, R2, R3 = H
11. R1 = OMe; R2, R3 = H
12.  R1, R2, R3 = Me
Triphenylmethanol
 
Scheme 4.4. Synthesis of phosphonochloridates of Class II and III by treatment of phosphonyldichlorides 
with 1.3 equivalents of alkoxide. 
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Scheme 4.5. Synthesis of the ring-closed phosphonate TPMP-I-12. 
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Scheme 4.6. Synthesis of triphenylmethyl phosphonate TPMP-I-11 via the dihydroxylation of TPMP-I-10.  
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4.3  Determination of IC50 values 
All compounds were evaluated for their ability to induce death in the UACC-62 and SK-
MEL-5 cell lines, both human malignant melanoma cell lines.  The UACC-62 cell line has 
known mutations in the braf, pten, and cdkn2a genes,
15
  and expresses Apaf-1 at intermediate 
levels.
16
  The SK-MEL-5 cell line is a human melanoma derived from an auxiliary node of a 
Caucasian female.
17
  It has known mutations in the braf and cdkn2a genes.
18
  Additionally, there 
is little-to-no expression of Apaf-1 in this cell line, making it resistant to apoptotic stimuli that 
require apoptosome formation.
16
   
The 25 TPMPs synthesized and the four compounds from Figure 4.1 were evaluated at a 
range of doses to obtain dose-response curves from which IC50 values could be calculated.  The 
IC50 value determinations for active compounds (IC50 values <100 μM) were made on at least 
three different occasions, in triplicate runs each time, according to the following protocol.  
UACC-62 or SK-MEL-5 cells (3000 cells/well in 96-well plates) were incubated in the presence 
of compounds for 72 hours at 37ºC.  The biomass was quantified by staining with 
sulforhodamine B; the results for each compound are displayed in Tables 4.1-3.  In general, 
select compounds in each structural class had low micromolar potency against these melanoma 
cell lines; the most potent compounds were taken into the cell cycle evaluation, described below.  
The IC50 values for the compounds in Figure 4.1 were also determined alongside the TPMPs, and 
the values are as follows (against the UACC-62 and SK-MEL-5 cell lines, respectively): 4BI = 
11.1 ± 1.1 and 13.1 ± 0.9 M, 4A = 13.4 ± 0.7 and 13.8 ± 3.0 M, clotrimazole = 9.0 ± 1.2 and 
11.2 ± 0.6 M, STLC = 0.8 ± 0.1 and 0.7 ± 0.3 M.   
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Table 4.1. The evaluation of Class I TPMPs against the human melanoma cell lines SK-MEL-5 and 
UACC-62 in cell culture.  Biomass was assessed by the sulforhodamine B assay after 72 h incubation.  
Average IC50 values and standard deviations were determined from at least 3 independent experiments. 
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Table 4.2. The evaluation of Class II TPMPs against the human melanoma cell lines SK-MEL-5 and 
UACC-62 in cell culture.  Biomass was assessed by the sulforhodamine B assay after 72 h incubation.  
Average IC50 values and standard deviations were determined from at least 3 independent experiments. 
 
Table 4.3. The evaluation of Class III TPMPs against the human melanoma cell lines SK-MEL-5 and 
UACC-62 in cell culture.  Biomass was assessed by the sulforhodamine B assay after a 72 h incubation. 
Average IC50 values and standard deviations were determined from at least 3 independent experiments. 
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4.4 Evaluation of cell cycle arrest 
As mentioned, TPMAs and clotrimazole are reported to arrest the growth of cancer cells 
in the G1-phase of the cell cycle, while STLC induces arrest in the M-phase.  To determine the 
cell cycle arresting properties of the novel phosphorous-containing analogues of the TPMAs, 
HL-60 cells (human leukemia cell line) were treated with the most potent compounds at 20 μM 
for 12 hours.  HL-60 cells grow rapidly and in suspension (not adhered to the culture flask) in 
culture, and thus readily lend themselves to cell cycle analysis experiments.  The population of 
cells in the different phases of the cell cycle was measured by propidium iodide staining and 
flow cytometry.  Interestingly, the TPMPs displayed a range of cell cycle arresting properties.  
The data is displayed for the previously known compounds (Figure 4.3A), the new compounds 
that induce G1-phase cell cycle arrest (Figure 4.3B), and the new compounds that induce G2/M-
phase cell cycle arrest (Figure 4.3C).  With this identification of several novel TPMPs that 
potently kill cancer cells (namely TPMP-II-2, TPMP-III-2, TPMP-III-4) and induce arrest in 
either the G1- or the G2/M-phase of the cell cycle, we set out to compare these novel compounds 
with the known compounds (from Figure 4.1) in assays examining the effect of compounds on 
mitosis, mitochondrial-bound hexokinase dissociation, and the effect of compounds on calcium-
dependent potassium channels.   
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Figure 4.3. Cell cycle arresting properties of compounds containing the triphenylmethyl group.  HL-60 
cells (human leukemia) were treated with the indicated compound at 20 μM for 12 h, and the cell cycle 
distribution was examined by propidium iodide staining and flow cytometry.  A) The cell cycle arresting 
properties of known triphenylmethyl compounds that possess anti-cancer activity.  Compound 4BI and 
clotrimazole induce cell cylce arrest in the G1-phase whereas STLC induces M arrest.  B) Certain TPMPs 
induce G1-phase cell cycle arrest, C) while others induce arrest in the G2/M-phase of the cell cycle.  
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Figure 4.3 (continued) 
 
 
4.5 Effects on mitosis and tubulin polymerization  
STLC has previously been shown to induce the arrest of cellular growth in the M-phase 
of the cell cycle, and cells treated with STLC display a “monoaster” phenotype when examined 
by fluorescence microscopy staining for tubulin and DNA.
11
  This monoaster phenotype is 
indicative of compounds that target the kinesin Eg5, and indeed STLC has been shown to be a 
potent and reversible Eg5 inhibitor in vitro (IC50 = 500 nM).
11
  Figure 4.4 shows the effect of 
both STLC and TPMP-III-2 on microtubules as examined by confocal microscopy.  Consistent 
with data in the literature, cells treated with STLC display the “monoaster” phenotype.  
Interestingly, while TPMP-III-2 also induces arrest in the M-phase of the cell cycle, cells treated 
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with this compound do not show the monoaster phenotype but rather possess fragmented mitotic 
spindles characteristic of cells treated with anti-microtubule compounds (Figure 4.4).  
 
Figure 4.4.  The effect of STLC and TPMP-III-2 on microtubule assembly in HeLa cells after an 18 h 
incubation in the presence of 20 μM compound.  Cells were fixed and the nuclei and microtubules were 
stained with propidium iodide (PI) and a FITC-conjugated anti-tubulin antibody, respectively.  The 
“monoaster” phenotype is visible for STLC, whereas TPMP-III-2 induces fragmented mitotic spindles. 
 
Given this data, we assessed the effect of TPMP-III-2 and several of the other 
triphenylmethyl-containing compounds on in vitro tubulin polymerization.  Tubulin 
polymerization can be monitored spectrophotometrically by the increase in optical density at 340 
nm.  Compounds such as Taxol are known to stabilize microtublules (and give an increased rate 
of polymerization in this assay), whereas compounds such as nocodazole prevent tubulin 
polymerization.  As shown by the data in Figure 4.5, TPMP-III-2 is clearly a compound that 
PI Tubulin Merge 
Control 
STLC 
TPMP-III-2 
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prevents the polymerization of tubulin.  The G1-phase arrestor TPMP-I-2 had no effect in this 
tubulin polymerization assay (Figure 4.5). Interestingly, 4,4’-dimethoxytriphenylmethanol 
(structurally similar to TPMP-III-2) did not affect tubulin polymerization, demonstrating the 
necessity of both the phosphonate moiety and the para-methoxy functionality (Figure 4.5).  
STLC and clotrimazole also did not affect tubulin polymerization, while TPMP-III-1 and 
TPMP-III-4 inhibited tubulin polymerization to a modest degree at higher compound 
concentrations, consistent with their G2/M-phase arresting properties.   
Figure 4.5.  The effect of TPMPs (10 μM) on in vitro tubulin polymerization.  As monitored by the optical 
density at 340 nm, TPMP-III-2 inhibits the polymerization of tubulin, whereas TPMP-I-2 and 4,4’-
dimethoxytriphenylmethanol have no effect. 
 
4.6 Effect of compounds on the detachment of mitochondrial-bound 
hexokinase   
Clotrimazole and other antifungal azole-derivatives such as bifonazole, econazole, 
miconazole, and ketoconazole have been identified as calmodulin antagonsists due to their 
ability to inhibit calmodulin-dependent phosphodiesterase activity in vitro.
19
  Clotrimazole 
exhibits a greater than 54-fold selective inhibition of calmodulin-dependent versus calmodulin-
independent phosphodiesterase activity in vitro with an IC50 value of 18 μM.
19
  As calmodulin 
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activity plays a central role in the maintenance of cellular metabolism, calmodulin antagonists 
may exert an antiproliferative effect by disrupting metabolic events such as glycolysis.
20
  In fact, 
treatment of melanoma B16F10 cells with clotrimazole and bifonazole causes detachment of the 
key glycolytic enzymes phosphofructokinase and aldolase from the cytoskeleton and hexokinase 
from the outer mitochondrial membrane prior to affecting cell viability.
21-23
  As elevated 
glycolytic activity is a major hallmark of cancer, compounds that inhibit glycolysis may prove to 
be an effective anti-cancer agents.
24, 25
  It has been proposed that clotrimazole’s ability to cause 
mitochondrial-bound hexokinase detachment is the result of an allosteric interaction rather than a 
result of calmodulin antagonistic acitivity.
26
  This is supported by the inability of other 
calmodulin antagonists to induce the dissociation of mitochondrial-bound hexokinase.
22
   
Given the structural similarity of clotrimazole and the other triphenylmethyl-containing 
compounds, it was of interest to determine whether these compounds could induce detachment of 
hexokinase from the mitochondrial outer membrane and thereby exert their antiproliferative 
effect by inhibiting glycolysis and reducing cellular ATP levels.  Melanoma B16F10 cells were 
incubated in the presence of modest concentrations of compound (15 μM) for a short period of 
time (2 hours) after which the cells were lysed and hexokinase activity of the mitochondrial-rich 
fraction was assessed and compared to vehicle-treated cells. As shown in Figure 4.6, treatment of 
cells with clotrimazole induced a 71% reduction in mitochondrial-bound hexokinase. This result 
is consistent with previous observations.
22
  Other triphenylmethyl compounds which exhibit 
equal or significantly greater antiproliferative activity than clotrimazole in cell culture were not 
able to detach mitochondrial-bound hexokinase as effectively as clotrimazole under the same 
conditions (Figure 4.6), suggesting that these compounds induce death through an alternate 
mechanism. 
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Figure 4.6.  The assessment of mitochondrial-hexokinase activity in murine melanoma B16F10 cells after 
2 h treatment with compound (15 μM), as compared to vehicle-treated control cells.  Clotrimazole causes 
a 71% reduction in mitochondrial-hexokinase activity whereas other triphenylmethyl containing 
compounds show limited effect (p values < 0.012). 
 
4.7 Effect of compounds on Gardos channel inhibition 
In addition to its calmodulin antagonist activity and ability to cause the detachment of 
hexokinase II from mitochondria, clotrimazole is also a potent inhibitor of the calcium-
dependent potassium channel, also known as the Gardos channel.
27
  A binding site model has 
been proposed for the inhibition of the Gardos channel by clotrimazole and another 
triphenylmethane derivative based on site directed mutagenesis.
28
  Inhibitors of the Gardos 
channel show promise for the treatment of sickle cell disease as they prevent red blood cell 
dehydration that may occur during oxygen-deoxygenation cycling.
29
  In fact, several 
triphenylmethyl-containing compounds with potent Gardos channel inhibition properties have 
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been previously described and a triphenylmethylamide is currently in phase III clinical trials for 
sickle cell disease.
29
  Interestingly, halide substitution the triphenylmethyl group appears to be 
required for potent Gardos channel inhibition.
30
 
Apart from the relevance of Gardos channel inhibition to sickle cell disease, the Gardos 
channel is also implicated in the proliferation of melanoma.
31, 32
  Blockers of the channels induce 
cell-cycle arrest by causing membrane depolarization, which reduces Ca
2+
 influx that would 
otherwise promote growth and proliferation.
31, 32
  It was therefore of interest to assess the 
inhibition properties of triphenylmethyl compounds on Gardos channel activity.  As rubidium 
efflux is mediated by the Gardos channel,
33
 human red blood cells were loaded with 
86
Rb and 
incubated in the presence of various concentrations of compound or vehicle.  Efflux was initiated 
by the addition of calcium and the calcium ionophore (A23187) and dose response curves were 
constructed upon analysis of rubidium content in the supernatant.  As shown in Table 4.4, 
clotrimazole is a potent inhibitor of the Gardos channel with an average IC50 value of 0.92 μM, 
consistent with previously reported results.
34
  The novel G1-phase arrestors TPMP-I-2, and 
TPMP-II-2 exhibited good-to-modest inhibition with average IC50 values of 1.7 and 13.8 μM, 
respectively.  The microtubule-inhibiting compound TPMP-III-2, the TPMAs, and STLC were 
poor inhibitors of the Gardos channel with IC50 values ranging from 35 to >100 μM.  Given the 
potent death inducing abilities of these triphenylmethyl compounds relative to clotrimazole, their 
generally modest inhibition of the Gardos channel would suggest that the inhibition of calcium-
dependent potassium channels is not the primary mechanism by which these compounds exert 
their anti-cancer activity.  
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Table 4.4.  Comparison of various triphenylmethyl-containing compounds and their IC50 values for 
86
Rb 
efflux inhibition in human red blood cells. 
 
 
4.8 Effect of compounds on multiple cell lines 
To investigate the general anti-cancer properties of the more potent TPMPs, compounds 
TPMP-II-2, TPMP-III-2, and TPMP-III-4 were tested for their ability to induce death in a 
variety of cancer cell lines.  As shown in Table 4.5, these compounds potently induced death in 
most of the cancer cell lines tested, with only the rat adrenal cell line PC-12 being resistant.  The 
microtubule-inhibiting compound TPMP-III-2 was, in general, slightly more potent that the 
other two compounds in the majority of the cell lines.   
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Table 4.5.  The effect of TPMP-II-2, TPMP-III-2 and TPMP-III-4 on multiple cancer cell lines in cell 
culture.  Cells were treated with the compounds for 72 h and death was quantified via the methods 
described in the Materials and Methods section.  Average IC50 values and standard deviations were 
determined from at least 3 independent experiments. 
 
 
 
4.9  TPMPs induce distinct types of cell death 
 In order to investigate the TPMPs further, we sought to characterize the type of cell death 
induced by TPMP-III-10 and RP239, another TPMP identified to be a potent inducer of cell 
death (Figure 4.7).  
 
Figure 4.7. TPMP-III-10 and RP239 were identified as lead TPMPs for further biological evaluation.  
 
 
A time course annexin V/propidium iodide (AV/PI) analysis of cell viability was 
performed in the HL-60 leukemia and U937 lymphoma cell lines. As shown in Figure 4.8, 
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TPMP-III-10 induced cell death more rapidly in both cell lines versus RP239. Furthermore, cell 
death induced by TPMP-III-10 appears to be caspase independent as the pan-caspase inhibitor, 
Q-VD-OPh, did not offer protection. In contrast, RP239 induced caspase-dependent cell death as 
caspase inhibition by Q-VD-OPh afforded significant protection in both cell lines. These results 
suggest that RP239 induces cell death through apoptosis, whereas TPMP-III-10 induces cell 
death through necrosis. Consistent with this observation, the AV/PI plots of TPMP-III-10 show 
a direct transition of viable AV-/PI- cells to the non-viable necrotic AV+/PI+ quadrant (Figure 
4.8B). RP239, on the other hand, induces transition of viable cells into the AV+/PI- quadrant 
which can be prevented by the pan-caspase inhibitor, consistent with caspase-mediated apoptosis 
(Figure 4.8B). 
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Figure 4.8. A) Time course assessment of AV/PI viability in HL-60 and U937 cells upon treatment with 
TPMP-III-10 or RP239 with and without the pan-caspase inhibitor, Q-VD-OPh. B) AV/PI plots of U937-
treated cells showing TPMP-III-10 induces necrosis while RP239 induces caspase-dependent apoptosis. 
 
 
4.10 Transcript profiling and Connectivity Map results 
 In order to biologically characterize the TPMPs further, we performed transcript profiling 
in U937 cells treated with 10 µM TPMP-III-10 or 25 µM RP239. As outlined in Chapter 1, 
transcript profiling provides mechanistic information on small molecule mechanism of action 
and may be used to identify molecules with similar modes of action through the Connectivity 
Map database. The top 20 elevated and repressed transcripts for TPMP-III-10 and RP239 are 
shown in Tables 4.6 and 4.7 respectively. The transcript profiles were significantly different for 
 
 
168 
 
the two compounds. Most notably, while TPMP-III-10 treatment resulted in the down-regulation 
of heat shock protein 70 (HSP70) transcripts, RP239 treatment significantly elevated HSP70 
transcripts. Heat shock protein 70 is a molecular chaperone whose elevation confers resistance to 
apoptosis. 
 
Table 4.6. U-937 cells were treated with TPMP-III-10 (10 µM) or 0.2% DMSO for 6 hours, at which time 
the mRNA was isolated and the global transcriptional profile was determined. The top 20 elevated and 
repressed transcripts from this experiment are listed. 
SYMBOL Protein & Function p value 
Fold 
Change 
DDIT3 DNA-damage-inducible transcript 3 Inhibits the DNA-binding 
activity of C/EBP and LAP 
0 5.2 
CTH Cysteine desulfhydrase converts cystathione derived from methionine 
into cysteine 
0 5.1 
ADFP adipose differentiation-related protein 0 3.3 
TRIB3 p65-interacting inhibitor of NF-kappa-B negative regulator of NF-
kappa, sensitizes cells to TNF/TRAIL-induced apoptosis 
0 3.3 
CTH Cysteine desulfhydrase converts cystathione derived from methionine 
into cysteine 
0 3.1 
ADFP adipose differentiation-related protein 0 2.9 
ASNS Cell cycle control protein TS11: blocks progression through the G1 
phase of the cell cycle 
0 2.9 
CTH Cysteine desulfhydrase converts cystathione derived from methionine 
into cysteine 
0 2.9 
ADM2 adrenomedullin 2: Activates the cAMP-dependent pathway 0 2.9 
NLRP12 NLR family, pyrin domain containing 12:attenuating factor of 
inflammation by suppressing inflammatory responses in activated 
monocytes 
0 2.8 
PSAT1 phosphoserine aminotransferase 1 0 2.7 
SESN2 sestrin 2: may function in the regulation of cell growth and survival. 0 2.7 
TSC22D3 TSC-22 related protein:  transcriptional regulator plays a role in anti-
inflammatory and immunosuppressive effects of glucocorticoids and 
IL-10 
0 2.6 
DDIT4 HIF-1 responsive protein  inhibits cell growth by regulating the 
FRAP1 pathway upstream of TSC1-TSC2 complex, downstream of 
AKT1 
4.66E-05 2.6 
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A: response is 
correlated with apoptosis 
0 2.6 
LY96 lymphocyte antigen 96: confers responsiveness to lipopolysaccyaride  0 2.5 
HERPUD1 homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1 
0 2.5 
FAM129A cell growth inhibiting protein 39: Regulates phosphorylation of 
EIF2A, EIF4EBP1 and RPS6KB1. May be involved in ER stress 
0 2.4 
TUBE1 tubulin, epsilon 1 1.00E-07 2.4 
TSC22D3 TSC-22 related protein:  transcriptional regulator plays a role in anti-
inflammatory and immunosuppressive effects of glucocorticoids and 
IL-10 
0 2.4 
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Table 4.6 (continued) 
SYMBOL Protein & Function p value 
Fold 
Change 
HSPA8 Heat shock 70kDa protein 8: stabilize preexistent proteins against 
aggregation, fold newly translated polypeptides, anti-apoptotic 
0 -2.9 
HSPA1B Heat shock 70kDa protein 1B: stabilize preexistent proteins against 
aggregation, fold newly translated polypeptides, anti-apoptotic 
4.78E-05 -2.9 
HSPA8 Heat shock 70kDa protein 1B: stabilize preexistent proteins against 
aggregation, fold newly translated polypeptides, anti-apoptotic 
0 -2.7 
HSPA1A Heat shock 70kDa protein 1A: stabilize preexistent proteins against 
aggregation, fold newly translated polypeptides, anti-apoptotic 
2.25E-05 -2.6 
CBX6 chromobox homolog 6:Involved in maintaining the transcriptionally 
repressive state of genes 
0 -2.5 
SBF1 SET-binding factor 1: Inhibits myoblast differentiation in vitro and 
induces oncogenic transformation in fibroblasts 
1.00E-07 -2.1 
DHRS9 3-alpha hydroxysteroid dehydrogenase May play a role in the 
biosynthesis of retinoic acid from retinaldehyde 
0 -2.0 
INSIG1 insulin induced gene 1: endoplasmic reticulum (ER) membrane 
protein that plays a critical role in regulating cholesterol 
concentrations in cells 
0 -2.0 
MAT2A Methionine adenosyltransferase 2 Catalyzes the formation of S-
adenosylmethionine from methionine and ATP 
4.66E-05 -2.0 
GEMIN6 gemin 6: plays a role in the cytoplasmic assembly of small nuclear 
ribonucleoproteins (snRNPs).  
0 -1.9 
TFRC transferrin receptor: Cellular uptake of iron occurs via receptor-
mediated endocytosis of ligand-occupied transferrin receptor into 
specialized endosomes 
7.66E-05 -1.9 
TUBB2C tubulin, beta 2C 0 -1.9 
LOC389816  1.44E-05 -1.9 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4: synthesis 
and degradation of fructose 2,6-bisphosphate 
0.0003653 -1.8 
RPL29 60S ribosomal protein L29 1.35E-05 -1.8 
H3F3B H3 histone, family 3B 5.97E-05 -1.8 
MYLIP cellular modulator of immune recognition 8.00E-07 -1.8 
C2CD2 C2 calcium-dependent domain containing 2 1.60E-06 -1.7 
SLC39A10 solute carrier family 39 (zinc transporter), member 10 5.76E-05 -1.7 
ISG20L2 interferon stimulated exonuclease gene 20kDa-like 2:xoribonuclease 
involved in ribosome biogenesis in the processing of the 12S pre-
rRNA 
5.00E-07 -1.7 
 
Table 4.7. U-937 cells were treated with RP239 (25 µM) or 0.2% DMSO for 6 hours, at which time the 
mRNA was isolated and the global transcriptional profile was determined. The top 20 elevated and 
repressed transcripts from this experiment are listed. 
SYMBOL Protein & Function p value 
Fold 
Change 
HSPA6 Heat shock 70kDa protein 6: stabilize preexistent proteins against 
aggregation, fold newly translated polypeptides, anti-apoptotic 
0 17.0 
RN7SK RNA, 7SK small nuclear 0 7.4 
HSPA6 Heat shock 70kDa protein 6: stabilize preexistent proteins against 
aggregation, fold newly translated polypeptides, anti-apoptotic 
0 7.2 
HSPA1A Heat shock 70kDa protein 1A: stabilize preexistent proteins against 
aggregation, fold newly translated polypeptides, anti-apoptotic 
0 6.3 
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Table 4.7 (continued) 
SYMBOL Protein & Function p value 
Fold 
Change 
HSPA1B Heat shock 70kDa protein 1B: stabilize preexistent proteins against 
aggregation, fold newly translated polypeptides, anti-apoptotic 
0 6.1 
SLC30A1 Zinc transporter 1 may transport zinc out of the cell 0 5.6 
SLC30A1 Zinc transporter 1 may transport zinc out of the cell 0 5.1 
DNAJB1 Heat shock 40kDa protein 1 chaperone of HSP70 and can stimulate 
HSP70 ATPase activity 
0 4.8 
TXNIP Thioredoxin-binding protein 2: oxidative stress mediator by inhibiting 
thioredoxin activity 
0 4.8 
DDIT3 DNA-damage-inducible transcript 3 Inhibits the DNA-binding 
activity of C/EBP and LAP 
0 4.5 
SLC3A2 solute carrier family 3 (activators of dibasic and neutral amino acid 
transport), member 2: mediates integrin-dependent signaling  
0 3.9 
DUSP1 MAP kinase phosphatase 1:inactivates mitogen-activated protein 
(MAP) kinase  
0 3.8 
RN7SK RNA, 7SK, nuclear 0 3.7 
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A: response is 
correlated with apoptosis 
0 3.5 
SLC3A2 solute carrier family 3 (activators of dibasic and neutral amino acid 
transport), member 2: mediates integrin-dependent signaling  
0 3.4 
WWP2 atrophin-1 interacting protein 2: ubiquitin-protein ligase activity 0 3.4 
ZNF564 zinc finger protein 564: May be involved in transcriptional regulation 0 3.3 
TNFAIP3 tumor necrosis factor inducible protein A20: expression is rapidly 
induced by the TNF; inhibits NF-kappa B activation as well as TNF-
mediated apoptosis 
0 3.3 
UTP11L U3 small nucleolar ribonucleoprotein, nucleolar processing of pre-
18S ribosomal RNA 
0 -9.5 
ZC3HAV1 Zinc finger CCCH type, antiviral 1 inhibits viral gene expression and 
induces immunity to viral infection 
0 -8.1 
SFRS10 Splicing factor, arginine/serine-rich 10 sequence-specific RNA-
binding protein controls pre-mRNA splicing 
0 -7.3 
ABCE1 RNase L inhibitor block the activity of ribonuclease L, ATP-binding 
cassette (ABC) transporters 
0 -7.1 
CCL2 Chemokine (C-C motif) ligand 2 cytokine 0 -7.1 
SFRS1 Splicing factor, arginine/serine-rich 1 constitutive and alternative pre-
mRNA splicing 
0 -6.2 
ABCE1 RNase L inhibitor block the activity of ribonuclease L, ATP-binding 
cassette (ABC) transporters 
0 -6.0 
DDX3X ATP-dependent RNA helicase DDX3X alteration of RNA secondary 
structure 
0 -6.0 
TFB2M Mitochondrial transcription factor B2 required for basal transcription 
of mitochondrial DNA 
0 -5.5 
C18orf55 chromosome 18 open reading frame 55 May participate in the 
translocation of transit peptide-containing proteins across the 
mitochondrial inner membrane  
0 -5.4 
DNAJB6 Heat shock protein J2 chaperone of HSP70 and can stimulate HSP70 
ATPase activity 
0 -5.0 
C18orf55 chromosome 18 open reading frame 55 May participate in the 
translocation of transit peptide-containing proteins across the 
mitochondrial inner membrane  
0 -4.9 
TFB2M transcription factor B2, mitochondrial 0 -4.9 
C1orf59 chromosome 1 open reading frame 59 0 -4.4 
 
 
 
171 
 
Table 4.7 (continued) 
SYMBOL Protein & Function p value 
Fold 
Change 
MAT2A Methionine adenosyltransferase 2 Catalyzes the formation of S-
adenosylmethionine from methionine and ATP 
0 -4.4 
SUPT16H suppressor of Ty 16 homolog transcribe DNA packaged into 
chromatin 
0 -4.3 
PSMD12 Proteasome 26S subunit ATPase 2 involved in the ATP-dependent 
degradation of ubiquitinated proteins 
0 -4.3 
CUL5 Vasopressin-activated calcium-mobilizing receptor ubiquitination and 
subsequent proteasomal degradation of target proteins 
0 -4.3 
WRB tryptophan rich basic protein 0 -4.2 
CSTF3 cleavage stimulation factor subunit 1 polyadenylation and 3'-end 
cleavage of mammalian pre-mRNAs 
0 -4.2 
 
Using the transcript profiles obtained, we queried the connectivity map database to 
identify the top 5 compounds in the database that have similar transcript profiles to TPMP-III-
10 and RP239. As shown in Table 4.8, the top matching compounds for the two TPMPs are 
dissimilar, consistent with our observations that these compounds likely induce death by 
different mechanisms. TPMP-III-10 best matched thapsigargin, an inducer of ER-stress 
mediated cell death. RP239 best matched emetine and cephaeline, two similar alkaloids that 
block protein synthesis by binding to the ribosome. These results suggest TPMP-III-10‟s 
mechanism may involve ER-stress induction while the action of RP239 may be due to inhibition 
of protein synthesis. Further experiments are required to validate these hypotheses. 
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Table 4.8. Top 5 A) TPMP-III-10- and B) RP239-correlating compounds in the CMAP database based 
upon permuted scores. 
A) 
rank cmap name mean n enrichment p specificity percent non-null 
1 thapsigargin 0.946 3 1 0 0 100 
2 gossypol 0.799 6 0.984 0 0 100 
3 valinomycin 0.788 4 0.977 0 0 100 
4 5707885 0.689 4 0.973 0 0 100 
5 alexidine 0.648 4 0.962 0 0 100 
B) 
rank cmap name mean n enrichment p specificity percent non-null 
1 emetine 0.796 4 0.987 0 0.007 100 
2 cephaeline 0.766 5 0.976 0 0.0137 100 
3 puromycin 0.777 4 0.968 0 0.0393 100 
4 ouabain 0.693 4 0.967 0 0.0051 100 
5 pyrvinium 0.725 6 0.966 0 0 100 
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4.11 Evaluation of TPMPs in animal models of cancer 
 To evaluate whether TPMP-III-10 and RP239 may be effective against cancers in vivo, 
we performed subcutaneous syngeneic tumor models in mice. TPMP-III-10 was evaluated 
against the 4T1 murine breast cancer and B16F10 murine melanoma models while RP239 was 
evaluated against the B16F10 model only. Once subcutaneous tumors were established in the 
right flank of mice, they were dosed daily for 5 consecutive days with TPMP-III-10 (300 mg/kg 
in corn oil/DMSO mixture), RP239 (150 mg/kg in corn oil/DMSO mixture) or vehicle only. 
Doses for compound administration were determined by maximum tolerated dose studies. The 
tumor volumes were measured by calipers every other day and both models were terminated on 
day 6. Tumors from the 4T1 model were excised on day 7, while B16F10 tumors were excised 
on day 6 and the tumor masses determined. As shown in Figure 4.9, TPMP-III-10 did not 
demonstrate efficacy in either the 4T1 or B16F10 model. Similarly, RP239 did not diminish 
tumor burden in the B16F10 model. These results suggest that the compounds may not be 
particularly effective against these aggressive models of cancer and further optimization may be 
required to demonstrate efficacy. 
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Figure 4.9. Assessment of TPMP-III-10 and RP239 treatment in A) 4T1 subcutaneous tumor model and 
B) B16F10 tumor model. Arrows indicate days of treatment and tumor mass was determined by excision 
of tumors on day 6 for B16F10 and day 7 for 4T1. Each treatment group had 6-8 mice and error bars 
represent the standard error. 
 
4.12 Conclusions and outlook 
We recently reported a class of small molecules, the TPMAs, which induce arrest of 
cancer cell lines in culture in the G1-phase of the cell cycle.
2
  From our initial analysis, the 
triphenylmethyl functional group was the critical pharmacophore, as diphenylmethyl derivatives 
had greatly reduced death-inducing properties.  It was interesting to note other compounds in the 
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literature that possess a triphenylmethyl motif, most notably STLC and clotrimazole, also appear 
to be potent anti-cancer agents.  We thus created a series of novel compounds containing this 
functional group, the TPMPs, and found that several of them induce death in cancer cell lines in 
culture.  These compounds were then tested in a battery of biological assays, and the results were 
compared to the TPMAs, clotrimazole, and STLC.  Interestingly, we have found that these 
structurally related compounds have very different mechanisms of action. 
From analysis of the data presented herein, the replacement of the TPMA amide with the 
phosphonate or phosphonochloridate motif provides many compounds possessing enhanced anti-
cancer activity.  Compounds TPMP-I-2 through -8, TPMP-I-10, TPMP-I-12, TPMP-II-2, 
TPMP-II-3, TPMP-III-1 through -10 all were reasonably potent versus both melanoma cell 
lines, with IC50 values ranging from 2.9-26.9 M.  An increase in activity was seen with 
compounds that had methyl ether substitutions on the aromatic rings; for example, TPMP-III-2 
and TPMP-III-4, were quite potent against the melanoma cell lines, with IC50 values ranging 
from 2.5-5 M.  Compounds containing functional groups that increased aqueous solubility were 
not very potent, such as TPMP-I-11, TPMP-III-7, and TPMP-III-8.   
The two phosphonochloridate derivatives created and evaluated were quite effective in 
killing melanoma cell lines (Table 4.3).  One of these compounds in particular, TPMP-II-2 was 
quite potent in the induction of cell growth inhibition, with IC50 values of 3.3-4.3 M.  To our 
knowledge this is the first demonstration of biological activity of triphenylmethyl 
phosphonochloridates.  Although certain compounds containing the phosphonochloridate moiety 
have been previously shown to rapidly hydrolyze in water,
35, 36
 our investigations show that 
compound TPMP-II-2 is fully stable in aqueous solutions for multiple months.  This compound 
is also stable in both acidic and basic aqueous solutions; no evidence of degradation is observed 
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when placed in aqueous solutions of pH 1.5 through pH 11.8 for 20 hours.  Given their 
potencies, further study of this interesting class of compounds is warranted. 
Additionally, while the phosphonochloridate moiety has been demonstrated to 
irreversibly inhibit serine proteases such as trypsin, chymotrypsin, and acetylcholine esterase,
35-
37
 TPMP-II-2 is only a modest chymotrypsin inhibitor in vitro with activities comparable to 
triphenylmethyl-containing compounds that do not possess functionalities that may irreversibly 
inhibit the serine protease.  Clotrimazole is a potent chymotrypsin inhibitor, and it is in fact 
known inhibit multiple enzymes non-specifically.
38
  Conversely, several of the TPMPs (such as 
TPMP-I-2 and TPMP-III-2) do not show this promiscuous inhibition.  
Due to the size and hydrophobic nature of the triphenylmethyl pharmacophore, it might 
be suspected that anti-cancer compounds possessing this functional group share a common mode 
of cell death induction.  However, we were able to clearly separate the triphenylmethyl-
containing compounds based on their cell cycle arresting properties.  Further assays related to 
mitosis, mitochondrial hexokinase II detachment, and Gardos channel inhibition, were conducted 
on the most potent compounds.  From the combined data a unified picture has emerged, 
revealing at least four distinct mechanisms of cell death induced by compounds containing the 
triphenylmethyl pharmacophore (Table 4.9):  1) STLC induces cell cycle arrest in the M-phase, 
consistent with its known inhibition of the kinesin Eg5.  STLC has no effect on tubulin 
polymerization, nor does it inhibit calcium-dependent potassium ion channels.  2) Clotrimazole 
induces cell death through a much different process.  It arrests cells in the G1-phase of the cell 
cycle, and it has been shown to cause the translocation of hexokinase II from the mitochondrial 
outer membrane thus inhibiting glycolysis resulting in the depletion of ATP.  Clotrimazole is 
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also a potent inhibitor of calcium-dependent potassium ion channels, which can affect the 
transition from G1- to S-phase by modulating intracellular calcium levels.
31
 
Based on the data reported herein neither the TPMAs, nor the class I, II, or III TPMPs 
behave in a manner similar to STLC or clotrimazole, and we believe these compounds can be 
placed into two further mechanistic classes.  3) The third class of compounds are 
triphenylmethyl-containing derivatives that inhibit tubulin polymerization.  TPMP-III-2 and 
TPMP-III-4 inhibit tubulin polymerization in vitro and induce M-phase arrest of cells in culture.  
There does appear to be a relationship between the anti-mitotic effect and the degree of methoxy 
substitution in these compounds.  These are the first examples of triphenylmethyl-containing 
compounds that are able to inhibit tubulin polymerization.  4) TPMAs and TPMPs that are G1-
phase arrestors (such as TPMP-I-2, TPMP-III-2) are in a final category.  In fact, the non-
functionalized triphenylmethyl TPMAs and TPMPs all appear to induce cell death in a similar 
fashion (causing G1-phase arrest), regardless of whether they contain an amide, phosphonate, or 
phosphonochloridate functional group.  Although TPMP-I-2 and TPMP-III-2 and TPMAs are 
modest inhibitors of calcium-dependent potassium channels in comparison to clotrimazole, the 
potency of Gardos channel inhibition does not correlate with the antiproliferative efficacy 
observed in cell culture.  The precise biological target of these compounds remains unknown at 
this point. 
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Table 4.9.  Comparison of various anti-cancer triphenylmethyl compounds based on their activity in a 
variety of assays. 
 
 
 
Several important pieces of information can be gleaned from this data.  First, assessment 
of these derivatives shows that subtle changes in chemical composition can dramatically alter the 
mechanism of action of a small molecule.  In this case, one level of mechanistic discrimination is 
made through the connection of the triphenylmethyl motif with either cysteine (STLC), 
imidazole (chotrimazole), or amides, phosphonates, phosphonochloridates (TPMAs/TPMPs).  
Mechanistically distinct classes of compounds further arise when substitutions are made on the 
aryl rings of TPMAs and TPMPs.  Second, a major drawback of the anti-tubulin drugs (such as 
paclitaxel and the vinca alkaloids) is the inability to penetrate the blood-brain-barrier (BBB) due 
to active efflux by P-glycoproteins, thus rendering these compounds less useful for CNS 
tumors.
39
  In fact, few compounds that have tubulin as their biological target penetrate the 
BBB.
39
  The lipophilic nature of the triphenylmethyl functional group and the known BBB 
penetrance of clotrimazole
40
 suggest that derivatives based on TPMP-III-2 may provide the rare 
anti-mitotic that penetrates the BBB.  Third, triphenylmethylphosphonates and triphenylmethyl 
phosphonochloridates are novel and potent anti-cancer compounds, and the G1-phase arresting 
subclass of these agents appear to operate by a unique mode of action, distinct from clotrimazole.  
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As shown in Table 4.5, several of these compounds are potent death inducers to a variety of 
cancer cell lines in culture. 
In summary, we have discovered that phosphonate and phophononchloridic acid 
analogues of triphenylmethylamides induce apoptosis in melanoma and other cancer cell lines, 
and arrest cellular growth in the G1- or M-phases of the cell cycle.  The G1 arresting TPMPs, 
RP239 and TPMP-III-10 appear to induce cell death by different mechanisms as assessed by 
AV/PI and transcript profiling. Evaluation of RP239 and TPMP-III-10 in murine models of 
breast cancer and melanoma failed to demonstrate efficacy suggesting further optimization of 
these agents is required for development as cancer therapeutics. 
 
4.13 Materials and methods 
General  
Dry acetonitrile, benzene, dichloromethane, and tetrahydrofuran were obtained by 
passing over activated alumina columns or molecular sieves in a commercial solvent purification 
system (Innovative Technologies).  Potassium osmate, 4-methylmorpholine N-oxide, 1 M boron 
tribromide (BBr3) in CH2Cl2, triphenylmethanol, triphenylmethyl chloride, 4-
methoxytriphenylmethyl chloride, 4,4‟-dimethoxytriphenylmethyl chloride, 4,4‟,4‟‟-
trimethoxytriphenylmethyl chloride, S-trityl-L-cysteine, trimethyl phosphite, triethyl phosphite, 
tributyl phosphite, phosphorous trichloride, clotrimazole, sodium hydride (60% dispersion in 
mineral oil), and sulforhodamine B sodium salt were obtained from Sigma Aldrich. 4-
Methoxytriphenylmethanol and 4,4‟,4‟‟-trimethyltriphenylmethanol were purchased from Alfa 
Aesar.  2-Chlorophenyldiphenylmethyl chloride was obtained from TCI America.  For biological 
assays, paclitaxel, nocodazole, propidium iodide, calcium ionophore A23187, phenazine 
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methosulfate, monoclonal anti-α-tubulin−FITC antibody, Ribonuclease A (from bovine 
pancreas), α-chymotrypsin (from bovine pancrease type II), N-Succinyl-Ala-Ala-Pro-Phe p-
nitroamide and Glucose-6-phosphate Dehydrogenase from baker's yeast were purchased from 
Sigma Aldrich.  The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium salt was obtained from Promega. 
 
Compound Analysis.  
All NMR experiments were recorded either in CDCl3 (Sigma), DMSO-d6 (Cambridge 
Isotope Laboratories) or Acetone-d6 (Sigma) on a Varian Unity 400 MHz or 500 MHz 
spectrometer with residual undeuterated solvent as the internal reference.  Chemical shift, δ 
(ppm); coupling constants, J (Hz); multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m 
= multiplet); and integration are reported.  High-resolution mass spectral data was recorded on a 
Micromass Q-Tof Ultima hybrid quadrupole/time-of-flight ESI mass spectrometer at the 
University of Illinois Mass Spectrometry Laboratory.  All melting points are uncorrected. 
 
Synthesis of dialkyl phosphonates by the Arbuzov reaction (Scheme 4.1). 
The phosphonates were prepared analogous to the procedure reported by Shi et al.
41
  
General procedure: In a 40 mL reaction flask charged with dry benzene (2 mL) under a N2 
atmosphere, was added the appropriate triphenylmethyl chloride (1 mmol). The trialkylphosphite 
(1.5-2.0 equiv.) was added and the reaction was refluxed for 2 h after which the solvent and 
excess trialkylphosphite were removed in vacuo. The residue was recrystallized from methanol 
or purified by column chromatography on silica (1:1 hexanes/ethyl acetate) to yield the desired 
product. The following products were obtained by this method: 
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TPMP-I-2 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.30 (m, 15H);  3.57 (d, 6H, J=10.6Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 141.23; 130.55; 127.90; 127.02; 62.90 (J=136.37Hz); 
53.81. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 29.67. 
HRMS (ESI): found: 353.1322 (M+H); calculated for C21H22O3P: 353.1307. 
IR (CH2Cl2, cm
-1
): 3058; 2952; 1492; 1444; 1241; 1054; 1026; 737; 700. 
m.p.: 153-154.5 °C. 
Description: white solid. 
 
TPMP-I-3 
NMR 
1
H (400 MHz, CDCl3) δ ppm: 7.29 (m, 15H); 4.01 ( pd, 2H, J=7.1Hz, J=10.2Hz);  3.82 
(qdd, 2H, J=7.1Hz, J=8.5Hz, J=10.2Hz);  1.09 (t, 6H, J=7.1Hz). 
NMR 
13
C (101 MHz, CDCl3) δ ppm: 141.58; 130.62; 127.76; 126.84; 63.29; 62.89 
(J=135.99Hz); 16.163. 
NMR 
31
P (162 MHz, CDCl3) δ ppm: 27.065. 
HRMS (ESI): found: 381.1622 (M+H); calculated for C23H26O3P: 381.1620. 
IR (CH2Cl2, cm
-1
): 3054; 2986; 1265; 1050; 747; 704. 
m.p.: 118.5-119.5 °C. 
Description: white solid. 
 
TPMP-I-6 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.36 (m, 6H); 7.29 (m, 9H); 3.98 (qd, 2H, J=6.5Hz, 
J=10.1Hz); 3.77 (qd, 2H, J=6.7Hz, J=10.1Hz);  1.42 (m, 4H); 1.20 (m, 4H); 0.83 (t, 6H, 
J=7.4Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 141.49; 130.58; 127.65; 126.70; 66.81; 62.86 
(J=136.27Hz); 32.10; 18.49; 13.39. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 26.90. 
HRMS (ESI): found: 437.2244 (M+H); calculated for C27H34O3P: 437.2246. 
IR (CH2Cl2, cm
-1
): 3059; 2961; 2237; 1599; 1493; 1446; 1238; 1029; 980; 909; 733; 700 
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m.p.: 110.5-111.5 °C. 
Description: white solid. 
 
TPMP-III-1 
NMR 
1
H (500 MHz, Acetone-d6) δ ppm: 7.30 (m, 10H); 7.18 (dd, 2H, J1=1.9Hz, J2=9.1Hz); 
6.87 (dd, 2H, J1=0.7Hz, J2=9.1Hz); 3.80 (s, 3H); 3.55 (d, 6H, J1=10.6Hz). 
NMR 
13
C (126 MHz, Acetone-d6) δ ppm: 149.70; 133.23; 124.47; 122.73; 121.61; 118.83; 
117.96; 104.12; 53.62; 52.53; 45.65; 44.04. 
NMR 
31
P (202 MHz, Acetone-d6) δ ppm: 29.61. 
HRMS (ESI): found: 383.1424 (M+H); calculated for C22H24O4P: 383.1412. 
IR (CH2Cl2, cm
-1
): 3056; 2953; 2848; 1607; 1579; 1511; 1463; 1445; 1293; 1250; 1187; 1053; 
1028; 818; 742; 701. 
m.p.: 127-128 °C. 
Description: white solid. 
 
TPMP-III-2 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.33 (m, 5H); 7.23 (d, 4H, J=7.7Hz); 6.84 (d, 1H, J=8.7Hz); 
3.81 (s, 6H); 3.58 (d, 6H, J=10.5Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 158.29; 141.81; 133.43; 131.66; 130.41; 127.87; 126.91; 
113.17; 61.41 (J=136.8 Hz); 55.14; 53.76. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 30.100. 
HRMS (ESI): found: 413.1521 (M+H); calculated for C23H26O5P: 413.1518. 
IR (CH2Cl2, cm
-1
): 3005; 2955; 2839; 2253; 1510; 1252; 1034; 908; 731; 649 
m.p.: 137-139 °C. 
Description: white solid. 
 
TPMP-III-3 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.35 (m, 3H); 7.26 (m, 6H); 6.82 (d, 4H, J=8.9Hz); 4.02 
(m, 2H); 3.83 (m, 2H); 3.78 (s, 6H); 1.11 (t, 6H, J=7.1Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 158.10; 142.01; 133.66; 131.57; 130.43; 128.16; 127.62; 
126.63; 112.93; 62.98; 61.31(J=136.70 Hz); 55.00; 16.07;  
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NMR 
31
P (202 MHz, CDCl3) δ ppm: 27.568. 
HRMS (ESI): found: 441.1832 (M+H); calculated for C25H30O5P: 441.1831.  
IR (CH2Cl2, cm
-1
): 3054; 2985; 1509; 1265; 1034; 737; 704. 
m.p.: 85-86 °C. 
Description: white solid. 
 
TPMP-III-4 
NMR 
1
H (500 MHz, Acetone-d6) δ ppm: 7.19 (dd, 6H, J=1.9Hz, J=8.9Hz); 6.86 (d, 6H, 
J=8.9Hz); 3.79 (m, 9H); 3.54 (d, 6H, J=10.5Hz). 
NMR 
13
C (126 MHz, Acetone-d6) δ ppm: 160.37; 135.90; 133.37; 114.80; 56.44; 54.77; 54.71;  
NMR 
31
P (202 MHz, Acetone-d6) δ ppm: 30.08. 
HRMS (ESI): found: 443.1643 (M+H); calculated for C24H28O6P: 443.1624. 
IR (CH2Cl2, cm
-1
): 3053; 2954; 2838; 1607; 1508; 1253; 1033; 821; 737. 
m.p.: 164-165 °C. 
Description: white solid. 
 
TPMP-III-5 
NMR 
1
H (400 MHz, CDCl3) δ ppm: 7.24 (m, 6H);  6.81 (m, 6H);  4.00 (m, 2H);  3.81 (m, 2H); 
3.80 (m, 9H);  1.11 (t, 6H, J=7.1Hz). 
NMR 
13
C (101 MHz, CDCl3) δ ppm: 157.94; 133.84; 131.41; 112.77; 62.88; 60.96; 59.87 
(J=137.1Hz); 54.86; 16.04. 
NMR 
31
P (162 MHz, CDCl3) δ ppm: 27.75. 
HRMS (ESI): found: 471.1941 (M+H); calculated for C26H32O6P: 471.1937. 
IR (CH2Cl2, cm
-1
): 2983; 1607; 1508; 1265; 1035; 738. 
m.p.: 143-144 °C. 
Description: white solid. 
 
TPMP-III-6 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 8.28 (d, 1H, J=7.8Hz); 7.58 (dd, 4H, J=1.6Hz, J=7.4Hz); 
7.39 (m, 1H); 7.30 (m, 8H); 3.40 (d, 6H, J=10.5Hz). 
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NMR 
13
C (126 MHz, CDCl3) δ ppm: 139.53; 137.01; 136.29; 133.00; 132.27; 130.71; 128.61; 
127.548; 126.96; 126.38; 62.84 (J=133.10); 54.16. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 27.68. 
HRMS (ESI): found: 387.0914 (M+H); calculated for C21H21O3PCl: 387.0917. 
IR (CH2Cl2, cm
-1
): 3056; 2954; 2851; 1493; 1265; 1241; 1047; 822; 736; 705. 
m.p.: 125-127 °C. 
Description: white solid. 
 
Synthesis of TPMP-III-7 
TPMP-III-7 was synthesized according to a published procedure.
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NMR 
1
H (500 MHz, DMSO-d6) δ ppm: 9.46 (s, 2H); 7.30 (m, 2H);  7.26 (m, 1H);  7.17 (d, 2H, 
J=7.6Hz);  6.94 (d, 4H, J=8.3Hz);  6.69 (d, 4H, J=8.6Hz);  3.47 (d, 6H, J=10.5Hz). 
NMR 
13
C (126 MHz, DMSO-d6) δ ppm: 156.00; 142.13; 131.45; 131.07; 129.84; 127.71; 
126.66; 114.51; 60.60 (J=136.9Hz); 53.30. 
NMR 
31
P (202 MHz, DMSO-d6) δ ppm: 30.35. 
HRMS (ESI): found: 385.1213 (M+H); calculated for C21H22O5P: 385.1205. 
IR (thin film, cm
-1
): 3221 (b); 2954; 1510; 1215; 1180; 1053; 1023; 826; 702. 
Description: white solid. 
 
Synthesis of TPMP-III-8 (Scheme 4.2 in manuscript text) 
To a 25 mL round bottom flask containing TPMP-III-4 (100 mg, 0.226 mmol) dissolved 
in dry CH2Cl2 (1 mL) at -78 ºC under a nitrogen atmosphere, BBr3 (0.9 mL of 1 M BBr3 in 
CH2Cl2, 0.9 mmol, 4 equiv.) was added dropwise. The reaction was warmed to 25 ºC and stirred 
for 25 h, after which 5 mL of water was added and reaction stirred for 1 h.  The insoluble creamy 
yellow precipitate was filtered and washed with cold water.  The precipitate was dissolved in the 
minimum amount of 50:50 methanol/ethyl acetate and purified by column chromatography on 
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silica using 10:90 methanol/ethyl acetate as the eluent to yield TPMP-III-8 (40 mg, 44% yield) 
as an orange solid.  
NMR 
1
H (500 MHz, DMSO-d6) δ ppm: 9.43 (s, 3H); 6.93 (d, 6H, J=7.8Hz); 6.67 (d, 6H, 
J=8.8Hz); 3.45 (d, 6H, J=10.4Hz). 
NMR 
13
C (126 MHz, DMSO-d6) δ ppm: 155.87; 131.97; 130.95; 114.41; 59.84 (J=137.0Hz); 
53.19. 
NMR 
31
P (202 MHz, DMSO-d6) δ ppm: 30.79. 
HRMS (ESI): found: 401.1165 (M+H); calculated for C21H22O6P: 401.1154. 
IR (thin film, cm
-1
): 3164 (b); 1509; 1274; 1179; 1050; 1024; 825; 758. 
Description: orange solid. 
 
Synthesis of TPMP-II-1 (Scheme 4.3 in manuscript text) 
Triphenylmethanol 10 (5 g, 19.206 mmol) was dissolved in a minimum volume of dry 
acetonitrile and the solution was placed in a 50 mL round bottom flask under a N2 atmosphere. 
The flask was cooled in an ice bath and phosphorus trichloride (1.85 mL, 2.9 g, 21.126 mmol, 
1.1 equiv.) was cautiously added dropwise.  The reaction was stirred at 25 ºC until the yellow 
color dissipated.  The reaction was cooled to 0 ºC and the white solid was filtered, washed with 1 
M NH4CO3 (20 mL), water (20 mL), and petroleum ether (20 mL), and dried in vacuo to yield 
triphenylphosphonyl dichloride (6.59 g, 95% yield) as a white solid. 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.40 (m, 15H). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 138.85; 130.70; 128.41; 75.68 (J=85.09). 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 60.20. 
HRMS (ESI): found: 383.0145 (M+Na
+
); calculated for C19H15Cl2OPNa: 383.0135. 
IR (CH2Cl2, cm
-1
): 3054; 2987; 2305; 1265; 896; 743; 705 
m.p.: 179-182°C. 
Description: white solid. 
 
 
 
186 
 
Synthesis of 13. (Scheme 4.4 in manuscript text) 
In a 40 mL reaction vessel under a N2 atmosphere was placed 4-
methoxytriphenylmethanol 11 (0.826 g, 2.845 mmol). Phosphorous trichloride (4 mL, 45.8 
mmol, 16.1 equiv.) was added drop wise and the reaction stirred vigorously at room temperature 
for 2 h after which the reaction was decomposed on crushed ice. The resulting precipitate was 
filtered, washed with 1 M NH4CO3 (20 mL), water (20 mL), petroleum ether (20 mL) and dried 
in vacuo to yield 4-methoxytriphenylmethylphosphonyl dichloride 13 (1.0 g, 90% yield) as an 
orange solid.  The crude material was used in the synthesis of TPMP-III-9 without further 
purification. 
 
Synthesis of 14.  (Scheme 4.4 in manuscript text) 
The phosphonyl dichloride 14 was synthesized using the procedure analogous to the 
synthesis of 13 employing 4,4‟,4‟‟-trimethyltriphenylmethanol 12 (1.0 g, 3.307 mmol) to yield 
4,4‟,4‟‟-trimethyltriphenylphosphonyl dichloride 14 (1.30 g, 97% yield) as a yellow solid. The 
crude material was used in the synthesis of TPMP-III-10 without further purification. 
 
Synthesis of phosphonates from triphenylmethylphosphonyl dichloride (Scheme 4.3 in 
manuscript text) 
General procedure: The synthesis of phosphonates from triphenylmethylphosphonyl 
dichloride was performed on a 0.5 mmol scale.  In a dry microwave irradiation vial, the 
appropriate alcohol (3.0 equiv.) was dissolved in 4 mL of THF and cooled to 0-5 ºC.  Sodium 
hydride (2.0-2.2 equiv. of 60% dispersion in mineral oil) was added to form the alkoxide in situ.  
The solution was stirred for 30 min at which time hydrogen evolution had ceased.  
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Triphenylmethylphosphonyl dichloride (0.5 mmol, 1 equivalent) was added as a solid and the 
reaction irradiated with microwaves (150 W power) at 110 ºC for 30-40 min.  Upon completion 
of the reaction (as judged by TLC) the solvent was removed in vacuo.  Water (5 mL) and CH2Cl2 
(5 mL) was added and the organic layer isolated, dried over anhydrous MgSO4, and solvent 
removed in vacuo.  The isolated material was subjected to column chromatography on silica 
using 1:1 ethyl acetate/hexane as the eluent.  The following products were synthesized using the 
procedure described:  
 
TPMP-I-4 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.33 (m, 15H);  4.32 (m, 2H);  3.81 (m, 2H). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 139.49; 130.37; 128.30; 127.71; 122.39; 63.45 
(J=135.17Hz); 62.87. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 29.63. 
HRMS (ESI): found: 489.1063 (M+H); calculated for C23H20F6O3P: 489.1054. 
IR (CH2Cl2, cm
-1
): 3062; 2968; 2250; 1599; 1492; 1290; 1249; 1173; 1100; 962; 909; 734; 700. 
m.p.: 125-126 °C. 
Description: white solid. 
 
TPMP-I-5 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.30 (m, 15H); 3.90 (qd, 2H, J=6.5Hz, J=10.0Hz);  3.70 
(qd, 2H, J=6.6Hz, J=9.9Hz);  1.44 (m, 4H);  0.75 (t, 6H, J=7.4Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 141.65; 130.71; 127.76; 126.80; 68.71; 63.00 
(J=136.40Hz); 23.65; 10.01. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 26.80. 
HRMS (ESI): found: 409.1935 (M+H); calculated for C25H30O3P: 409.1933. 
IR (CH2Cl2, cm
-1
): 2973; 2253; 1471; 1282; 1235; 997; 909; 732; 650 
m.p.: 106.5-108 °C. 
Description: white solid. 
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TPMP-I-7 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.30 (m, 15H);   4.72 (s, 2H); 4.58 (s, 2H). 
 4.04 (ddd, 2H, J=6.7Hz, J=10.2Hz, J=13.4Hz); 3.83 (qd, 2H, J=6.9Hz, J=10.1Hz); 2.10 (m, 
4H); 1.60 (s, 6H). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 141.38; 130.75; 130.69; 127.80; 126.90; 112.42; 65.34; 
63.03 (J=135.85Hz); 38.28; 22.22. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 27.03. 
HRMS (ESI): found: 461.2245 (M+H); calculated for C29H34O3P: 461.2246. 
IR (CH2Cl2, cm
-1
): 3054; 2928; 2306; 1492; 1445; 1265; 1036; 896; 739; 703 
Description: yellow oil 
 
TPMP-I-8 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.31 (m, 15H); 4.65 (m, 2H);  4.32 (m, 2H);  2.47 (m, 2H). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 140.51; 130.51; 128.03; 127.22; 77.86; 75.57; 63.14 
(J=135.75Hz); 54.51. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 29.581. 
HRMS (ESI): found: 401.1310 (M+H); calculated for C25H22O3P: 401.1307. 
IR (CH2Cl2, cm
-1
): 3303; 3054; 2987; 2305; 1422; 1265; 896; 740; 705 
m.p.: 121.5-122.5 °C. 
Description: white solid. 
 
TPMP-I-9 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.30 (m, 15H); 4.59 (ddd, 2H, J=2.2Hz, J=8.3Hz, 
J=14.9Hz); 4.29 (ddd, 2H, J=2.2Hz, J=10.6Hz, J=14.9Hz); 1.81 (s, 6H). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 140.95; 130.65; 127.92; 127.01; 83.65; 73.76; 63.15 
(J=134.85Hz); 55.32; 3.70. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 28.98. 
HRMS (ESI): found: 429.1629 (M+H); calculated for C27H26O3P: 429.1620. 
IR (CH2Cl2, cm
-1
): 3058; 2920; 2241; 1599; 1493; 1445; 1240; 1026; 970; 732; 700 
m.p.: 146-147 °C. 
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Description: white solid. 
 
TPMP-I-10 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.33 (m, 15H); 5.72 (ddd, 2H, J=5.3Hz, J=10.6Hz, 
J=22.1Hz); 5.10 (m, 4H); 4.51 (m, 2H); 4.27 (tddd, 2H, J=1.5Hz, J=5.2Hz, J=8.1Hz, 
J=13.3Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 141.22; 132.74; 130.58; 127.79; 126.89; 117.18; 67.36; 
63.04 (J=136.13Hz). 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 27.84. 
HRMS (ESI): found: 405.1610 (M+H); calculated for C25H26O3P: 405.1620. 
IR (CH2Cl2, cm
-1
): 3058; 2945; 2887; 2240 1599; 1492; 1444; 1239; 1030; 931; 732; 700 
m.p.: 86.5-87.5 °C. 
Description: white solid. 
 
Synthesis of TPMP-I-12 (Scheme 4.5 in manuscript text) 
A procedure analogous to the synthesis of phosphonates, using TPMP-II-1 was 
employed with the exception that 1.1 equivalents of 1,2-ethanediol was used with 2.2 equivalents 
of sodium hydride to yield TPMP-I-12. 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.45 (m, 6H); 7.32 (m, 9H); 4.30 (m, 2H); 3.43 (m, 2H). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 140.32; 130.56; 128.15; 127.40; 66.51; 63.83 
(J=125.43Hz). 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 47.55. 
HRMS (ESI): found: 351.1159 (M+H); calculated for C21H20O3P: 351.1150. 
IR (CH2Cl2, cm
-1
): 2913; 2251; 1496; 1447; 1257; 1045; 908; 819; 733; 650 
m.p.: 190-192 °C. 
Description: white solid. 
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Synthesis of TPMP-I-11 (Scheme 4.6 in manuscript text) 
In a 25 mL round bottom flask, TPMP-I-10 (79 mg, 0.1953 mmol) was dissolved in 2:1 
mixture of t-butanol/water (2 mL). Potassium osmate (3.6 mg, 5 mol%) and 4-methylmorpholine 
N-oxide (63.4 mg, 0.469 mmol, 2.4 equiv.) was added and the reaction stirred at 25 ºC for 18 h. 
The solvent was removed in vacuo, and water (5 mL) was added and the flask subsequently 
cooled to 0 ºC to precipitate the product. The precipitate was filtered, washed with ice-cold water 
(10 mL) and dried in vacuo to yield TPMP-I-11 (63.7 mg, 69.0%) as a white solid. 
NMR 
1
H (500 MHz, DMSO-d6) δ ppm: 7.31 (m, 9H); 7.22 (m, 6H); 4.84 (m, 2H); 4.53 (td, 2H, 
J=5.6Hz, J=8.7Hz); 3.87 (m, 1H); 3.60 (m, 2H); 3.43 (td, 2H, J=4.9Hz, J=9.7Hz); 3.15 (m, 4H); 
NMR 
13
C (126 MHz, DMSO-d6) δ ppm: 141.22; 130.08; 127.81; 126.90; 70.08; 67.89; 62.28 
(J=136.97Hz); 61.74; 
NMR 
31
P (202 MHz, DMSO-d6) δ ppm: 27.32; 
HRMS (ESI): found: 473.1725 (M+H); calculated for C25H30O7P: 473.1729 
IR (CH2Cl2, cm
-1
): 3200 (b) 3155; 2253; 1448; 1382; 908; 734; 650 
m.p.: 210-213 °C 
Description: white solid. 
 
Synthesis of TPMP-I-1 
TPMP-I-1 was synthesized according to a published procedure.
43
 
 
Synthesis of phosphonochloridates from triphenylmethylphosphonyl dichloride (Scheme 4.4 in 
manuscript text) 
General procedure: A 40 mL reaction vessel under a N2 atmosphere was charged with 5 
mL dry THF and the appropriate triphenylmethylphosphonyl dichloride (0.5-1.0 mmol) and 
alcohol (1.3 equiv.) was added.  Sodium hydride (1.3 equiv. of 60% dispersion in mineral oil) 
was added and the reaction was refluxed for 4 h.  The solvent was removed in vacuo, and CH2Cl2 
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(15 mL) and water (15 mL) were added to the vessel.  The organic layer was isolated, dried over 
anhydrous MgSO4, and the solvent removed in vacuo.  The resulting residue was subjected to 
column chromatography on silica (1:3 ethyl acetate/ hexanes).  The following products were 
obtained by this method: 
 
TPMP-II-2  
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.34 (m, 15H); 4.83 (m, 1H); 4.67 (m, 1H); 2.53 (t, 1H, 
J=2.5Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 139.66; 130.65; 128.21; 127.78; 76.74; 76.48; 68.88 
(J=112.71Hz); 54.97. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 47.64. 
HRMS (ESI): found: 381.0821 (M+H); calculated for C22H19ClO2P: 381.0811. 
IR (CH2Cl2, cm
-1
): 3308; 3063; 2252; 1598; 1493; 1446; 1254; 1024; 908; 734; 700 
m.p.: 133-134 °C. 
Description: white solid. 
 
TPMP-II-3 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.35 (m, 15H); 4.80 (m, 1H); 4.66 (m, 1H); 1.83 (t, 3H, 
J=2.4Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 139.85; 130.67; 128.12; 127.65; 85.28; 72.29; 68.81 
(J=113.32Hz); 56.14; 3.71. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 47.08. 
HRMS (ESI): found: 395.0965 (M+H); calculated for C23H21ClO2P: 395.0968. 
IR (CH2Cl2, cm
-1
): 3059; 2245; 1597; 1492; 1445; 1255; 1011; 971; 910; 732; 699 
m.p.: 115.5-117 °C. 
Description: white solid. 
 
 
 
 
 
 
192 
 
TPMP-III-9 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.36 (m, 4H); 7.33 (m, 6H); 7.26 (dd, 2H, J=2.0Hz, 
J=8.8Hz); 4.75 (dddd, 2H, J=2.5Hz, J=10.9Hz, J=14.4Hz, J=15.4Hz); 3.81 (m, 3H); 2.54 (t, 
1H, J=2.5Hz). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 158.87; 139.98; 131.85; 131.42; 130.54; 128.17; 127.69; 
113.46; 76.71; 76.53; 68.25 (J=112.44 Hz); 55.17; 54.91. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 48.00. 
HRMS (ESI): found: 428.1184 (M+NH4
+
); calculated for C23H24NClO3P: 428.1182. 
IR (CH2Cl2, cm
-1
): 3297; 3058; 2838; 1511; 1255; 1188; 1020; 985; 737; 700 
m.p.: 101-103 °C. 
Description: white solid. 
 
TPMP-III-10 
NMR 
1
H (500 MHz, CDCl3) δ ppm: 7.25 (m, 6H); 7.14 (d, 6H, J=8.2Hz); 4.75 (dddd, 2H, 
J=2.5Hz, J=11.0Hz, J=14.5Hz, J=15.4Hz); 2.54 (t, 1H, J=2.5Hz); 2.36 (m, 9H). 
NMR 
13
C (126 MHz, CDCl3) δ ppm: 137.36; 136.85; 130.44; 128.82; 76.65; 76.584; 67.99 
(J=111.96 Hz); 54.81; 20.96. 
NMR 
31
P (202 MHz, CDCl3) δ ppm: 48.29. 
HRMS (ESI): found: 440.1549 (M+NH4
+
); calculated for C25H28NClO2P: 440.1546. 
IR (CH2Cl2, cm
-1
): 3300; 3238; 3029; 2922; 2130; 1510; 1255; 1196; 1020; 986; 810; 736. 
m.p.: 119-120 °C. 
Description: white solid. 
 
Cell culture conditions 
All cells were grown in RPMI 1640 media supplemented with 10% fetal bovine serum 
(FBS) and incubated at 37 ºC in a 5% CO2, 95% humidity atmosphere. 
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Sulforhodamine B cell proliferation assay 
UACC-62, SK-MEL-5, SKNSH, IGROV-1 or MCF-7 (3000 cells in 198 μL of RPMI 
1640 media) cells were placed into each well of a 96-well plate. Compound stock solutions in 
100% ethanol were added to the wells in triplicate such that the final concentrations of 
compound ranged between 0.001-100 μM. The plates were incubated in a 37 ºC, 5% CO2 
incubator for 72 h.  The media was removed from the plate and ice-cold 10% w/v trichloroacetic 
acid (200 μL) was added and the plates incubated at 4 ºC for 1 hour. The trichloroacetic acid was 
removed, and the plates washed with 200 μL of deionized water 5 times.  Sulforhodamine B (200 
μL of 0.04% sodium salt dissolved in 1% acetic acid) was added and the plates incubated at 
room temperature for 30 min.  The plates were washed 5 times with 1% acetic acid.  The dye 
was released by the addition of tris-base (200 μL of 10 mM solution) and absorbance of each 
well was measured at 510 nm on a Molecular Devices SpectraMax 384 plus plate reader after 30 
min incubation at room temperature. 
 
MTS assay 
HL-60, U-937, or PC-12 cells in RPMI 1640 media were added to 96-well plates (99 μL 
containing 1 x 10
4 
cells).  Ethanol solutions of compounds were added in triplicate (1 μL to each 
well) to achieve concentrations ranging between 0.005-100 μM.  The cells were incubated in a 
37 ºC, 5% CO2, 95% humidity incubator for 24 hours.  A solution containing the soluble 
tetrazolium salt ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt; MTS) and the electron coupling reagent, phenazine methosulfate 
(PMS) was prepared according to the manufacturer‟s instructions (Promega) and 20 μL of this 
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solution was added to each well.  The plates were incubated at 37 ºC for 15-30 min and then read 
at 490 nm on a Molecular Devices SpectraMax 384 plus plate reader. 
 
Cell cycle arrest 
HL-60 cells (2 mL of 1 x 10
6
 cells/mL) were treated with 20 μL ethanol stocks of the 
various compounds to achieve a final concentration of 20 or 50 μM.  The cells were incubated at 
37 ºC for 12 hours.  The cells were centrifuged (400g for 5 min), washed with PBS (2 mL), and 
fixed by the addition of ice-cold 70% ethanol (1 mL) with gentle vortexing.  The samples were 
placed in a 4 ºC fridge overnight.  The fixed cells were centrifuged (1000g for 5 min), washed 
with PBS (1 mL), and RNase treated (50 μL of 0.14 mg/mL RNase A in PBS) for 2 hours at 4 
ºC. Propidium iodide (400 μL of 50 μg/mL in PBS) was added to the samples and the DNA 
content was measured on a Benton Dickinson LSR II cell flow cytometer. Cell cycle population 
distribution was analyzed using the software FCS Express. 
 
Confocal microscopy 
HeLa cells were grown to 90% confluency on 22 mm square cover slips and treated with 
either DMSO vehicle, 30 μM STLC or 3B for 16 h in RPMI 1640 media such that the DMSO 
did not exceed 1%.  The cells were washed with PBS, fixed using 1-2% glutaraldehyde, 
quenching with freshly made 1 mg/mL NaBH4 for 1 min.  This was repeated 3 times.  Cells were 
made permeable with 0.5% Triton X-100 for 10 min and rinsed with 0.1% Triton X-100 three 
times.  The FITC anti-α-tubulin (Sigma) was added as a 1:50 dilution and the cells incubated for 
1 h. The cells were blocked in goat serum containing 100 μg/mL RNase A for 1 hr.  Propidium 
iodide was added in the last 15 min to achieve a final conc. of 50 μg/mL.  The cells were washed 
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3 times with TBS buffer, drained, mounted onto microscope slides using 10 μL of mounting 
media.  The cover slips were sealed and the samples visualized immediately on a Zeiss LSM 510 
scanning confocal laser microscope.  
 
In vitro tubulin polymerization assay 
Ice-cold assay buffer (39 μL of 80 mM PIPES pH 6.9, 0.5 mM EGTA, 2 mM MgCl2, 5% 
glycerol and 1 mM GTP) was placed in the wells of a 384-well plate.  Compound (1 μL of 0.5 
mM in DMSO) was added to each well to achieve a final drug concentration of 10 μM.  Tubulin 
(10 μL of 15 mg/mL tubulin in ice-cold 500 mM K-PIPES, 0.5 mM MgCl2, pH 6.9 buffer) was 
added to each well. The plate was placed immediately in a Molecular Devices SpectraMax 384 
plus plate reader preheated to 37 ºC and the progress of the polymerization monitored at 340 nm 
for 60 min.  The microtubule stabilizer and destabilizer, paclitaxel and nocodazole respectively 
were used as controls at a final concentration of 10 μM. 
 
Assessment of mitochondrial-bound hexokinase activity  
Mitochondrial-bound hexokinase activity was assessed by a method previously described 
with minor modifications.
44, 45
 In 10 cm diameter Petri dishes, murine melanoma B16F10 cells 
were cultured to confluency.  The cells were washed with PBS and incubated for 2 hours at 37 ºC 
in the presence of 10 mL PBS (pH 7.4) containing 5 mM glucose and 15 μM of the 
triphenylmethyl-containing compound. The cells were isolated using a scraper, centrifuged at 
270g for 10 min and resuspended in 1.2 mL of ice-cold sucrose buffer (250 mM sucrose, 20 mM 
Tris, 1 mM EGTA pH 7.4).  The cells were lysed for 90 seconds using a mechanical dounce 
homogenizer. The lysate was centrifuged at 1500g for 10 min to pellet debris and 900 μL of the 
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supernatant was isolated and centrifuged at 27000g at 4 ºC for 15 min to isolate the 
mitochondria-rich pellet which was resuspended in 100μL of sucrose buffer.  The protein 
concentration was determined by the BCA titration method and the samples were normalized to 
achieve a final protein concentration between 1.2-1.8 mg/mL. To determine the hexokinase 
activity of the mitochondria-rich fraction, 10 μL of the mitochondria-rich fraction was added  to 
180 μL of assay buffer (50 mM triethanolamine, 7.5 mM MgCl2, 0.5 mM EGTA, 11 mM 
mercaptoethanol, 4 mM glucose, 0.5 mg/mL NADP
+
, 0.5 U/mL Glucose-6-phosphate 
dehydrogenase at pH 8.5) in a 96-well plate. After the addition of ATP to a final concentration of 
6.6 mM, the initial velocity of NADPH production was monitored at 340 nm using a Molecular 
Devices SpectraMax 384 plus plate reader. Controls were conducted in the absence of ATP and 
subtracted. Mitochondrial hexokinase activity for compound-treated cells was calculated as a 
percentage of the activity of vehicle-treated cells and four independent experiments were 
performed. 
 
Gardos channel inhibition 
Gardos channel inhibition was assessed by the method of Brugnara with minor 
modifications.
33
  Sodium heparinized whole human blood (Bioreclamation inc.) was diluted 1:1 
in modified flux buffer (MFB)- 140 mM NaCl, 5 mM KCl, 10 mM Tris-base, 0.1 mM EGTA, 
pH 7.4. The cells were centrifuged at 400g for 10 min, washed 3 times with 20 mL MFB and 
resuspended in MFB in a total volume of 10 mL.  Rubdium-86 chloride (Perkin-Elmer) was 
added to achieve a final concentration of 5 μCi/mL.  The cells were incubated at 37 ºC for 2 
hours after which they were washed four times with 40 mL of chilled MFB and resuspended to a 
total volume of 10 mL.  The loaded cells (100 μL) were then added to 100 μL MFB containing 
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compound in a 96-well plate and incubated in the presence of compound or vehicle for 10 min at 
room temperature.  To initiate 
86
Rb efflux, 2 mM CaCl2 and 5 μM of the calcium ionophore 
A23187 were added with mixing and after a 10 min incubation at room temperature the cells 
were centrifuged at 3000g for 5 min.  The supernatant was collected and analyzed for Rb
86
 
content using a LS6500 Beckman liquid scintillation counter. Three independent experiments 
were conducted, averaged and IC50 values were determined using the software TableCurve 2D. 
 
In vitro chymotrypsin inhibition assay 
In a 96-well plate, 80 μL of 0.1 mg/mL of α-chymotrypsin (from bovine pancrease type 
II, Aldrich), in assay buffer (100 mM NaCl, 100 mM Tris-HCl, 1 mM CaCl2, pH 7.2) was 
incubated in the presence of various concentrations (0.01-100 μM)  of the triphenylmethyl-
containing compounds for 40 min at room temperature. Chymotrypsin substrate N-Succinyl-Ala-
Ala-Pro-Phe p-nitroamide (Aldrich) was added (20 μL of 1 mg/mL) and the room temperature 
kinetics of p-nitroaniline formation was at 410 nm using a Molecular Devices SpectraMax 384 
plus plate reader. Chymotrypsin activity was determined using initial velocities where a velocity 
of zero represented 100% chymotrypsin inhibition and chymotrypsin activity in the presence of 
1% ethanol vehicle only was regarded as 0% inhibition. The IC50 values were determined using 
the software TableCurve 2D. 
 
Gene expression analysis 
U937 cells (3 x 10
6
 cells in 6 mL RPMI 1640 with 10% FBS) were incubated in the 
presence of TPMP-III-10 (10 µM), RP239 (25 µM) or DMSO vehicle (0.2% final DMSO v/v) 
for 6 hours in a 12-well plate. Aliquots (500 μL) were taken at 6 and 24 hours to assess viability 
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(by annexin V/PI staining and flow cytometry) in order to ensure no toxicity occurred at 6 hours 
but toxicity was observed at 24 hours. After 6 hours of incubation, 5 mL of cells were pelleted 
(500 x g, 5 min) and RNA isolated with on-column DNase digestion. RNA integrity was 
assessed using an Agilent Bioanalyzer. Whole genome transcript profiling was performed on the 
Illumina HumanHT-12 bread array for seven compounds and DMSO control from three 
independent experiments. The raw bead-level files were processed with Illumina® BeadStudio 
3.1, Gene Expression Module v3.2.6 
46
, without background correction or normalization, to get 
one value per beadtype for each array. These 48,803 beadtype values were then input into R 
47
 
using the beadarray package 
48
 from the Bioconductor Project 
49
. The vsn algorithm 
50
 was used 
for background correction, normalization and transformation of the beadtype values to the glog2 
scale. Differential expression was assessed using a mixed linear model using the Limma package 
51
, which uses an empirical Bayes correction 
52 
that helps to improve power by borrowing 
information across beadtypes. All the desired pair-wise comparisons between the 8 treatment 
groups (control + TPMP-III-10 + RP239 + 5 unrelated compounds) were pulled as contrasts 
from the model and the p-values were corrected for multiple hypothesis testing using the False 
Discovery Rate method 
53
 separately for each contrast. In order to facilitate comparisons of our 
results with those of Connectivity Map database we used Illumina‟s probe mapping file that 
matched probes from Illumina‟s HumanWG-6v3 array (same probes as the HumanHT-12 array) 
to Affymetrix‟s  U133Plus2.0 array54. The top 50 up- and down-regulated probe set IDs ordered 
according to fold change were used to create the seed for the connectivity map (CMAP) database 
matching.  
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B16F10 tumor model 
B16F10 cells in HBSS (100 μL of 1 x 107 cells/mL) were injected subcutaneously into 
the right flank of shaved and sedated C57BL/6 female mice (6-8 weeks old). Seven days after 
inoculation, the mice were randomized based upon tumor size with 7 mice per group. Vehicle or 
compound (TPMP-III-10 at 300 mg/kg or RP239 at 150 mg/kg) was administered 
intraperitoneally as a corn oil DMSO suspension (300 μL of 10% DMSO in trans fat-free corn 
oil) once daily for 5 consecutive days. Tumor measurements were performed every other day 
using a caliper and tumor volume was calculated using the equation (0.5 x l x w
2
).  On day 6 
after the commencement of treatment, the mice were sacrificed as the average tumor volume in 
the control group had reached 1800 mm
3
. The tumors were then surgically removed and their 
mass measured.  
 
4T1 tumor model 
4T1 murine breast cancer cells in HBSS (100 μL of 1 x 107 cells/mL) were injected 
subcutaneously into the right flank of shaved and sedated Balb/c female mice (6-8 weeks old). 
Six days after inoculation, the mice were randomized based upon tumor size with 7 mice per 
group. Vehicle or compound (TPMP-III-10 at 300 mg/kg) was administered intraperitoneally as 
a corn oil DMSO suspension (300 μL of 10% DMSO in trans fat-free corn oil) once daily for 5 
consecutive days. Tumor measurements were performed every other day using a caliper and 
tumor volume was calculated using the equation (0.5 x l x w
2
).  On day 7 after the 
commencement of treatment, the mice were sacrificed as the average tumor volume in the 
control group had reached 1000 mm
3
. The tumors were then surgically removed and their mass 
measured.  
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CHAPTER 5. THE DEVELOPMENT OF SMALL MOLECULE 
INHIBITORS OF LACTATE DEHYDROGENASE-A AS CANCER 
THERAPEUTICS 
 
The information and contents of this chapter were partially taken from: Palchaudhuri R. “The 
Development of Small Molecule Inhibitors of Lactate Dehydrogenase-A as Tools to Validate 
Glycolysis Inhibition as an Effective Anti-cancer Strategy” 2009 Original Research Proposal. 
Part of the results in this chapter have been published in Granchi, C.; Roy, S.; Giacomelli, C.; 
Macchia, M.; Tuccinardi, T.; Martinelli, A.; Lanza, M.; Betti, L.; Giannaccini, G.; Lucacchini, 
A.; Funel, N.; Leon, L. G.; Giovannetti, E.; Peters, G. J.; Palchaudhuri, R.; Calvaresi, E. C.; 
Hergenrother, P. J.; Minutolo, F. "Discovery of N-Hydroxyindole-Based Inhibitors of Human 
Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents Against Cancer Cells" J. Med. 
Chem. 2011, 54, 1599-1612. The work in this chapter could not have been performed without the 
help of Dr. Rob Huigens (University of Illinois) and Dr. Carlotta Granchi (University of Pisa) 
who performed the organic synthesis of the compounds investigated, and Karen C. Morrison 
who performed the transcript profile experiments. Emilia Calvaresi aided the biological 
characterization of the LDH-A inhibitors. The inhibition of lactate dehydrogenase-A as an anti-
cancer strategy is currently an active collaborative effort between the labs of Professor Paul J. 
Hergenrother (University of Illinois Urbana-Champaign), Professor Filippo Minutolo (University 
of Pisa) and Professor Pankaj Seth (Harvard Medical School). 
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5.1 Introduction 
Effective and highly selective cancer treatments remain an elusive and outstanding goal 
of modern medicine. Molecules that target rapidly dividing cells by affecting DNA synthesis or 
targets associated with the M-phase of the cell cycle, such as tubulin and topoisomerase II, 
constitute a significant proportion of clinically used anti-cancer agents today, yet result in side 
effects due to toxicity to rapidly dividing normal cells. With the advent of powerful genetic 
techniques, focus has turned to development of personalized medicines in the hope that this 
strategy will yield more effective cancer specific treatments that exhibit minimal toxicity to 
normal cells. Despite this shift, there remain promising anti-cancer targets of broad applicability 
that have been largely overlooked. Although the glycolytic phenotype has been associated with 
cancer for over 70 years and constitutes the basis of 
18
F-2-deoxyglucose (FDG) positron 
emission tomography (PET), we are only starting to realize the implications of this metabolic 
transformation and its contribution to cancer progression. The development of potent inhibitors 
of glycolysis may yield molecules that have the potential to significantly impair cancer growth 
with minimal effects on normal cells. 
 
5.1.1 The link between glycolysis and cancer is well established 
 In the 1930s Otto Warburg observed that > 60% of tumors depended largely on 
glycolysis for producing energy even under sufficiently aerobic conditions.
1, 2
 Targeting this 
metabolic transformation may be an attractive anti-cancer strategy.
3-6
 Although as many as 36 
ATP molecules may be generated by mitochondrial oxidative phorphorylation (glucose 
oxidation) from each glucose molecule, glycolysis only yields 2 ATP molecules per glucose 
molecule.
7
 Despite this considerable inefficiency, cancers may depend on glycolysis for as much 
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as 50% of their energy requirements under aerobic conditions and therefore require high glucose 
consumption.
8
 In stark contrast, normal cells derive over 90% of their ATP from oxidative 
phosphorylation.
9
 In fact, the uptake of 
18
F- 2-deoxyglucose (FDG) by cancers as assessed by 
positron emission tomography (PET) has been effectively used as a tool to monitor tumors.
10-18
  
Over one million FDG-PET studies have indisputably identified increased glucose uptake as a 
hallmark of metastatic cancer in humans.
19  
 
5.1.2 Glycolysis and lactic acid production confers survival benefits to cancers 
The dependency on glycolysis may confer a survival advantage to cancers by enabling 
energy production without the need for oxygen, thus permitting the cells to proliferate in hypoxic 
regions without the development of adequate vasculature.
20
 Elevation of glycolysis contributes to 
malignancy as lactic acid, the end product of glycolysis, is excreted by cancer cells resulting in 
the recruitment of metallo-matrix proteins that degrade the extracellular matrix and promote 
metastasis.
19-23
 Elevated levels of lactate in plasma inhibit the proliferation of cytotoxic T-cells 
and cytokine production by 95%, decreasing their cytotoxic activity by 50% and thereby allow 
cancers to evade immuno-surveillance.
24
 Lactic acid also inhibits the prolyl hydroxylases which 
degradade the transcription factor HIF-1, allowing this transcription factor to act on target genes 
which include the glycolytic enzymes hexokinase II and lactate dehydrogenase (Figure 5.1).
25
 
The generation of lactic acid as an end product of glycolysis therefore serves as a feed-forward 
loop promoting HIF-1 expression and glycolysis. Furthermore, over expression of mitochondrial 
hexokinase II by HIF-1 inhibits mitochondrial permeability transition pore (MPTP) formation by 
preventing the interaction of pro-apoptotic Bax and the voltage dependent anion channel 
(VDAC) thereby conferring resistance to apoptosis
26, 27
  Disruption of the VDAC-hexokinase II 
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interaction by a small molecule results in a decrease in glycolysis, reduction in resistance to 
apoptosis and selectivity against cancer.
28
 Glycolysis and HIF-1 expression together are 
implicated in 6 of the 7 hallmarks of cancer including the evasion of apoptosis, avoidance of 
immuno-surveillance, insensitivity to growth signals, limitless replicative potential, sustained 
angiogenesis and tissue invasion/metastasis.
29
 
 
Figure 5.1.  Hypoxia inducible factor (HIF) upregulates the glycolytic enzymes, hexokinase II (HK-II) and 
lactate dehydrogenase (LDH), while inhibiting oxidative phosphorylation by upregulating pyruvate 
dehydrogenase kinase (PDK) which prevents entry of pyruvate into the TCA cycle by inhibition of 
pyruvate dehydrogenase (PDH). Lactate dehydrogenase activity produces NAD
+
 which feeds into the 
conversion of glucose to pyruvate further promoting glycolysis. Inhibition of the TCA cycle by PDH 
inhibition results in a reduction of the cofactor NADH which is required for oxidative phosphorylation by 
the electron transport chain complexes I-IV. This figure was adapted from Simon et al.
30
 
 
 
5.1.3 Lactate dehydrogenase-A (LDH-A) may be an ideal anti-cancer target 
Lactate dehydrogenase (LDH) is a 35 kDa enzyme that is responsible for the conversion 
of pyruvate to lactic acid in the last step of glycolysis, yielding NAD+ which feeds back into 
glycolysis by promoting the conversion of glucose to pyruvate (Figures 5.1 and 5.2). There are 
three isoforms of human lactate dehydrogenase: A, B and C with 69–75% similarity in amino 
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acid sequences.
31, 32
 LDH-A is expressed in tissues that must accommodate anaerobic 
metabolism, including the liver and skeletal muscle.
31
 LDH-B is present in aerobic tissues such 
as cardiac muscle, while LDH-C is expressed in spermatozoa and testes.
31
 Unlike the other 
isoforms, LDH-A expression is under the control of HIF-1 and the development of LDH-A 
inhibitors is an attractive anti-cancer strategy that has yet to be exploited.
33
 Analysis of tumors 
from the uterine cervix, head and neck, colorectal region revealed that elevated levels of lactate 
versus surrounding non-cancerous tissues correlated with metastasis and poor prognosis with 
concentrations of lactate reaching as high as 40 μM/g.34 Knockdown of LDH-A in tumor cells by 
short hairpin RNAs, (shRNA) as demonstrated in the Neu4145 murine breast cancer line, 
severely compromised the ability of cells to proliferate under hypoxia but did not significantly 
affect proliferation under normoxia.
33
 An orthotopic murine breast cancer study revealed that 
LDH-A knockdown can significantly attenuate tumor growth, increasing the median survival of 
rats from 58 to 162 days.
33
 Although several glycolytic enzymes may be potential anti-cancer 
targets LDH-A is a particularly appealing target as its inhibition, unlike other enzymes involved 
in glycolysis, is not expected to inhibit the TCA cycle/oxidative phosphorylation (Figure 5.1).
7
 
As LDH-A inhibition will not interfere with glucose uptake and transport, it is possible that it 
will not affect normal tissues with high glucose consumption such as the brain, retina, kidneys 
and testes.
7
 Encouragingly, humans with hereditary LDH-A deficiency are asymptomatic under 
normal circumstances and exhibit myogloburina only after intense anaerobic exercise.
35-38
 These 
data suggest LDH-A inhibition may be a highly effective anti-cancer strategy with 
minimal/tolerable side effects. 
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Figure 5.2.  Lactate dehydrogenase converts pyruvate to lactic acid reversibly using NADH as the 
cofactor. 
 
5.1.4 Currently known LDH-A inhibitors 
Lactate dehydrogenase inhibitors reported in the literature have not been extensively 
investigated as cancer therapeutics due to lack of specificity or poor potency. Oxamates, with Ki 
values in the mM range, are competitive inhibitors of the pyruvate binding site and have been 
synthesized as potential antimalarial drugs that selectively inhibit plasmodium LDH relative to 
human LDH (Figure 5.3).
39
 A small molecule natural product obtained from cotton seed, 
gossypol, is a modest μM inhibitor of LDH-A that binds to the NADH binding domain and has 
been investigated for its anti-cancer and anti-HIV properties (Figure 5.3).
40
 Unfortunately 
gossypol lacks specificity among lactate dehydrogenases and also binds to the BH3 domain of 
anti-apoptotic proteins thereby inducing apoptosis.
32, 41
 The 2,3-dihydroxy-1-naphthoic acids, 
inspired by the structure of gossypol, are potent inhibitors of LDH-A, -B and -C in vitro with Ki 
values in the range of 34-0.03 μM for human LDH-A (Figure 5.3). The structural similarities of 
the 2,3-dihydroxy-1-naphthoic acids to gossypol may be a source for off-target effects. 
Encouragingly though, a 2,3-dihydroxy-1-naphthoic acid derivative LDH-A inhibitor, FX-11, 
recently been shown to be active in animal models of cancer.
42
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Figure 5.3.  Oxamates, gossypol and FX-11 as LDH-A inhibitors with their corresponding Ki values. 
 
5.2  N-hydroxyindoles as a novel scaffold for development of LDH-A 
inhibitors 
Computational design studies in the lab of Professor Filippo Minutolo (University of 
Pisa) led to the development of N-hydroxyindole carboxylic acids as a novel scaffold for LDH-A 
inhibitors. Approximately 90 N-hydroxyindole derivatives were synthesized and screened for 
activity against LDH-A in vitro which led to the identification of CG-289 and CG-290 (Figure 
5.4) as lead compounds.
43
 Unlike the naphthoic acid derivatives which are competitive for the 
NADH binding site only, the N-hydroxyindoles compete with both the pyruvate and NADH 
binding sites which may reduce off-target effects.
43
 
In order to validate the inhibition of LDH-A as an anti-cancer strategy we decided to 
evaluate the 2,3-dihydroxy-1-naphthoic acids and N-hydroxyindoles under the same 
experimental conditions. Addition of a hydroxyl group to the para position of FX-11 yielded 
RH2-31, a derivative expected to possess an additional hydrogen-bonding contact in the binding 
pocket that may aid selectivity as suggested by in-silico docking. As poor cell permeability of the 
free carboxylic acids was anticipated we also evaluated the methyl ester versions of the RH and 
CG series in our biological assays.  
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Figure 5.4.  A) 2,3-Dihydroxy-1-Napthoic acid derivatives and B) N-hydroxyindole derivatives investigated 
as LDH-A inhibitors 
 
 
5.3  Evaluation of LDH-A inhibition in vitro 
Commercially available lactate dehydrogenase-A was used to assess inhibition by the RH 
and CG compounds. Kinetic assays for LDH-A activity were performed by monitoring the 
decrease in absorbance of NADH at 340 nm as pyruvate is converted to lactate.
32
  As shown in 
Figure 5.5, RH-2-31 proved to be a potent LDH-A inhibitor with an IC50 of 1.91 µM and this 
compound showed similar activity to the parent FX-11 (IC50 of 1.75 µM). The methyl ester 
versions of the RH compounds were considerably less active with RH2-59 displaying a 6 fold 
loss in activity while 100 µM of RH2-103 was unable to inhibit LDH-A activity by 50%. 
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Consistent with the literature, we found that the 2,3-dihydroxy-1-naphthoic acid RH2-59 was 
more active than the natural product gossypol by approximately 3.3 fold. 
The N-hydoxyindoles CG compounds were considerably less potent than the naphthoic 
acids with the most potent being CG-287 with an IC50 of 9.9 µM (Figure 5.5). In contrast to the 
RH series, the CG methyl ester analogs were more potent than the free carboxylic acids. In 
addition, the presence of the trifluoromethyl group appears to be important for activity as 
removal resulted in a loss in activity for both the free carboxylic acid and methyl ester pairs. 
These in vitro experiments identified CG-287 as the most promising lead compound of the N-
hydroxyl indole series. 
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B) 
  IC50 (µM) % Inhibition at 100 µM Max Inhibition Reached? 
RH1-281 NA 29 ? 
RH2-31 1.91 90 YES 
RH2-59 11.8 65 YES 
FX-11 1.75 88 YES 
RH2-101 NA 25 YES 
RH2-103 NA 39 YES 
CG-287 9.9 56 YES 
CG-288 61 54 ? 
CG-289 NA -19 YES 
CG-290 15.8 87 ? 
Gossypol 5.84 87 YES 
 
Figure 5.5.  A) Lactate dehydrogenase inhibition curves in an in vitro enzymatic assay and B) tabularized 
data obtained from the in vitro lactate dehydrogenase inhibition assay. 
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5.4  Evaluation against cancer cell lines in culture 
 The LDH-A inhibitors were next assessed for their ability to inhibit the proliferation of 
HeLa cervical cancer cells and PANC-1 pancreatic cancer cells in cell culture. These cancer cell 
lines are expected to depend significantly on glycolysis. As LDH-A knockdown under hypoxic 
conditions more potently inhibits cell proliferation, we assessed the effects of the LDH-A 
inhibitors under both normoxic (20% O2) and hypoxic (1% O2) cell culture conditions. Growth 
inhibition assays were performed using sulforhodamine staining to quantify biomass after a 48 
hour incubation in the presence of various doses of compound.
44
 
As shown in Table 5.1, similar trends in activity were observed between the two cell 
lines. Gossypol was the most potent inhibitor of cell proliferation with IC50 values < 10 µM 
under normoxic conditions. RH2-59 was the most potent of the 2,3-dihydroxynapthoic acid 
derivative in cell culture even though its efficacy against LDH-A enzyme in vitro was modest 
compared to FX-11 and RH2-31. This increase in potency may be due to an increase in cell 
permeability from masking of the carboxylic acid with a methyl ester.  
The activity of the CG compounds in cell culture was modest with methyl ester 
derivatives CG-287 and CG-289 being more potent than the carboxylic acid counterparts, 
similar to the trend observed in vitro against LDH-A enzyme. While CG-287 and CG-288 were 
similarly potent against HeLa cells, CG-287 was the more potent analog against PANC-1 cells. 
In comparison to the most potent naphthoic acid derivative (RH2-59), CG-287 was found to be 
approximately 3-fold less potent. 
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Table 5.1.  A) Cell growth inhibition IC50 values obtained in A) HeLa cells and B) PANC-1 cells in a 48 h 
cell culture assay. Cell biomass was quantitated by the sulforhodamine B assay. 
A) 
 Normoxia (µM) Hypoxia (µM) Normox/Hypox 
Gossypol 4.4 11.5 0.4 
RH2-31 98 125 0.8 
RH2-59 17.5 22 0.8 
FX-11 35 100 0.4 
RH2-103 108 155 0.7 
CG-287 56 120 0.5 
CG-288 57 68 0.8 
CG-289 150 36 4.2 
CG-290 107 131 0.8 
2-Deoxyglucose 10,000 >10,000   
B) 
 Normoxia (µM) Hypoxia (µM) Normox/Hypox 
Gossypol 9.2 14 0.7 
RH2-31 108 111 1.0 
RH2-59 20 25 0.8 
FX-11 73 104 0.7 
RH2-103 120 152 0.8 
CG-287 58 56 1.0 
CG-288 90 103 0.9 
CG-289 240 226 1.1 
CG-290 153 214 0.7 
2-Deoxyglucose >10,000 >10,000   
 
 
The potency of gossypol diminished slightly under hypoxic conditions as did the potency 
of the RH and CG series of compounds with the exception of CG-289 in HeLa cells. This 
general decrease in potency under hypoxic conditions is concerning as LDH-A knockdown in 
several cell lines results in potentiation of cell growth inhibition in hypoxic conditions.
33, 45
 
However as immortalized cancer cell lines may be completely dependent on glycolysis under 
normoxic conditions, perhaps subjecting them to hypoxic conditions does not cause an increased 
dependence on glycolysis. Alternatively, as LDH-A transcription may be positively regulated by 
HIF-1, hypoxic conditions may elevate levels of LDH-A resulting in a decrease of the potency of 
the compounds. The recent biological characterization of FX-11 demonstrated that the cells 
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treated with this LDH-A inhibitor die through a ROS-dependent mechanism.
42
 The increased 
generation of ROS was also observed upon LDH-A knockdown which suggests that 
pharmacological inhibition of LDH-A may rely on ROS generation to effect cell death.
42, 45
 As 
hypoxic environments hinder the ability of cells to generate ROS due to the lack of oxygen, this 
may account for the reduction in potency observed with the LDH-A inhibitors. While CG-289 
was the only agent that exhibited selectivity under hypoxic conditions, this may be unrelated to 
LDH-A inhibition as the compound was inactive in the in vitro enzyme assay.  
 
5.5  Inhibition of lactate productions in whole cells  
In order to confirm that the compounds inhibit cellular production of lactic acid, whole 
cells (HeLa) were incubated in DMEM or cell culture media (prepared with 10% dialyzed fetal 
bovine serum) supplemented with 10 mM [1,6-
13
C2]glucose and the rate of production of [3-
13
C]lactate assessed by 
13
C-NMR in the presence of the inhibitors for 12 hours and compared to 
control untreated cells.
46
 Inhibition of LDH-A will result in a lower rate of [3-
13
C]lactate 
production and a decrease in [1,6-
13
C2]glucose consumption.  
To verify that this whole cell assay is functional, we employed positive and negative 
regulators of glycolysis. As shown in Figure 5.6, treatment of the cells with 2-deoxyglucose, an 
inhibitor of glycolysis resulted in a dose dependent decrease in lactate production. Colchicine, an 
inhibitor of microtubule polymerization, was unable to perturb lactate production suggesting the 
suitability of this assay to monitor glycolsysis rather than toxicity. Rapamycin treated cells 
however exhibited a significant increase (60%) in lactate production. This is presumably due to 
hyperactivation of Akt through a compensatory mechanism which is observed upon treatment of 
cells with rapamycin.
47
 As Akt activation promotes the association of hexokinase II to VDAC at 
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the mitochondrial membrane this facilitates the first step of glycolysis and may account for the 
increase in lactate production.
48
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Figure 5.6. Effect of 2-deoxyglucose (2DG), colchicine and rapamycin on [3-
13
C]lactate production from 
[1,6-
13
C2]glucose in HeLa cells after a 12 h incubation. DMSO treated control was defined as 100% 
lactate production. 
 
Since the positive and negative controls performed as expected in the 
13
C-lactate 
production whole-cell assay, we proceeded to investigate the effect of the RH and CG LDH-A 
inhibitors at multiple concentrations (Figure 5.7). While gossypol had demonstrated a 48 h IC50 
of 4.4 µM against HeLa cell proliferation, relatively high concentrations were required for it to 
signficantly inhibit lactate production in the 12 h assay which may indicate off-target effects. 
RH2-103 was found to be largely inactive even at high concentrations of 100 µM, consistent 
with its poor efficacy in the cell proliferation assay and in vitro enzyme assay. RH2-31 and FX-
11 exhibited similar dose dependent responses in inhibiting lactate production in HeLa even 
though FX-11 was significantly more potent in the cell proliferation assay. Of the naphthoic acid 
compounds, RH2-59 proved to be the most potent in inhibiting lactate production which is 
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consistent with its activity in the cell proliferation assay. In contrast to gossypol, the RH 
compounds were able to inhibit lactate production at concentrations similar to their cell 
proliferation IC50 values suggesting these inhibitors have less off-target effects.  
 The CG-289 and CG-290 derivatives demonstrated poor or no activity consistent with 
the 48h cell proliferation suggesting these compounds may be cell impermeable. The methyl 
esters were considerably more active with CG-287 being the most potent of the two in inhibiting 
lactate prodcution, consistent with its greater potency in the cell proliferation assay.   
 RH2-59 at 32 µM  is able to elicit similar levels of lactate production inhibition as 5 mM 
2-deoxyglucose, suggesting at least ≈160 fold greater potency in inhibiting glycolysis. FX-11, 
which was recently shown to elicit anti-tumor activiity in vivo, was slightly less active than the 
most potent of the CG compounds, CG-287, with both achieving similar lactate production 
inhibition at ≈50 fold lower concetrations than 2-deoxyglucose. 
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Figure 5.7. Effect of LDH-A inhibitors on [3-
13
C]lactate production from [1,6-
13
C2]glucose in HeLa cells 
after a 12 h incubation. DMSO treated control was defined as 100% lactate production. 
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5.6  Whole genome transcript profile results 
 To understand the effect that CG-287 and FX-11 have on cells, we performed transcript 
profiling on HL-60 human leukemia cells treated with the compounds for 6 hours. We performed 
the experiment using this short incubation period in order to identify primary responses. The 
transcript profiles of the two compounds were highly similar even though they are of two 
different scaffolds. CG-287 treatment resulted in the down-regulation of 102 transcripts and up-
regulation of 364 transcripts. For FX-11, 960 transcripts were up-regulated and 487 down-
regulated (p values <0.05). Of the 102 down-regulated transcripts of CG-287, 101 were also 
down-regulated in FX-11 with 75 (74%) of them having p values of < 0.05 versus DMSO. Of the 
364 transcripts up-regulated by CG-287, 363 were up-regulated in FX-11 with 336 (92%) having 
p values of < 0.05 versus DMSO. Based on these results 88% of the transcripts affected in CG-
287 are similarly affected in FX-11. 
Using the transcript profiles, we queried the Connectivity Map database collection of 
transcript profiles that contains data from 1300 biologically active small molecules in multiple 
cell lines. This method may be used to identify other molecules in the database with similar 
mechanisms. As there are various ways the query results may be analyzed, a summary of the 
results obtained from the different methods are shown in Tables 5.2 and 5.3 for CG-287 and FX-
11 respectively. A score of 1 represents perfect correlation, a score of 0 represents no correlation, 
and a score of -1 represents perfect anti-correlation. Of substantial note was the matching of the 
glycolysis inhibitor 2-deoxyglucose to CG-287 (Table 5.2A). In addition both CG-287 and 
RH2-59 strongly matched instances of gossypol transcript profiles obtained in HL-60 cells. This 
suggests that CG-287 and FX-11 have similar mechanisms to gossypol which is a fairly potent 
inhibitor of LDH-A in vitro. Gossypol is also thought to have other cellular targets in the cell, 
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such as Bcl-2, and its ability to inhibit LDH-A in a cellular context is yet to be adequately 
characterized. However, in light of the highly similar transcript profiles of CG-287, FX-11 and 
gossypol suggest that these compounds have very similar mechanisms despite the diversity of 
their scaffolds. FX-11 also matched the transcript profile of gefitinib (iressa), a small molecule 
inhibitor of epidermal growth factor receptor (EGFR). As the EGFR pathway is a known 
activator of PI3K/Akt, it is likely EGFR inhibition may negatively regulate glycolysis given 
Akt‟s role in activating glycolysis by promoting association of hexokinase II with VDAC.48-51  
 
Table 5.2 Top two matching compounds in the connectivity map database to the transcript profile of CG-
287 as assessed by A) sorted permuted scores (all cell lines), B) sorted permuted scores (single cell line) 
and C) sorted non-permuted single instance. 
 
rank cmap name mean n enrichment p specificity percent non-null
665 2-deoxy-D-glucose 0.584 1 0.998 --- --- 100
10 valinomycin 0.537 4 0.897 0.0001 0.0233 100
rank cmap name and cell line mean n enrichment p specificity percent non-null
1241 gossypol - HL60 1 1 1 --- --- 100
1242 alexidine - HL60 0.711 1 1 --- --- 100
rank batch cmap name dose cell score up down instance_id
1 645 gossypol 8 µM HL60 1 0.569 -0.455 2202
2 649 alexidine 7 µM HL60 0.711 0.426 -0.302 2576
A)
B)
C)
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Table 5.3 Top two matching compounds in the connectivity map database to the transcript profile of FX-
11 as assessed by A) sorted permuted scores (all cell lines), B) sorted permuted scores (single cell line) 
and C) sorted non-permuted single instance. 
 
rank batch cmap name dose cell score up down instance_id
1 645 gossypol 8 µM HL60 1 0.387 -0.415 2202
2 619 minocycline 8 µM HL60 0.957 0.323 -0.444 2405
rank cmap name and cell line mean n enrichment p specificity percent non-null
876 gossypol - HL60 1 1 1 --- --- 100
877 minocycline - HL60 0.957 1 1 --- --- 100
rank cmap name mean n enrichment p specificity percent non-null
411 gefitinib 0.691 1 0.998 --- --- 100
12 5224221 0.686 2 0.997 0.00002 0.0112 100
A)
B)
C)
 
 
5.7 Effect of LDH-A inhibition in animal models of cancer 
Since FX-11 inhibition of LDH-A was recently validated to inhibit tumor growth in vivo 
animal models, we focused our attention to the validating the CG derivatives. The assays 
performed thus far had identified CG-287 as the lead compound. In order to further improve on 
its activity, CG-287 was conjugated to a glucose molecule to yield Gluc-287 (Figure 5.8). 
Conjugation of small molecule anti-cancer agents to glucose is a strategy to increase selectivity 
towards cancer cells which express high levels of glucose transporters at the cell membrane. In 
fact several cancers have been identified that overexpress GLUT1 and GLUT4 as a means to 
increase glucose uptake and facilitate the high avidity of cancer cells for glucose. While Gluc-
287 is inactive against LDH-A enzyme in vitro, glycohydrolases present in the cytosol may 
possibly remove the glucose and yield free CG-287 capable of inhibiting LDH-A in the cell. In 
order to verify an increased uptake, Gluc-287 and CG-287 were assessed for their ability to 
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inhibit the murine 4T1 breast cancer cell line in cell culture. As shown in Figure 5.8, Gluc-287 
was 2-fold more potent than CG-287 in inhibiting 4T1 proliferation.  
 
Figure 5.8. The structures of CG-287 and its glucose conjugated derivative Gluc-287 and their efficacy 
against 4T1 murine breast cancer in 72 h proliferation assays. Cell biomass was measured by the 
sulforhodamine B assay. 
 
As Gluc-287 was more potent than CG-287, we investigated the efficacy of Gluc-287 in 
a syngeneic subcutaneous model of 4T1 in Balb/c mice. The tumor volume was measured using 
a caliper and calculated using the formula volume (mm
3
) = width
2
 x length/2. Once tumors 
reached a size of 100 mm
3
, Gluc-287 was administered at 150 mg/kg intraperitoneally once a 
day for 5 consecutive days with the tumor volume measured every other day. On day 7, the 
tumors were excised and weighed. As shown in Figure 5.9, Gluc-287 was unable to inhibit 
tumor growth to any significant extent under these conditions. The efficacy of Gluc-287 and 
other LDH-A inhibitors will need to be investigated further to identify optimal conditions. 
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Figure 5.9. A) 4T1 breast cancer subcutaneous tumor growth in Balb/c mice over the course of 6 days 
and B) 4T1 tumor weight obtained by excision of tumors from mice at day 7. 
 
 
5.8 Conclusions and outlook 
 In recent years, the inhibition of glycolysis as an anti-cancer strategy has been the focus 
of considerable attention and effort. This metabolism-centric targeting of cancer may be a magic 
bullet that can potentially eliminate side effects of traditional therapeutics that typically target all 
rapidly dividing cells whether they are cancerous or not. While there are many enzymes involved 
in the glycolytic cascade, it remains to be determined which particular enzymes may be best 
suited for intervention by small molecule inhibitors. Considerable cell culture and in vivo 
evidence supports lactate dehydrogenase-A as a suitable target. However, there remains much 
work to be done to develop highly potent inhibitors of LDH-A to validate this hypothesis.  
 The N-hydroxyindoles and 2,3-dihydroxy-1-naphthoic acids are the two most potent 
classes of LDH-A inhibitors currently known. While FX-11 was recently shown to exhibit anti-
tumor effects in vivo, the N-hydroxyindoles may also prove useful biological tool molecules due 
to their ability to compete with both pyruvate and NADH binding sites. This dual binding site 
inhibition may allow development of more potent and specific inhibitors of LDH-A. The work 
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presented in this chapter demonstrates that both classes of molecules are capable of inhibiting 
LDH-A enzyme in vitro. In addition they are able to inhibit cell proliferation and prevent lactate 
production in whole cells, indicative of LDH-A inhibition in a cellular context. While the N-
hydroxyindole based Gluc-287 failed to demonstrate in vivo efficacy in this one specific murine 
tumor model, further efforts will be aimed at assessing other analogs and optimizing in vivo 
activity will be required. 
While LDH-A is highly expressed in cancer cells relying on aerobic glycolysis, it remains 
unknown exactly how much inhibition will be sufficient to elicit inhibition of cell growth. It is 
also unknown whether small molecule-based LDH-A inhibition is likely to succeed as a 
monotherapeutic strategy or will likely require combination/potentiation with other standard 
therapeutics. In addition, whether LDH-A inhibition will succeed in hypoxic regions where 
LDH-A expression is upregulated by HIF-1 and where the lack of oxygen may prevent oxidative 
stress-induced cell death downstream of LDH-A inhibition remains to be determined. Having a 
potent, specific, easily synthesizable small molecule LDH-A inhibitor will enable us to answer 
these questions. 
 
5.9  Materials and methods 
General 
Human LDH-A (LDH-5) was purchased from GenWay Biotech Inc. (San Diego, CA). 
Sulforhodamine B, gossypol, colchicine, rapamycin, pyruvate, and NADH were purchased from 
Aldrich. MTS was purchased from Promega Inc. D-[1,6-
13
C2]-glucose was obtained from 
Omicron Biochemicals Inc. RNA isolation was conducted using the Qiagen mini-prep RNeasy 
kit (Qiagen) with on-column DNase digest performed using RNase-free DNase (Qiagen). 
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Illumina HumanHT-12 bread array was purchased from Illumina. Balb/c female mice (6-8 weeks 
old) were purchased from Charles River. 
 
Cell culture conditions 
All cells were grown in RPMI 1640/DMEM/IMDM media supplemented with 10% FBS, 
1% penicillin-streptomycin and incubated at 37 ºC in 5 % CO2, 95% humidity incubator. 
Hypoxic experiments were conducted in a hypoxic incubator at 37 ºC in 5 % CO2, 1 % O2, 95 % 
humidity environment. 
 
Lactate dehydrogenase inhibition 
Human lactate dehydrogenase-5 (LDH-5) was dissolved in 100 mM Tris buffer (pH 7.5) 
at a concentration of 0.003 units/mL. The enzyme solution (79 µL) was added to a 96-well plate 
containing 1 µL DMSO stocks of the LDH-A inhibitors. The plate was incubated for 30 minutes 
at 37 ºC. A solution containing sodium pyruvate and NADH in 100 mM Tris was added (20 µL) 
to each well to achieve final concentrations of 10 mM pyruvate and 1 mM NADH. A kinetic read 
was performed for 1 hour at 37 ºC measuring the absorbance at 340 nm. The slopes of linear 
portions of the kinetic curves were used to determine LDH-A activity.  
 
Sulforhodamine B cell proliferation assay 
Serial dilutions of compound in 100% DMSO were added in triplicate (2 μL to each well) 
to empty wells of a 96-well plate. Adherent cells (HeLa or PANC-1) were added to each well (8 
x 10
3
 cells in 198 μL of RPMI 1640 or DMEM media). The plates were incubated for 48 hours in 
normoxic or hypoxic cell culture incubators. The media was removed from the plate and ice-cold 
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trichloroacetic acid (100 μL of 10% w/v trichloroacetic acid) was added to the plates which were 
then incubated at 4 ºC overnight to fix the cells. The trichloroacetic acid was removed and the 
wells washed with 200 μL of de-ionized water 5 times. Sulforhodamine B (200 μL of 0.04 % 
sodium salt dissolved in 1% acetic acid) was added to each well and the plates incubated at room 
temperature for 30 min. Excess sulforhodamine B was removed by washing the plates 5 times 
with 1% acetic acid. The bound dye was released by the addition of unbuffered Tris-base (200 
μL of 10 mM solution) and after a 30 min incubation at room temperature the absorbance at 510 
nm was measured (Molecular Devices SpectraMax Plus 384 plate reader).  
 
NMR experiments on perfused cell cultures.  
These experiments were conducted as previously reported.
43
 Briefly, HeLa cells were 
grown in 24-well plates in RPMI-1640 media supplemented with 10% FBS and 1% 
Penicillin/Streptomycin, at 37 °C in a 5% CO2, 95% humidity incubator to a confluency of 
>90%. The media was aspirated and the cells washed by incubating with glucose-free DMEM 
(10% dialyzed FBS) without phenol red for 15 minutes and the media was replaced with 990 μL 
DMEM supplemented with 10 mM D-[1,6-
13
C2]-glucose. DMSO stocks of each compound for 
each concentration were prepared at 100x the final desired concentration and added to the cells 
(1% DMSO final concentration in wells). Vehicle controls were included in each plate. Plates 
were incubated under normoxia in a 37 ºC, 5% CO2, 95% humidity incubator. After an 
incubation time of 6 and 12 hours, 500 L from each well were collected and the samples were 
stored at –20 °C. For preparing NMR tubes, the samples were defrosted and 100 L of deuterium 
oxide was added. The resulting solutions were transferred to 5-mm NMR tubes. 
13
C-spectra were 
acquired (200 scans) with a 500 MHz Varian spectrometer under fully relaxed conditions with no 
 
 
229 
 
N.O.E. using a 60º pulse angle and spectral width of 15,000 Hz. Line broadening of 3 Hz was 
used for the spectra. NMR spectra were analyzed by using MestReC software. 
 
Gene expression analysis 
HL-60 cells (3,000,000 in 6 mL IMDM 1640 with 10% FBS) were incubated in the 
presence of 50 μM CG-287, 100 μM FX-11 or DMSO vehicle (0.2% final DMSO v/v) for 6 
hours in a 12-well plate. Aliquots (500 μL) were taken at 6 and 24 hours to assess viability (by 
annexin V/PI staining and flow cytometry) in order to ensure no toxicity occurred at 6 hours but 
toxicity was observed at 24 hours. After 6 hours of incubation, 5 mL of cells were pelleted 
(500xg 5 min) and RNA isolated with on-column DNase digestion. A total of three independent 
treatments and isolations were performed. RNA integrity was assessed using an Agilent 
Bioanalyzer. Whole genome transcript profiling was performed on the Illumina HumanHT-12 
bread array for seven compounds and DMSO control from three independent experiments. The 
raw bead-level files were processed with Illumina® BeadStudio 3.1, Gene Expression Module 
v3.2.6 
52
, without background correction or normalization, to get one value per beadtype for each 
array. These 48,803 beadtype values were then input into R 
53
 using the beadarray package 
54
 
from the Bioconductor Project 
55
. The vsn algorithm 
56
 was used for background correction, 
normalization and transformation of the beadtype values to the glog2 scale. Differential 
expression was assessed using a mixed linear model using the Limma package
57
, which uses an 
empirical Bayes correction
58 
that helps to improve power by borrowing information across 
beadtypes. All the desired pair-wise comparisons between the 8 treatment groups (control + FX-
11 + CG-287 + 5 unrelated compounds) were pulled as contrasts from the model and the p-
values were corrected for multiple hypothesis testing using the False Discovery Rate method 
59
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separately for each contrast. In order to facilitate comparisons of our results with those of 
Connectivity Map database we used Illumina‟s probe mapping file that matched probes from 
Illumina‟s HumanWG-6v3 array (same probes as the HumanHT-12 array) to Affymetrix‟s  
U133Plus2.0 array.
60
 The statistically significant (p value < 0.05) up- and down-regulated probe 
set IDs ordered according to fold change were used to create the seed for the connectivity map 
(CMAP) database matching. Analysis of the canonical pathways was performed using Ingenuity 
Pathway Analysis (IPA, Ingenuity Systems) software using a p-value cutoff of 0.05 to define the 
network eligible genes. 
 
Subcutaneous tumor growth model 
4T1 murine breast cancer cells in HBSS (100 μL of 1 x 107 cells/mL) were injected 
subcutaneously into the right flank of shaved and sedated Balb/c female mice (6-8 weeks old). 
Six days after inoculation when tumors averaged 100 mm
3
, the mice were randomized with 7 
mice per group. Vehicle or Gluc-287 (150 mg/kg) was administered intraperitoneally as a corn 
oil DMSO suspension (300 μL of 10% DMSO in trans fat-free corn oil) once daily for 5 
consecutive days. Tumor measurements were performed every other day using a caliper and 
tumor volume was calculated using the equation (0.5 x l x w
2
).  On day 7 after the 
commencement of treatment, the mice were sacrificed as the average tumor volume in the 
control group had reached 1000 mm
3
. The tumors were then surgically removed and their mass 
measured.  
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CHAPTER 6.  MECHANISM OF CRIBROSTATIN 6- AND DNQ-INDUCED 
CYTOTOXICITY 
 
The information and contents for this chapter were reproduced in part with permission from i) 
Bair, J. S.; Palchaudhuri, R.; Hergenrother, P. J. "Chemistry and Biology of Deoxynyboquinone, 
a Potent Inducer of Cancer Cell Death" J. Am. Chem. Soc. 2010, 132, 5469-5478. Copyright 
2010, American Chemical Society; and ii) Hoyt, M.T.; Palchaudhuri, R.; Hergenrother, P. J. 
“Cribrostatin 6 Induces Death in Cancer Cells Through a Reactive Oxygen Species (ROS)-
Mediated Mechanism” Invest. New Drugs 2011, 29, 562-573. This work could not have been 
accomplished without Joseph S. Bair and Mirth T. Hoyt who performed the synthesis and aided 
biological characterization of DNQ and cribrostatin 6 respectively. Josepeh S. Bair and 
Elizabeth Parkinson contributed to the characterization of DNQ as an inducer of NQO1-
dependent cell death. I would also like to acknowledge Professor David A. Boothman 
(University of Texas Southwestern Medical School) for the discovery of DNQ’s dependence on 
NQO1 activity for cell death and for experimental discussion. 
 
6.1 Introduction 
 Several quinones have clinical relevance in the treatment of cancer, including FDA-
approved mitoxantrone, mitomycin C and doxorubicin. In addition to the propensity to undergo 
bioreduction and subsequent redox cycling to produce reactive oxygen species (ROS), quinones 
may have other mechanisms of action such as topoisomerase inhibition (e.g. streptonigrin, 
doxorubicin, and mitoxantrone),
1, 2
 DNA alkylation (mitomycin C, EO9)
3-6
 and Hsp90 inhibition 
(e.g. geldanamycin).
7, 8
 The mechanistic diversity of quinone-containing molecules warrants the 
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continued investigation of quinones whose mode-of-action is unknown in the pursuit of 
identifying therapeutically-promising candidates. Deoxynyboquinone (DNQ), a quinone 
originally derived from the natural product antibiotic nybomycin, was first synthesized at the 
University of Illinois by Professor Rinehart in the 1960s (Figure 6.1).
9
 DNQ was found to 
exhibit potent anti-cancer activity in the National Cancer Institute 60 cancer cell line panel and 
was re-discovered by the Hergenrother lab as a potent inducer of cell death in a high-throughput 
toxicity screen against human HL-60 leukemia cells. A revised bottom-up synthesis of DNQ was 
accomplished in the Hergenrother lab enabling further characterization of the biological activity 
of this molecule.
10
 
Cribrostatin 6 (Figure 6.1), is a natural product quinone belonging to the cribrostatin 
family of quinones isolated from sea sponge Cribrochalina or Petrosia.
11-13
 Quinones of the 
cribrostatin family have been noted for their antineoplastic activity with IC50 values of 0.045–25 
μM against P-388 murine leukemia cells, as well as for their anti-bacterial and anti-fungal 
activities.
11-13
 Cribrostatin 6 has an IC50 value of 1.1 μM for growth inhibition against P-388 
cells.
12
 This chapter describes the use of a variety of tools which include transcript profiling, cell 
cycle arrest experiments and cytoprotection studies using small molecule inhibitors to further 
characterize the mechanisms by which DNQ and cribrostatin 6 induce cytotoxicity in cancer 
cells. 
 
Figure 6.1. Structures of DNQ and cribrostatin 6, quinones with anti-cancer activity. 
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6.2 Global transcription profiling of cribrostatin 6- and DNQ-treated cells 
As described in Chapter 1, the analysis of global transcriptional changes in response to 
compound treatment can be used to identify cellular pathways affected by a small molecule, and 
in some cases can suggest a macromolecular target.
14-16
  Whole genome transcriptional profiling 
of human lymphoma U-937 cells treated with cribrostatin 6 (15 μM) or DNQ (350 nM) for 6 
hours was performed using the Illumina humanHT-12 array.  This concentration and time point 
were selected so that the data gathered could be compared to the Connectivity Map, a database of 
small molecule transcript profiling experiments.
16
 The transcripts that were elevated and reduced 
(top 20 for both) in response to cribrostatin 6 treatment of U-937 cells are shown in Table 6.1 
and for DNQ-treated cells are shown in Table 6.2. 
 
Table 6.1. U-937 cells were treated with cribrostatin 6 (15 µM) or 0.2% DMSO for 6 hours, at which time 
the mRNA was isolated and the global transcriptional profile was determined. The top 20 elevated and 
repressed transcripts from this experiment are listed. 
Symbol Protein Function p value 
Fold 
Change 
HMOX1 Heme oxygenase 1  antioxidant 0 28.7 
IL8 interleukin 8 inflammation 0 4.7 
IL8 interleukin 8 inflammation 0 4.1 
SRXN1 sulfiredoxin 1 homolog oxidative stress 0 3.5 
OKL38 
oxidative stress induced growth inhibitor 
1 oxidative stress 0 3.5 
TNF Tumor Necrosis Factor death ligand 0 3.3 
FTH1 ferritin, heavy polypeptide-like 1 intracellular iron storage 0 3.3 
FTHL12 ferritin, heavy polypeptide-like 12 intracellular iron storage 0 2.8 
FTHL8 ferritin, heavy polypeptide-like 8 intracellular iron storage 0.0000001 2.8 
SQSTM1 sequestosome 1  regulation of NF-kB) 0.0000003 2.6 
GCLM 
glutamate--cysteine ligase modifier 
subunit glutathione synthesis 0 2.6 
SLC7A11 Solute carrier family 7 member 7  cationic amino acid transporter 0 2.6 
FTHL11 ferritin, heavy polypeptide-like 11 intracellular iron storage 0.0000006 2.5 
MAFB 
V-maf musculoaponeurotic fibrosarcoma 
oncogene homolog B  represses ETS1-mediated transcription 0 2.5 
RIT1 Ras-like without CAAX 1  
activation of EPHB2 and MAPK14 
signaling 0 2.5 
TM4SF1 transmembrane 4 L six family member 1 
cell surface antigen expressed in 
carcinomas 0.0000001 2.4 
FTHL3 ferritin, heavy polypeptide-like 3 intracellular iron storage 0.0000036 2.3 
FTHL2 ferritin, heavy polypeptide-like 2 intracellular iron storage 0.0000235 2.3 
FTHL11 ferritin, heavy polypeptide-like 11 intracellular iron storage 0.0001174 2.3 
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Table 6.1 (continued) 
Symbol Protein Function p value 
Fold 
Change 
CDKN1A Cyclin-dependent kinase inhibitor 1A p53-dependent G1 phase arrest  0 2.3 
     
FAM46C hypothetical protein LOC54855  0.0000003 -2.0 
LOC201164 
phosphatidylcholine-hydrolyzing 
phospholipase D6  0.0000225 -1.8 
TFRC transferrin receptor cellular iron uptake 0.0011374 -1.8 
VCX variably charged protein X-B1  0.0000998 -1.7 
LOC649856   0.001137 -1.7 
PTPLAD1 
protein tyrosine phosphatase-like A 
domain containing 1 Rac1-signaling 0.0000882 -1.6 
VCX-C variably charged protein X-C  0.0001519 -1.6 
FAM46A hypothetical protein LOC55603  0.0002401 -1.6 
PFKFB4 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 4 fructose 2,6-bisphosphate synthesis  0.0479886 -1.6 
VCX3A variably charged protein X-3A  0.0002669 -1.5 
ELOVL3 cold-inducible glycoprotein of 30 kDa neutral lipid formation 0.0012824 -1.5 
NFE2 leucine zipper protein NF-E2 hemoglobin production 0.0243916 -1.5 
CD47 CD47 molecule membrane transport/signal transduction 0.0046719 -1.5 
MYB c-myb protein transcriptional activator 0.0000765 -1.5 
SYNC1 syncoilin, intermediate filament 1  0.0033578 -1.5 
ZNF395 zinc finger protein 395 papilloma virus genes transcription 0.0040402 -1.5 
DHRS9 3-alpha hydroxysteroid dehydrogenase retinoic acid biosynthesis 0.0031682 -1.5 
GJB2 gap junction protein beta 2 cell-to-cell ion/small molecules transfer 0.0081905 -1.5 
GFI1 
growth factor independent 1 transcription 
repressor S-phase gene transcription 0.0006575 -1.4 
PDYN proenkephalin B  0.023222 -1.4 
 
Cells treated with cribrostatin 6 or DNQ both had elevated levels of transcripts for heme 
oxygenase 1 (HMOX1) (28.7 fold change for cribrostatin 6 and 8.8 fold for DNQ) which is 
under the transcriptional control of Nrf2, a transcription factor activated under oxidative stress 
(Tables 6.1 and 6.2).
17, 18
 HMOX1 encodes for HO-1, a 32 kDa heat-shock protein, which 
regulates cellular heme and iron concentrations.
17, 19
 Elevated levels of this protein prevent cell 
death by converting heme to biliverdin, a potent antioxidant.
20
 This conversion also results in the 
production of carbon monoxide (a potential neurotransmitter), and free iron, which serves as an 
oxidative stress signal.
19
  Biliverdin produced by heme oxygenase is rapidly degraded into 
bilirubin, another potent small molecule antioxidant.
20
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Other common transcripts elevated in both cribrostatin 6- and DNQ-treated cells include 
those for various ferritins, which are also under the transcriptional control of Nrf2.
18
 Ferritins are 
responsible for the storage of free iron in a non-toxic form and soluble form.
18
 In addition, both 
compounds up-regulated oxidative stress transcripts for sulfiredoxin 1 (SRXN1) and oxidative 
stress induced growth inhibitor (OKL38). 
21, 22
  Furthermore cribrostatin 6-treated cells up-
regulated the glutamate-cysteine ligase modifier subunit (GCLM) involved in glutathione 
synthesis and down-regulated transferrin receptor (TFRC) involved in iron uptake and the 
leucine zipper protein NF-E2 involved in hemoglobin production (Table 6.1). Other notable 
transcripts changes in DNQ-treated cells included the elevation of the chemokine interleukin-8 
(IL-8), a stimulator of the inflammatory response and angiogenesis; the down regulation of 
interferon-inducible cytokine IP-10 (CXCL10) which stimulates monocytes, natural killer cells 
and T-cell migration; the elevation of cell membrane glucose transporters (SLC2A3 and 
SLC2A14). 
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Table 6.2. U-937 cells were treated with DNQ (350 nM) or 0.2% DMSO for 6 hours, at which time the 
mRNA was isolated and the global transcriptional profile was determined. The top 20 elevated and 
repressed transcripts from this experiment are listed.  
a
These are different probes for the same transcript. 
Symbol Protein Function p value Fold 
Change 
HMOX1 heme oxygenase 1 antioxidant 0 8.8 
ADM adrenomedullin hypotensive and vasodilatator agent 0.0000002 4.0 
IL8
a
 interleukin 8 inflammation 0 3.7 
IL8
a
 interleukin 8 inflammation 0 3.5 
DDIT4 DNA damage inducible transcript 4 cell growth inhibition 0.0000017 3.4 
FTH1 ferritin, heavy polypeptide-like 1 intracellular iron storage 0.0000002 2.3 
CDKN1A cyclin-dependent kinase inhibitor 1A p53-dependent G1 phase arrest  0 2.3 
FTHL12 ferritin, heavy polypeptide-like 12 intracellular iron storage 0.0000012 2.3 
FTHL8 ferritin, heavy polypeptide-like 8 intracellular iron storage 0.0000187 2.2 
SLC2A3 facilitative glucose transporter glucose transport 0.0000018 2.2 
TNF tumor necrosis factor death ligand 0 2.2 
OKL38 oxidative stress induced growth inhibitor 1 oxidative stress 0.0000005 2.2 
FTHL11 ferritin, heavy polypeptide-like 11 intracellular iron storage 0.0000399 2.1 
FTHL2 ferritin, heavy polypeptide-like 2 intracellular iron storage 0.0002126 2.1 
CCL3L3 G0/G1 switch regulatory protein 19-2 cytokine 0 2.1 
SRXN1 sulfiredoxin 1 homolog oxidative stress 0 2.1 
MAFB V-maf musculoaponeurotic fibrosarcoma 
oncogene homolog B 
represses ETS1-mediated 
transcription 
0.0000005 2.1 
CCL3 G0/G1 switch regulatory protein 19-1 HIV-suppressive factor 0.0000003 2.1 
SLC2A14 glucose transporter type 14 glucose transport 0.0000044 2.0 
NDRG1 N-myc downstream regulated 1 p53-mediated caspase 
activation/apoptosis 
0.0000098 2.0 
VCX variably charged protein X-B1  0.0000004 -2.0 
VCX-C variably charged protein X-C  0.0000005 -1.9 
VCX3A variably charged protein X-A  0.0000001 -1.9 
GJB2 gap junction protein beta 2 cell-to-cell channel for ion/small 
molecules transfer 
0.0000094 -1.8 
MS4A7 CD20 antigen monocyte maturation 0.0000163 -1.7 
RBBP9 retinoblastoma-binding protein 9 resistance to TGF-beta1 growth 
inhibition  
0.0002341 -1.7 
ZFYVE26 zinc finger, FYVE domain containing 26  0.0000159 -1.7 
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Table 6.2 (continued) 
 
Symbol Protein Function p value Fold 
Change 
DHRS9 3-alpha hydroxysteroid 
dehydrogenase 
retinoic acid biosynthesis 0.0000457 -1.7 
RBM17 RNA binding motif protein 17 sickle cell anemia 0.0000303 -1.6 
FARP1 chondrocyte-derived ezrin-like protein  0.0000568 -1.6 
CCDC26 coiled-coil domain containing 2  0.0003167 -1.6 
CD47 CD47 molecule membrane transport/signal 
transduction 
0.0016747 -1.6 
MEF2D myocyte enhancer factor 2D transcription factor 0.0001738 -1.5 
CCDC136 coiled-coil domain containing 136  0.0005653 -1.5 
CXCL10 interferon-inducible cytokine IP-10 immune cell migration 0.0045669 -1.5 
CENPE centromere protein E G2-phase motor protein 0.001486 -1.5 
MS4A7 CD20 antigen monocyte maturation 0.0002341 -1.5 
KIF20A mitotic kinesin-like protein 2  0.0005729 -1.5 
TXNIP thioredoxin-binding protein 2 oxidative stress mediator 0.0252104 -1.5 
C5orf29 GRB2-binding adaptor protein transmembrane protein 0.0003523 -1.5 
 
 
The statistically most significant canonical pathways affected by cribrostatin 6 were the 
Nrf2 oxidative stress mediated pathway (p value 9.51 x 10
-11
), followed by the TREM1 (p value 
3.06 x 10
-7
) and the glucocorticoid receptor signaling pathways (p value 1.7 x 10
-5
), which 
modulate inflammatory responses (Table 6.3). The involvement of Nrf2-oxidative stress pathway 
was also the most strongly implicated pathway for DNQ according to Ingenuity Pathway 
Analysis software (p value 2.70 x 10
-8
, Table 6.4). In summary, global transcriptional profiling 
provides strong evidence that cribrostatin 6 and DNQ induce the oxidative stress response, 
consistent with a ROS-based mechanism of cell death.  
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Table 6.3. The top 10 canonical pathways implicated by Ingenuity Pathway Analysis software of 
transcripts affected by cribrostatin 6 treatment. Transcripts with p values < 0.05 were used for the 
analysis. 
 
 
 
Table 6.4. The top 10 canonical pathways implicated by Ingenuity Pathway Analysis software of 
transcripts affected by DNQ treatment. Transcripts with p values < 0.05 were used for the analysis. 
 
 
6.3 Cribrostatin 6 and DNQ elevate heme monooxygenase 1 (HO-1) protein  
  In order to confirm that treatment of cells with cribrostatin 6 or DNQ elevates HO-1 at 
the protein level, a Western blot was performed on cells treated with cribrostatin 6 or DNQ for 
six hours.  Hemin, a compound that induces the transcription of Nrf2 and HMOX-1,
23
 was used 
as a positive control for elevation of HO-1 protein.  As shown in Figure 6.2, cribrostatin 6 
treatment (at 15 and 30 μM) or DNQ treatment (0.5 and 1 μM) elevated HO-1 protein levels in 
U-937 cells.  This elevation could be prevented by co-treatment of cells with the antioxidant N-
acetyl-L-cysteine (NAC), strongly suggesting that HO-1 up-regulation is ROS-mediated. 
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Figure 6.2. Treatment of U937 human lymphoma cells with A) cribrostatin 6 and B) DNQ induces heme 
oxygenase 1 (HO-1) protein expression that can be prevented by the antioxidant NAC. Hemin is a 
positive control for HO-1 induction. 
 
It has been noted that oxidative stress can activate the heat shock response (HSR) 
expression pathway and up-regulate HSP-70 in response to oxidative stress inducing molecules 
such as elesclomol.
24-26
 Thus, HSP-70 protein levels in cells treated with DNQ were analyzed by 
Western blot. Both DNQ and elesclomol caused an increase in HSP-70 levels in U-937 cells 
(Figure 6.3), consistent with oxidative stress induction. 
 
 
 
247 
 
HSP-70
β-actin
DNQ (μM)
Elesclomol (μM)
-
-
0.25
-
0.5
-
-
0.01
-
0.1
-
0.25
 
Figure 6.3.  DNQ treatment enhances the levels HSP-70 protein in U937 cells. Elesclomol is a positive 
control for oxidative stress induced elevation of HSP-70.  
 
6.4 Connectivity Map (CMAP) database results 
The gene expression signature of cribrostatin 6- and DNQ-treated U-937 cells was 
compared to analogous signatures for over 1300 biologically active small molecules; the 
macromolecular target is known for most of these compounds.  Thus, use of this Connectivity 
Map database can allow the identification of the mechanism of action of bioactive molecules by 
comparison to the gene expression signature of molecules with known mode of actions 
15
.  This 
database contains several quinones and multiple topoisomerase inhibitors, including doxorubicin, 
daunorubicin, mitoxantrone, etoposide, camptothecin, and irinotecan. As shown in Table 6.5, the 
topoisomerase inhibiting quinones were not in the top 5 matches to DNQ or cribrostatin 6. 
Instead menadione, a quinone that induces cell death through ROS generation matched best with 
DNQ (score 0.693).
27
 In the case of cribrostatin 6, anisomycin and 15-delta prostaglandin J2, 
compounds that induce cell death through ROS generation, matched the best (scores of 0.644 and 
0.553 respectively).
28, 29
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Table 6.5. Top 5 A) DNQ- and B) cribrostatin 6-correlating compounds in the CMAP database. 
 
A) 
rank cmap name mean n enrichment p specificity percent non-null 
1 menadione 0.639 2 0.981 0.00064 0.0133 100 
2 spiperone 0.561 2 0.98 0.00074 0.0101 100 
3 terfenadine 0.542 3 0.955 0.0001 0.0246 100 
4 phenoxybenzamine 0.532 4 0.985 0 0.0545 100 
5 1,4-chrysenequinone 0.531 2 0.97 0.00163 0.0109 100 
 
B) 
rank cmap name mean n enrichment p specificity percent non-null 
1 anisomycin 0.644 4 0.976 0 0.0155 100 
2 oxyphenbutazone 0.633 4 0.974 0 0 100 
3 15-delta prostaglandin J2 0.553 15 0.727 0 0.0223 80 
4 thioridazine 0.267 20 0.581 0 0.1416 50 
5 trichostatin A 0.251 182 0.508 0 0.2796 57 
 
 
6.5  DNQ induces G0/G1-phase cell cycle arrest  
Modes of cell death may be broadly categorized by their effects on the progression of 
actively dividing cells through the cell cycle. For example, DNA damaging agents and 
microtubule disrupters or stabilizers frequently arrest cells in mitosis (M-phase) whereas 
compounds that inhibit DNA synthesis or replication arrest in the synthesis (S) phase. Common 
biological properties of anthracycline-type compounds similar in structure to DNQ include DNA 
binding, topoisomerase inhibition, and cell cycle arrest in the S or G2/M phases.
30-33
 Gene 
expression analysis of DNQ revealed the elevation of several transcripts related to p53 
dependent pathways and G0/G1 cell cycle regulation (CDKN1A, CCL3L3, CCL3, NDRG1, 
OKL38). The down regulation of G2/M associated motor kinesin transcripts was also observed 
(CENPE and KIF20A, Table 6.2). The effect of DNQ on cell cycle progression was observed by 
treating HL-60 cells with DNQ for 6 hours (Figure 6.4A). Consistent with the transcript profiling 
results DNQ caused significant cell cycle arrest in the G1 phase. In contrast, doxorubicin-treated 
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cells exhibited weak G2/M-phase arrest at low concentrations and a pronounced S-phase arrest at 
higher concentrations (Figure 6.4B).  
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Figure 6.4. A) DNQ treatment leads to arrest of cells in the G1-phase of the cell cycle, while B) 
doxorubicin treatment leads to S-phase arrest.  HL-60 cells were treated with the indicated concentrations 
of compound (or DMSO control) for 6 hours, at which point DNA levels were analyzed by propidium iodide 
staining. Error bars represent standard deviation of the mean, n = 3. 
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6.6 DNQ induces NQO1-dependent programmed necrosis 
Quinones may be activated to produce superoxide anion radicals by a 1- or 2-electron 
reduction (Figure 6.5).
34
 One-electron reductions may be mediated by a number of reducing 
enzymes including cytochrome P-450s, which are ubiquitously expressed in all cells.
34
 Two-
electron reductions, on the other hand, are mediated almost exclusively by NAD(P)H quinone 
oxidoreductase 1 (NQO1).
34
 As NQO1 is significantly up-regulated in a variety of solid tumors 
(adrenal, breast, ovarian, colon, cornea, lung, prostate and breast cancer) versus normal tissues, 
NQO1-mediated activation of quinones may prove to be a powerful anticancer strategy.
35
 
Mitomycin C, which is bioreduced by NQO1 to a DNA-alkylating species, is an example of a 
NQO1-dependent drug in clinical use.
3, 36
 One of the best characterized quinones activated by 
NQO1 is β-lapachone which has shown promise in animal models of cancer and was in phase II 
clinical trials in humans.
37-40
 Unlike β-lapachone which has cell death IC50 values of 
approximately 5 µM, DNQ is considerably more potent with IC50 values in the 50-200 nM range. 
It was therefore of interest to determine whether DNQ toxicity is solely mediated by 2-electron 
reduction by NQO1. A collaboration with Professor David A. Boothman at UT Southwestern 
Medical School led to the identification of DNQ as a substrate for NQO1. This finding was 
supported by cell protection afforded by chemical inhibition of NQO1 using dicoumarol, genetic 
silencing of NQO1, and the use of isogenic cell lines expressing or not expressing NQO1. In 
addition, in vitro NQO1 enzymatic assays confirm DNQ is a substrate for the enzyme and is 
processed significantly faster processed than β-lapachone. 
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Figure 6.5. The reduction of quinones to generate superoxide anion radical reactive oxygen species may 
proceed through a 1- or 2-electron process. 
 
 
 Studies involving β-lapachone in the Boothman lab have previously demonstrated that 
NQO1 activation of β-lapachone induces significant amounts of ROS resulting in rapid buildup 
of PAR through a calcium dependent mechanism.
41
 PARP-1 down-regulation by RNAi or 
chelation of intracellular calcium using BAPTA-AM is able to significantly inhibit PAR build up 
and prevent TUNEL positive staining.
41
 Based on these results we sought to confirm that DNQ 
induces cell death in a similar manner to β-lapachone in A549 non-small cell lung carcinoma 
cells which express high levels of NQO1.  
A549 cells were pre-treated with potential protective small molecule inhibitors for 1 hour 
and then co-treated with 500 nM DNQ for a period of 10 hours after which cell viability was 
assessed by Annexin V/PI staining. As shown in Figure 6.6, dicoumarol, the small molecule 
inhibitor of NQO1, was able to completely prevent DNQ-induced cell death. The small molecule 
superoxide dismutase mimic, MnTBAP, also afforded significant protection consistent with the 
involvement of ROS in DNQ-mediated cell death.  In addition, BAPTA, the calcium chelator 
was able to afford quantitative protection, consistent with previous studies implicating the 
involvement of calcium in NQO1-dependent cell death.
41, 42
 The mechanism by which calcium 
 
 
252 
 
may play a role in hyper-activating PARP-1 is currently unknown although it has been proposed 
that this may be mediated by atypical PARP-1 cleavage by μ-calpain in MCF-7 cells.43 However, 
as shown in Figure 6.6, the use of a covalent inhibitor of calpains failed to afford protection from 
DNQ toxicity suggesting calpains may not be involved in DNQ-mediated toxicity in A549 cells.  
 
Figure 6.6. Annexin V/PI analysis of A549 cell viability of DNQ treated cells in the presence of small 
molecule cytoprotective agents. Cells were pretreated with protective agents for 1 hour and treated with 
500 nM DNQ for 10 hours. Viable cells are AV-/PI- and non-viable cells are AV+/PI-, AV-/PI+ and 
AV+PI/+.  
 
It has been reported that NQO1 dependent cell death results in programmed necrosis 
(necroptosis) mediated by PAR production.
37
 Menadione, the quinone that best matched DNQ in 
the CMAP query, has been noted to induce ROS dependent cell death through a PARP-1 
activated pathway.
27
 Immunoblots have confirmed the production of PAR for DNQ and β-
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lapachone but whether inhibition of PARP-1 is sufficient to afford long term protection remains 
unclear.
37
 As shown in Figure 6.6, the PARP-1 inhibitor, PJ34, was unable to afford protection. 
The induction of PAR may play a role in necroptosis by facilitating the release of AIF, an 
endonuclease, from the mitochondria which degrades nuclear DNA.
44, 45
 While the exact 
mechanism of AIF release is poorly defined, knockout or chemical inhibition of JNK1 and 
RIP1/TRAF2 have been shown to prevent AIF release in MNNG-induced necroptosis without 
affecting the synthesis of PAR.
46
 These results indicate RIP1 and JNK1 are downstream of PAR 
and are critical for AIF-release. In addition, pharmacological inhibition of RIP1 by necrostatin-1 
can aid identification of programmed necrosis.
47, 48
 As shown in Figure 6.6, the use of SP600125, 
a chemical inhibitor of JNK1 and the use of necrostatin-1, a chemical inhibitor of RIP1, both 
significantly protected cells from DNQ-mediated toxicity. In addition, SP600125 was able to 
confirm long term protection from DNQ and β-lapachone in 24 hour continuous incubation 
assays with 6.9 and 3.9 fold reduction in IC50 values respectively (Figure 6.7). The protection 
afforded by JNK1 inhibition may not only prevent AIF release but mitochondrial JNK1 may be 
involved in amplification of ROS generation from Complex I of the mitochondrial respiration 
chain.
28
 Further studies in determining the effects of RIP1 and JNK1 inhibition on ROS 
production in DNQ-treated cells are required to verify this scenario. In addition, the caspase-
independent aspect of necroptosis is supported by the lack of protection in the presence of the 
pan-caspase inhibitor Q-VD-OPh in both the 10 hour and 24 hour assays (Figures 6.6 and 6.7). 
In summary, the cytoprotection studies strongly implicate necroptosis as the mode of cell death 
with the involvement of NQO1, ROS, calcium, RIP1 and JNK1 as outlined in Figure 6.8. 
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24h IC50 (µM) Fold Protection
DMSO SP600125 Q-VD-OPh SP600125 Q-VD-OPh
β-Lapachone 3.2  1.0 12.6  1.6 3.5  0.9 3.9 1.1
DNQ 0.089  0.24 0.618  0.096 0.083  0.016 6.9 0.9
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Figure 6.7. Cell viability dose response curves for A) β-lapachone and B) DNQ in the presence of JNK1 
inhibitor SP600125 (100 μM) and pan-caspase inhibitor Q-VD-OPh (50 μM). IC50 values obtained from 
the dose response curves are tabularized in C). 
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Figure 6.8. Schematic of programmed necrosis (necroptosis) pathway implicated by small molecule-
mediated cytoprotection studies of DNQ-mediated cell death. 
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6.7 Whole genome pooled shRNA screen for modulators of DNQ toxicity 
 In order to further characterize DNQ-induced cell death in a NQO1 expressing cell line, 
we performed a whole genome pooled shRNA screen in MIA PaCa-2 cells. The cells were 
transduced with 200,000 shRNA constructs targetting 37,500 genes at a multiplicity of infection 
of 0.7. The cells were then treated with three rounds of DNQ over 20 days which involved 
exposure to 250 nM DNQ for 1 hour followed by replacement of the cell culture media with 
drug-free media. At the end of 20 days, the total RNA was isolated and the shRNA constructs 
identified by PCR amplification and hybridization to the Affymetrix human U133 plus 2.0 
microarrays. By comparing the DNQ sample to untreated cells we were able to identify shRNAs 
that were enriched or depleted in DNQ treated cells. 
Table 6.6. The shRNA constructs for necroptosis and their fold changes in response to DNQ-treatment. 
Responses for DNQ are compared to those for 4150 (trials A and B), an unrelated compound that was 
tested at the same time. 
 
GeneBank# Gene FC 4150 A FC 4150 B FC DNQ 
G4507564 Homo sapiens tumor necrosis factor receptor superfamily, member 11a, activator of 
NFKB (TNFRSF11A), mRNA.  
1.5 0.9 37.5 
G5032192 Homo sapiens TNF receptor-associated factor 1 (TRAF1), mRNA.  9.0 1.1 17.7 
G2811125 Homo sapiens MAP kinase kinase Jnkk2 mRNA, complete cds.  3.7 0.8 36.2 
G7656958 Homo sapiens calpain 7 (CAPN7), mRNA.  0.9 1.7 36.4 
G4505414 diaphorase (NADHNADPH) (cytochrome b-5 reductase) (NQO1) 1.0 1.2 1.4 
G190266 Human poly(ADP-ribose) polymerase mRNA, complete cds.  1.8 1.7 -9.0 
G4505608 Homo sapiens poly (ADP-ribose) glycohydrolase (PARG), mRNA.  -1.1 1.3 -36.0 
G4506064 Homo sapiens protein kinase, cAMP-dependent, regulatory, type II, beta (PRKAR2B), 
mRNA.  
1.0 1.1 -203.0 
G10863938 Homo sapiens TNF receptor-associated factor 2 (TRAF2), mRNA.  -1.6 0.9 -108.0 
G10863938 Homo sapiens TNF receptor-associated factor 2 (TRAF2), mRNA.  -2.0 1.0 -30.0 
G1463136 Human JNK1 beta1 protein kinase (JNK1B1) mRNA, complete cds.  2.0 4.5 -18.5 
G1463136 Human JNK1 beta1 protein kinase (JNK1B1) mRNA, complete cds.  6.7 2.5 -7.3 
G1463130 Human JNK1 alpha2 protein kinase (JNK1A2) mRNA, complete cds.  2.3 5.0 -12.1 
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 Some of the transcripts affected that are implicated in necroptosis are listed in Table 6.6. 
The screen was also performed twice with an unrelated compound 4150, whose results are also 
listed in Table 6.6 as a control to aid identification of DNQ-specific responses. Constructs that 
were enriched include those targetting TNF receptor, TRAF1, JNK2 and calpain 7. The roles of 
TNF receptor have been implicated in necroptosis.
49, 50
 While JNK2 knockout has also been 
shown to protect against necroptosis, it is not as protective as JNK1 knockout which suprisingly 
had several shRNA constructs that were depleted suggesting they potentiate DNQ toxicity.
46
 
Similarly TRAF2 RNAi unexpectedly potentiated DNQ-toxicity while TRAF1 RNAi protected. 
These results also implicated the involvement of calpain 7 in DNQ induced toxicity. While 
substantial evidence exisits for the involvement of NQO1 in DNQ-mediated toxicity in Mia-Paca 
cells, shRNAs against NQO1 were not enriched. This may be due to insufficient knockdown in 
order to confer protection against DNQ.  
Consistent with the involvement of PARP-1 in DNQ-mediated toxcity, constructs against 
PARP-1 and PARG were depleted (Table 6.6). While PARP-1 knockdown protects against DNQ 
in short term studies, in long term experiments the downregulation of this DNA damage repair 
protein is expected to potentiate DNQ toxicity. Similarly the depletion of PARG shRNA 
constructs suggest PAR is involved in DNQ-toxicity as the prevention of PAR degradation by 
PARG RNAi would be expected to facilitate DNQ-induced cell death.  
 Seventy-two other shRNA constructs were significantly enriched (50-352 fold) whose 
targets may play a role in necroptosis or DNQ-specific toxicity (Table 6.7). The targets obtained 
from this primary screen require validation in single-well experiments in a non-pooled format. 
Of particular interest was a shRNA construct targetting NADPH dependent cytochrome p450 
that was enriched 55.5 fold suggesting one electron reduction may contribute to DNQ-toxicity. 
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Further studies are required to quantitate the relative contributions of cytochrome p450-mediated 
1-electron reductions and NQO1-mediated 2-electron reductions to DNQ-mediated toxicity.   
 
Table 6.7. The 72 shRNA constructs enriched in DNQ treated MIA PaCa-2 cells as detected in a whole-
genome shRNA screen. Responses for DNQ are compared to those for 4150 (trials A and B), an 
unrelated compound that was tested at the same time. 
 
GeneBank# Gene name FC 4150 A FC 4150 B FC DNQ 
Z70200 H.sapiens gene for U5 snRNP-specific 200kD protein 2.9 2.6 352.2 
AL031778 Human DNA sequence from clone 34B21 on chromosome 6p12.1-21.1. Contains part of a 
gene for a novel protein with ZU5 domain similar to part of Tight Junction Protein ZO1 
(TJP1) and UNC5 Homologs, the gene for a novel BZRP (peripheral benzodiazapine...  
0.8 1.2 351.1 
G5031782 Homo sapiens interferon gamma receptor 2 (interferon gamma transducer 1) (IFNGR2), 
mRNA.  
6.1 2.3 304.9 
G4557744 Homo sapiens multiple endocrine neoplasia I (MEN1), mRNA.  6.4 4.1 267.8 
AA196245 exostoses (multiple) 2  1.3 5.9 246.7 
AI359472 KIAA1096 protei 2.5 6.9 230.4 
G13375765 Homo sapiens hypothetical protein FLJ23142 (FLJ23142), mRNA.  2.8 2.9 214.7 
G5032086 Homo sapiens splicing factor 3a, subunit 1, 120kD (SF3A1), mRNA.  0.9 6.3 213.3 
AI805587 ribosomal protein S 4.8 1.3 203.2 
AK026465 Homo sapiens cDNA: FLJ22812 fis, clone KAIA2955 1.2 3.3 201.3 
G13324676 Homo sapiens ectonucleotide pyrophosphatasephosphodiesterase 1 (ENPP1), mRNA.  1.2 2.1 188.6 
G1280040 Human serum aryldialkylphosphatase precursor mRNA, complete cds.  1.7 8.2 177.0 
G5453835 Homo sapiens melanoma-associated antigen recognised by cytotoxic T lymphocytes 
(MAAT1), mRNA.  
1.9 2.0 173.2 
G9256522 Homo sapiens calcium channel, voltage-dependent, alpha 1G subunit (CACNA1G), 
mRNA.  
1.7 3.3 153.0 
G7662323 Homo sapiens lectomedin-2 (KIAA0821), mRNA.  3.1 2.4 151.7 
W63731 actinin, alpha 2  5.0 3.5 150.9 
AL031777 Human DNA sequence from clone 34B20 on chromosome 6p21.31-22.2. Contains 
seventeen Histone (pseudo)genes and a 40S Ribosomal protein S10 pseudogene. Contains 
ESTs, STSs and GSS 
1.6 6.3 149.5 
BC039470 Homo sapiens, clone IMAGE:5503432, mRNA 10.0 6.9 149.2 
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Table 6.7 (continued) 
 
GeneBank# Gene name FC 4150 A FC 4150 B FC DNQ 
G3005015 Homo sapiens G protein-coupled receptor kinase 6, splice variant B (GRK6) mRNA, 
complete cds.  
1.0 0.9 147.7 
G2072422 Human huntingtin interacting protein (HIP1) mRNA, complete cds.  0.7 2.6 129.6 
BG532929 Sjogren syndrome antigen B (autoantigen La)  3.2 1.8 124.9 
G11034828 Homo sapiens hypothetical protein FLJ10033 (FLJ10033), mRNA.  2.8 3.4 116.7 
U08626 Human glutamine synthetase pseudogen 8.9 6.1 114.1 
AI382123 ESTs, Highly similar to A59252 myosin heavy chain, nonmuscle, form IIB (H.sapiens 2.3 1.5 108.0 
AA577695 matrin 3  1.1 2.3 104.4 
W81196 Cdc42 effector protein  2.3 3.6 99.0 
G9910371 Homo sapiens 5(3)-deoxyribonucleotidase (dNT-2); nuclear gene for mitochondrial 
product (LOC56953), mRNA.  
0.3 1.6 96.9 
G11527399 Homo sapiens zinc finger protein 6 (CMPX1) (ZNF6), mRNA.  0.4 2.1 95.0 
BE748563 Homo sapiens clone 24463 mRNA sequenc 2.2 2.3 93.0 
AK024231 Homo sapiens cDNA FLJ14169 fis, clone NT2RP2002056 1.6 1.5 92.7 
G8922666 Homo sapiens hypothetical protein FLJ10783 (FLJ10783), mRNA.  3.0 2.1 92.4 
G8980616 Homo sapiens mRNA for postreplication repair protein hRAD18p, complete cds.  0.8 2.4 91.4 
AB011133 Homo sapiens mRNA for KIAA0561 protein, partial cds.  2.3 1.2 87.3 
AB023191 Homo sapiens mRNA for KIAA0974 protein, partial cds.  0.9 5.1 85.9 
AF043586 Homo sapiens clone CPRF1-T2 immunoglobulin lambda chain VJ region, (IGL) mRNA, 
partial cds.  
1.5 1.0 82.7 
AW051856 filamin A, alpha (actin-binding protein-280 2.0 2.6 81.6 
BG423052 G protein-coupled receptor kinase 6  1.7 1.5 79.4 
G4826915 Homo sapiens polo (Drosophia)-like kinase (PLK), mRNA.  3.5 0.8 78.8 
G7706100 Homo sapiens pparl (LOC51288), mRNA.  5.4 6.7 78.4 
BF514975 EST 1.2 1.4 75.6 
G7706414 Homo sapiens prothymosin a14 (LOC51685), mRNA.  1.1 4.2 73.6 
G4505904 Homo sapiens phosphomannomutase 1 (PMM1), mRNA.  0.2 0.2 73.2 
AA807959 Human HepG2 3 region MboI cDNA, clone hmd4f09m3 0.8 1.6 73.0 
BE407516 cyclin B 1.0 4.3 72.4 
G8923790 Homo sapiens rTS beta protein (HSRTSBETA), mRNA.  0.5 1.3 71.2 
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Table 6.7 (continued) 
 
GeneBank# Gene name FC 4150 A FC 4150 B FC DNQ 
AK092103 Homo sapiens cDNA FLJ34784 fis, clone NT2NE2004255 1.5 2.6 69.3 
AL031777 Human DNA sequence from clone 34B20 on chromosome 6p21.31-22.2. Contains 
seventeen Histone (pseudo)genes and a 40S Ribosomal protein S10 pseudogene. Contains 
ESTs, STSs and GSS 
1.1 1.9 67.2 
AB018338 Homo sapiens mRNA for KIAA0795 protein, partial cds.  3.0 3.8 65.5 
G12053186 Homo sapiens mRNA; cDNA DKFZp434H152 (from clone DKFZp434H152); complete 
cds.  
1.5 1.1 64.3 
AI571719 EST 0.7 2.1 62.5 
BF195165 hypothetical protein MGC324 5.5 0.9 61.3 
G4505040 Homo sapiens leukotriene C4 synthase (LTC4S), mRNA.  4.9 4.4 60.0 
G7657175 Homo sapiens transmembrane protein 4 (TMEM4), mRNA.  0.3 0.5 59.9 
AK000851 Homo sapiens cDNA FLJ20844 fis, clone ADKA01904.  0.3 0.3 59.1 
G184310 Human heterochromatin protein homologue (HP1) mRNA, complete cds.  2.8 1.3 58.7 
G9651998 Homo sapiens WBSCR15 protein (WBSCR15) mRNA, complete cds.  1.3 1.4 58.1 
G13383467 Homo sapiens DC-SIGN mRNA, complete cds.  0.5 0.8 57.9 
BF062694 EST 0.6 1.7 57.4 
AL356414 Human DNA sequence from clone RP11-352D3 on chromosome 20 Contains a 60S 
ribosomal protein L21 (RPL21) pseudogene, ESTs, STSs and GSS 
0.5 2.3 56.2 
G13540554 Homo sapiens phosphatidylserine synthase 2 (PTDSS2), mRNA.  1.6 1.6 56.1 
G4885348 Homo sapiens G protein-coupled receptor kinase 5 (GPRK5), mRNA.  1.0 1.2 55.9 
G13027623 Homo sapiens Huntingtin interacting protein E (HYPE), mRNA.  5.5 2.0 55.9 
G4501912 Homo sapiens a disintegrin and metalloproteinase domain 23 (ADAM23), mRNA.  4.5 1.1 55.8 
G9964002 Homo sapiens NADPH-cytochrome P450 reductase mRNA, complete cds.  1.4 6.4 55.5 
G4506808 Homo sapiens sodium channel, voltage-gated, type V, alpha polypeptide (long 
(electrocardiographic) QT syndrome 3) (SCN5A), mRNA.  
0.3 0.8 54.9 
G8923220 Homo sapiens hypothetical protein FLJ20245 (FLJ20245), mRNA.  1.0 2.1 54.6 
NM_006510 Homo sapiens ret finger protein (RFP), mRNA.  4.8 5.4 53.9 
G4504646 Homo sapiens interleukin 13 receptor, alpha 1 (IL13RA1), mRNA.  4.2 2.8 53.9 
G3834394 Homo sapiens monocarboxylate transporter 2 (MCT2) mRNA, complete cds.  0.1 0.6 52.4 
L41657 Homo sapiens synthetic myelin basic protein 21.5 kDa isoform gene, complete cd 1.3 1.2 51.6 
BC043275 Homo sapiens, clone IMAGE:5297130, mRNA 0.9 1.1 51.2 
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Table 6.7 (continued) 
 
GeneBank# Gene name FC 4150 A FC 4150 B FC DNQ 
G8922150 Homo sapiens I-kappa-B-interacting Ras-like protein 2 (KBRAS2), mRNA.  8.5 1.5 51.1 
G4885586 Homo sapiens small inducible cytokine subfamily A (Cys-Cys), member 13 (SCYA13), 
mRNA.  
1.0 0.7 50.6 
G7019500 Homo sapiens protein phosphatase 2A 48 kDa regulatory subunit (PR48), mRNA.  0.6 0.9 50.5 
4866540_RC Cluster Incl. AL022316:Human DNA sequence from clone 126B4 on chromosome 
22q13.2-13.31. Contains two or three novel genes, ESTs, STSs and GSSs /cds=(0,842) 
/gb=AL022316 /gi=4691242 /ug=Hs.183807 /len=1191 
0.5 2.6 50.1 
BF541557 eukaryotic translation initiation factor 5 0.3 0.9 50.1 
 
6.8 Conclusions and outlook 
  The weight of evidence from the biological studies conducted on DNQ and cribrostatin 
6 suggest these compounds induce cell death by generation of reactive oxygen species. This is 
supported by: 1) transcript profiling in U937 lymphoma cells which implicate a Nrf-2 mediated 
oxidative stress response to these compounds; 2) ROS-measuring assays confirm the generation 
of ROS and the ability of antioxidants such as NAC to significantly protect cell viability suggest 
that the ROS plays a role in inducing cell death;
10, 51
 and 3) studies have found that DNQ is more 
dependent on oxygen than other ROS inducing agents, some of which are in clinical trials.
10
 
DNQ may therefore serve as a powerful tool molecule to investigate ROS generation as an 
anticancer strategy. Investigation of the DNA-binding propensity of these compounds, and in 
vitro topoisomerase inhibition assays fail to show significant perturbation of these processes, 
consistent with the cell cycle arrest studies that suggest DNA alkylation or topoisomerase 
inhibition is not involved in the induction of cell death.
10, 51
 
 Recent studies have identified the involvement of NQO1-dependent activation of DNQ 
through a 2-electron reduction mechanism. This dependence on NQO1 is particularly appealing 
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as several cancers have high levels of NQO1 relative to normal tissues and would therefore 
enable cancer-selective cell death. A potential concern is toxicity of DNQ to NQO1-expressing 
normal tissues. In fact, while NQO1 is not detectable in the human liver, immunohistochemistry 
studies on normal human tissues have observed NQO1 expression in respiratory, breast duct, 
thyroid follicle, colonic epithelium, stomach, kidney, as well as in the corneal and lens 
epithelium of the eye.
35, 52
 In addition NQO1 was detected in the endothelial lining of the aorta 
but not in myocardium.
35
 As with any chemotherapy, the clinical success of targeting NQO1 will 
depend on the therapeutic benefits outweighing undesirable toxicity and side effects. 
Characterization of the mode of cell death induced by DNQ suggests that the cells 
undergo programmed necrosis that is dependent on calcium signaling and activation of the JNK1 
and RIP1 kinases which are thought to be critical for AIF-dependent cell death. The whole 
genome shRNA experiment performed on MIA PaCa-2 cells have identified several candidate 
proteins that may be involved in DNQ-mediated toxicity. The validation of the shRNAs in 
follow up experiments is expected to aid mechanistic characterization of necroptosis whose 
comprehensive understanding is at an early stage. 
 Future studies will investigate the efficacy of DNQ in animal models of cancer using 
cancer cell lines expressing high levels of NQO1. While NQO1-dependent ROS generation has 
yet to be proven as an anti-cancer strategy in the clinic, the increased potency of DNQ relative to 
β-lapachone is expected to considerably enable the validation of this strategy. 
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6.9 Materials and methods 
General 
Anti-β-actin mouse monoclonal antibody (sc-8432) and MnTBAP hydrochloride were 
purchased from Santa Cruz Biotechnology. Anti-HSP70 monoclonal mouse antibody (SPA-810) 
and anti-HMOX-1 rabbit polyclonal antibody (SPA-896) were purchased from Stressgen. RIPA 
lysis buffer was purchased from Cell Signaling Technology. Annexin V-FITC conjugate was 
obtained from SouthernBiotech. Propidium iodide, sulforhodamine B, necrostatin-1, SP600125, 
β-lapachone, doxorubicin, MNNG, PJ-34, calpain inhibitor I, dicoumarol and U0126 MEK 
inhibitor were obtained from Sigma Aldrich. Q-VD-OPh was obtained from Calbiochem. 
BAPTA-AM was obtained from Tocris biosciences. RNA isolation was conducted using the 
Qiagen mini-prep RNeasy kit (Qiagen) with on-column DNase digest performed using RNase-
free DNase (Qiagen). Illumina HumanHT-12 bread array was purchased from Illumina. The 
GeneNet human 50K plasmid siRNA Library in pSIF1-H1-copGFP was purchased from System 
Biosciences Inc. Human U133 plus 2.0 microarrays were purchased from Affymetrix Inc. 
 
Gene expression analysis 
U-937 cells (3 x 10
6
 in 6 mL RPMI 1640 with 10% FBS) were incubated in the presence 
of 350 nM DNQ, 15 µM cribrostatin 6 or DMSO vehicle (0.2% final DMSO v/v) for 6 hours in 
a 12-well plate. Aliquots (500 μL) were taken at 6 and 24 hours to assess viability (by annexin 
V/PI staining and flow cytometry) in order to ensure no toxicity occurred at 6 hours but toxicity 
was observed at 24 hours. After 6 hours of incubation, 5 mL of cells were pelleted (500 x g, 5 
min) and RNA isolated with on-column DNase digestion. RNA integrity was assessed using an 
Agilent Bioanalyzer. Whole genome transcript profiling was performed on the Illumina 
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HumanHT-12 bread array for seven compounds and DMSO control from three independent 
experiments. The raw bead-level files were processed with Illumina® BeadStudio 3.1, Gene 
Expression Module v3.2.6
53
, without background correction or normalization, to get one value 
per beadtype for each array. These 48,803 beadtype values were then input into R
54
 using the 
beadarray package
55
 from the Bioconductor Project.
56
 The vsn algorithm
57
 was used for 
background correction, normalization and transformation of the beadtype values to the glog2 
scale. Differential expression was assessed using a mixed linear model using the Limma 
package
58
, which uses an empirical Bayes correction
59 
that helps to improve power by borrowing 
information across beadtypes. All the desired pair-wise comparisons between the 8 treatment 
groups (control + DNQ + cribrostatin 6 + 5 unrelated compounds) were pulled as contrasts 
from the model and the p-values were corrected for multiple hypothesis testing using the False 
Discovery Rate method
60
 separately for each contrast. In order to facilitate comparisons of our 
results with those of Connectivity Map database we used Illumina‟s probe mapping file that 
matched probes from Illumina‟s HumanWG-6v3 array (same probes as the HumanHT-12 array) 
to Affymetrix‟s  U133Plus2.0 array61. The top 50 up- and down-regulated probe set IDs ordered 
according to fold change were used to create the seed for the connectivity map (CMAP) database 
matching. Analysis of the canonical pathways was performed using Ingenuity Pathway Analysis 
(IPA, Ingenuity Systems) software using a p value cutoff of 0.05 to define the network eligible 
genes. 
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Western blot analysis 
Human lymphoma U-937 cells (8 mL of 0.5 x 10
6
 cells/mL) were treated with compound 
for 6 hours (1% final DMSO v/v). After centrifugation and washing, the cells were lysed with 
RIPA lysis buffer containing protease inhibitor and cell debris removed by centrifugation (16000 
x g for 5 min). Protein concentration was determined by Bradford assay and whole cell lysate 
(40-60 μg) was resolved by 12% SDS-PAGE gel electrophoresis at 120 V for 90 min after which 
proteins were transferred onto nitrocellulose membranes (50 V for 2 hours) and blocked in 5% 
BSA TBST for 2 h at room temperature. The membranes were blotted for molecules of interest 
with anti-HMOX-1 (1:5000 in 5% BSA TBST), anti-HSP70 (1:1000 in 0.5% BSA TBST), anti-
actin (1:1000 in 5% BSA TBST) overnight at 4 ºC. The bound primary antibodies were detected 
using appropriate secondary HRP conjugated antibodies (1:20,000 in 0.5% BSA TBST) for 1 h 
at room temperature and visualized by ECL autoradiography. The membranes were stripped in 
acidic methanol and re-probed as necessary.  
 
Cell cycle arrest 
Human leukemia HL-60 cells (1 x 10
6
 in 1 mL RPMI 1640 with 10% FBS) were treated 
with 0, 500, 1000, and 2000 nM of DNQ (0.5% final DMSO v/v) in triplicate and incubated for 6 
hours (37 ºC 5% CO2 incubator) in a 24-well plate. The cells were isolated by centrifugation 
(400 x g for 5 min), washed with PBS and fixed with 70% ice-cold ethanol for 1 hour at -20 ºC. 
The cells were pelleted (1200 x g 5 min), washed with PBS, RNase treated (50 μL of 1 mg/mL 
RNase A in PBS) for 1 hour, after which propidium iodide was added (450 μL of 50 μg/mL in 
PBS). DNA content was assessed by flow cytometry on a Benton Dickinson LSR II flow 
cytometer. Distribution of cells in the different phases was determined using FCS Express 
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software. Doxorubcin‟s effect on HL-60 cell cycle (8 hour treatment) was investigated using the 
same procedure.  
 
Annexin V/propidium iodide assessment of cytoprotection 
A549 cells were pre-plated in RPMI 1640 media in a 12-well plate so that 70% 
confluency was obtained the next day. RPMI 1640 media containing 0.5% DMSO vehicle or the 
following cytoprotective agents were added to cells: dicoumarol (50 µM), PJ34 (20 µM), Q-VD-
OPh (50 µM), necrostatin-1 (10 µM), calpain inhibitor (50 µM), BAPTA-AM (10 µM), 
MnTBAP (100 µM), SP600125 (100 µM), MEK inhibitor U0126 monoethanolate (50 µM). The 
cells were pre-treated with the cytoprotective agents for 1 hour, after which 500 nM DNQ was 
added such that the final DMSO content was 1% v/v. The cells were incubated for 10 hours, after 
which the media was collected, cells detached by trypsin and combined with the collected media. 
The cells were pelleted, washed with PBS and resuspended in 500 µL Annexin V binding buffer 
containing 1:100X dilution of FITC-annexin V and 1 µg/mL propidium iodide. Cell viability was 
assessed immediately by cell flow cytometry.  
 
 
Sulforhodamine B cell proliferation assay 
  
To empty wells of 96-well plates, 1 µL of DMSO or 200X concentrated stocks of 
SP600125 (JNK1 inhibitor) or Q-VD-OPh in DMSO were added such that 100 µM or 50 µM of 
the inhibitors respectively would be reached in a total volume of 200 µL. DMSO stocks of DNQ 
and β-lapachone were added to the wells (1 µL of 200X stock) so that 1% final DMSO v/v would 
be achieved upon addition of 198 µL cells. Cells in RPMI 1640 media were then added to the 
wells (198 µL of 5 x 10
4
 cells/mL) and the plates incubated for 24 hours. The media was 
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removed and the cells were fixed with 10% trichloroacetic acid (TCA) overnight at 4 ºC. The 
plates were washed in water and stained with sulforhodamine B (50 µL of 0.04% sulforhodamine 
B in 1% v/v acetic acid) for one hour at room temperature. Excess dye was removed by washing 
in 1% acetic acid and the dye released by addition of 10 mM unbuffered Tris base (200 µL). 
After 30 minutes incubation at room temperature the absorbance at 510 nm was measured. IC50 
values were determined using TableCurve 2D. 
 
Whole genome shRNA screen in MIA-PaCa-2 cells. 
The GeneNet Human 50K Plasmid siRNA Library in pSIF1-H1-copGFP vector (200,000 
shRNA constructs targeting 47,400 transcripts) were packaged into pseudoviral FIV particles by 
transfecting HEK-293TN cells with the library and packaging vectors as per the manufacturer‟s 
instructions. The viral particles were isolated from the culture medium at 48 and 72 h by 
precipitation with PEG-IT as per the manufacturer‟s instructions. The viral pellet was 
resuspended in HBSS and stored at -80 ºC until further use. The amount of virus required to 
transduce MIA PaCa-2 cells at an appropriate multiplicity of infection (MOI) was determined. 
Once the conditions required to transduce cells at an MOI of 0.5-0.7 (40-50% GFP positive) 
were identified, the transduction was scaled up such that the library would be represented 100 
fold. A total of 37.5 million MIA PaCa-2 cells were plated into 15 cm cell culture dishes (9.4 x 
10
6
 cells/plate in 20 mL DMEM) 24 h prior to transduction. Cells were transduced at 90% 
confluency with viral particles in DMEM containing 10 µg/mL polybrene. After 24 h of 
incubation, the media was replaced and the cells expanded in culture for another 72 h and the 
%GFP positive cells quantitated by flow cytotmetry. The cells were then pooled and 40 million 
cells in 160 mL DMEM were treated with DNQ (250 nM) for 1 hour and the media replaced 
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with drug free media or control cells were left untreated in 15 cm dishes. After 5-6 days, another 
1 hour treatment was performed with a total of three rounds of over a 20 day period with at least 
40 million cells being passaged at each round of treatment to maintain 100-fold library 
representation. At the end of the experiment, the cells were pooled and total RNA was isolated 
from 8 million cells using the Qiagen RNeasy kit without on-column DNAse digest. The RNA 
samples were submitted for Agilent Bioanalyzer quality control. After cDNA synthesis, the 
shRNA constructs were PCR amplified, biotinylated, lambda exonuclease treated (as per 
manufacturer‟s instructions) and hybridized to Affymetrix human U133 plus 2 microarrays.  
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CHAPTER 7.  DISCOVERY OF N-((1-BENZYL-1H-1,2,3-TRIAZOL-4-
YL)METHYL)ARYLAMIDES AS NOVEL ANTIMICROTUBULE 
AGENTS 
 
The information and contents for this chapter were reproduced in part with permission from 
Stefely, J. A.; Palchaudhuri, R.; Miller, P. A.; Peterson, R. J.; Moraski, G. C.; Hergenrother, P. 
J.; Miller, M. J. “N-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a New Scaffold that 
Provides Rapid Access to Antimicrotubule Agents: Synthesis and Evaluation of Antiproliferative 
Activity Against Select Cancer Cell Lines” J. Med. Chem. 2010, 53, 3389-3395. Copyright 2010, 
American Chemical Society. This work could not have been accomplished without the aid of 
Jonathan A. Stefely who synthesized the triazole derivatives and the performed the NCI-60 
COMPARE analysis. We would also like to thank Professor Timothy Mitchison (Harvard 
Medical School) for the kind gift of purified bovine tubulin.   
 
7.1  Introduction 
Microtubules are dynamic protein polymers that play an essential role in formation of the 
mitotic spindle during cell division.
1, 2
 The microtubule polymers are composed of heterodimers 
of α-tubulin and β-tubulin.3 Deregulation of microtubule polymerization by small molecules may 
be achieved by inhibiting tubulin polymerization or by preventing microtubule depolymerization 
and these small molecules are referred to as destabilizers or stabilizers respectively. Given the 
necessity of tubulin in cell division, compounds that interfere with tubulin induce M-phase cell 
cycle arrest, and ultimately lead to cell death through caspase-dependent apoptosis or CDK1-
mediated mitotic catastrophe.
4
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Several tubulin targeting agents are approved for the treatment of cancer in the clinic and 
these include stabilizers such as the taxanes (docetaxel and paclitaxel), and destabilizers from the 
vinca alkaloid family (vincristine, vinblastine, and vinorelbine).
3, 4
 Taxanes are approved for the 
treatment of breast, prostate, ovarian and non-small cell lung cancer and are currently in clinical 
trials for the treatment of gastric, pancreatic, head and neck, soft tissue sarcoma, melanoma, 
bladder and cervical cancer.
4
 The vinca alkaloids are approved for the treatment of Hodgkin and 
non-Hodgkin lymphoma, testicular cancer, Kaposi sarcoma, acute leukemia, neuroblastoma, 
rhabdomyosarcoma, Wilms tumour and non-small-cell lung cancers and are being investigated 
for the treatment of bladder, small-cell lung, myeloma, brain and ovarian cancers.
4
  
Tubulin targeting agents also affect rapidly dividing normal cells, however the side-
effects have been manageable enough to allow the use of anti-tubulin agents in the clinic.
4
 Given 
the diverse cancers against which antimitotics are effective against, tubulin still represents a 
major target for which there continue to be efforts towards clinical development of novel 
antimitotics. In 2008, there were 17 destabilizers under clinical investigation and an epothilone 
derivative was approved for the treatment of breast cancer. The continued enthusiasm in clinical 
development of novel tubulin targeting drugs is a testimony to the importance of tubulin as an 
anti-cancer target but also represents efforts to overcome the current limitations of anti-tubulin 
drugs that have been in clinical use for decades. These limitations include a narrow therapeutic 
window as a result of neurotoxicity due to tubulin‟s role in the maintenance of cytoskeletal 
structure in interphase cells, in addition to the occurrence of P-glycoprotein (P-gp)-mediated 
drug resistance.
5-7
 Efforts towards developing anti-tubulin agents that are not substrates of P-gp 
or small molecule inhibitors that target other components of mitosis that only function or are 
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expressed during mitosis are underway and include inhibition of Aurora kinases (A and B), polo-
like kinase (PLK1), mitotic kinesin (EG5) and centromeric protein E (CENPE).
4, 8, 9
  
 
7.2  Discovery of the anti-cancer activity of triazoles 
Mycobactin S, a natural product produced by Mycobacterium smegmatis, exhibits anti-
tuberculosis activity in culture with an IC50 of 3.9 μM (Figure 7.1).
10
 Structural activity 
relationship studies revealed that fragment 2 (Figure 7.1) of the natural product retained the anti-
tuberculosis activity (IC50 4.2 μM) and this fragment served as the basis for the development of 
additional compounds.
11, 12
 Copper-catalyzed click chemistry was employed to obtain access to 
the N-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide derivative 4e (Figure 7.1) which 
unfortunately, in contrast to fragment 2 and Mycobactin S, was considerably less active against 
M. tuberculosis.
13
 Despite the loss in activity against M. tuberculosis, it was serendipitously 
discovered that 4e exhibited potent antiproliferative activity against MCF-7 human breast cancer 
cells in culture (IC50 0.56 μM) whereas fragment 2 was inactive (>20 μM). Given the promising 
anti-cancer activity of 4e, it was of interest to further optimize the structural features and 
elucidate the mechanism by which 4e elicits activity against cancer cells.  
 
 
Figure 7.1. Structures of anti-tuberculosis compound 2 and anti-cancer compound 4e, both derived from 
a fragment of mycobactin S (1).  MIC values for 1–2 indicate in vitro anti-tuberculosis activity against M. 
tuberculosis H37Rv in a standard GAST assay, and the IC50 value for 4e indicates in vitro anti-cancer 
activity against human breast cancer cell line MCF-7. 
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Various derivatives of 4e were synthesized and tested for antiproliferative activity against 
MCF-7 human breast cancer and U937 human lymphoma cells in 72 hour assays (Table 7.1). It 
was determined that a meta-phenoxy substitution on the right hand side of the molecule was 
necessary for optimal potency of this class of molecules. Various substituents however were 
tolerated at R2 and a pyridine derivative 13e was found to be significantly more potent than the 
parent compound 4e. As shown in Table 7.1, the potency of 13e approaches that of colchicine 
and is substantially more potent than that of 2-methoxyestradiol, two antimitotic compounds 
noted for their anti-cancer activity. 
 
Table 7.1. Antiproliferative activities (IC50) of compounds 4e, 13a-e, 14, colchicine, and 2-
methoxyestradiol against human breast cancer cell line MCF-7 and human lymphoma cell line U937 in 72 
hour assays in cell culture. The average IC50 values were obtained from 3 independent experiments with 
the errors representing the standard deviation. 
 
 
Compound R
2
 
IC50 (μM) 
MCF-7 U937 
4e 
 
0.56 ± 0.11 1.40 ± 0.18 
13a 
 
0.33 ± 0.045 1.13 ± 0.44  
13b 
 
1.9 ± 1.4 Nd  
13c 
 
0.66 ± 0.31 3.75 ± 1.78 
13d 
 
0.64 ± 0.35 2.19 ± 0.58 
13e 
 
0.046 ±  0.022 0.58 ± 0.42 
13f 
 
0.245 ± 0.007 Nd 
14 
 
6.4 ± 1.3 28 ± 19 
Colchicine 0.0134 0.008 ± 0.003 
2-methoxyestradiol 0.842 ± 0.090 2.91 ± 1.17 
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 7.3  NCI-60 COMPARE analysis 
In order to facilitate the elucidation of the mechanism of 4e, the compound was submitted 
to the National Cancer Institute for biological evaluation against the NCI 60 cancer cell line 
panel in cell culture. The NCI has tested over 150,000 small molecules using this platform. It has 
been noted that the pattern of selectivity against the 60 cancer cell lines may be informative of 
the mechanism of action is strong correlations are observed to the activity of compounds with 
known mechanisms that are present in the database.
14-16
 The pattern of selectivity of 4e was input 
into the COMPARE analysis algorithm and the compounds of known mechanism that best 
matched the GI50, TGI, and LC50 patterns of 4e are shown in Table 7.2 with the corresponding R 
values. An R value of 1 represents a perfect correlation, 0 represents no correlation and -1 
represents perfect anti-correlation. As shown in Table 7.2 various agents that target microtubule 
dynamics (paclitaxel, maytansine, vincristine, vinblastine, and rhizoxin) positively correlated 
with 4e with several R values >0.5, suggesting the targeting of tubulin as the antiproliferative 
mechanism of 4e. 
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Table 7.2. Standard COMPARE analysis of 4e. The Target Set was the Standard Agent Database and 
the Target Set Endpoints were set equal to the Seed Endpoints (GI50, TGI, and LC50). Correlation values 
(r) are Pearson’s correlation coefficients. Some hits appear multiple times because they were tested by 
the NCI for the Standard Agent Database at multiple concentration ranges.  
 
rank Compound R 
Based on GI50 Mean Graph  
1 Paclitaxel 0.541 
2 Maytansine 0.534 
3 vincristine sulfate 0.500 
4 Trimetrexate 0.480 
5 soluble Baker's Antifol 0.460 
Based on TGI Mean Graph  
1 Paclitaxel (hiConc = 10
-5
 M) 0.654 
2 Paclitaxel (hiConc = 10
-6
 M) 0.646 
3 Paclitaxel (hiConc = 10
-4.6
 M) 0.642 
4 Maytansine 0.621 
5 vinblastine sulfate 0.606 
Based on LG50 Mean Graph  
1 Rhizoxin (hiConc = 10
-9
 M) 0.681 
2 Rhizoxin (hiConc = 10
-4
 M) 0.650 
3 vinblastine sulfate (hiConc = 10
-7.6
 M) 0.558 
4 α-2'-deoxythioguanosine 0.545 
5 vinblastine sulfate (hiConc = 10
-4
 M) 0.540 
 
 
 
7.4  Triazoles induce G2/M-phase arrest 
Based on the COMPARE analysis, we hypothesized the triazoles may be affecting 
microtubule dynamics. As microtubule targeting agents induce a characteristic arrest in M-phase 
of the cell cycle, we used cell flow cytometry to determine the effect of the triazole derivatives 
on the cell cycle progression of HeLa human cervical cancer cells. The cells were treated with 5 
μM of various derivatives for a period of 18 hours. As shown in Figure 7.2, 4e, 13a, 13d and 13e 
all induced significant arrest in the G2/M phase of the cell cycle. In fact over 90% of the cells 
accumulate in the G2/M phase in comparision to 13% in untreated control. Furthermore, while 
4e, 13a, 13d and 13e all induce this large G2/M phase arrest, derivative 14, which has poor 
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antiproliferative activity did not significantly induce G2/M-phase arrest suggesting a correlation 
between antiproliferative activity and the ability to induce G2/M-phase arrest.  
 
Figure 7.2. Effects of 4e, 13a, 13d, 13e, and 14 on the cell cycle distribution of HeLa cells as measured 
by propidium iodide staining and flow cyotometry. HeLa cells were treated with 5 μM compound for 18 
hours in triplicate. 
 
7.5  Triazoles induce fragmented microtubules in whole cells 
While, the G2/M cell cycle arrest data observed by flow cytometry for the triazole 
derivatives is consistent with compounds that interefere with microtubules, flow cytometry itself 
is not able to distinguish between G2- and M-phase arrrest. As microtubule targetting agents 
induce arrest specifically in the M-phase of the cell cycle, we sought to idenitfy whether the 
triazoles specifically induce M-phase arrest. To achieve this, HeLa cells were treated with 5 μM 
of triazoles 4e or 13e for 18 hours and the cells were fixed and the DNA (propidium iodide) and 
microtubules (FITC conjugated anti-tubulin antibody) stained and visualized by confocal laser 
microscopy (Figure 7.3). As a positive control for M-phase arrest, we used the known tubulin 
polymerization inhibitor, Nocodazole. As shown in Figure 7.3, triazole 4e and 13e induced 
similar pronounced nuclear staining of condensed DNA as nocodazole. This increase in DNA 
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staining is indicative of cells that are in M-phase where the DNA has condensed in preparation 
for cell division. In addition, in comparison to control cells, cells treated with compounds 4e and 
13e displayed abnormal fragemented microtubules, a phenotype characeteristic of microtubule 
disruptors.
17
 These results furhter supported the hypothesis that the triazole compounds affect 
tubulin polymerization dynamics and induce M-phase arrest which ultimately leads to an 
antiproliferative effect by inducing programmed cell death/apoptosis. 
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Figure 7.3. Confocal microscopy images of HeLa cells after 18 h incubation in the presence of 5 μM 
inhibitor. Nocodazole is a known tubulin polymerization inhibitor. Nuclear DNA was stained with propidium 
iodide and tubulin was stained with FITC-conjugated anti-α-tubulin antibody. Compounds 4e and 13e 
disrupted normal microtubule structures, caused fragmentation of mitotic spindles, and induced M-phase 
arrest.  
 
Control 
13e 
4e 
Nocodazole 
FITC α-Tubulin Propidium Iodide Merge 
 
 
283 
 
7.6  Triazoles inhibit tubulin polymerization in vitro 
In order to determine whether the Triazoles can directly affect tubulin polymerization 
dynamics we employed a kinetic spectrophotometric in vitro assay that monitors GTP-driven 
polymerization of purified tubulin protein to microtubules which absorb light at 340 nm. As 
shown in Figure 7.4, the triazoles 4e, 13a and 13e all completely inhibit tubulin polymerization 
similar to the positive control Nocodazole. The microtubule stabilizer, paclitaxel, as expected, 
promotes the rate of tubulin polymerization relative to control. This data confirms that 4e, 13a 
and 13e are able to inhibit the polymerization of tubulin and in combination with the cell culture 
experiments strongly supports the modulation of tubulin polymerization as the mechanism of 
action of these agents. 
 
 
Figure 7.4. Inhibition of tubulin assembly by 4e, 13a, and 13e in vitro. All compounds were tested at a 
concentration of 10 µM. Effects of compounds on tubulin polymerization were assessed by monitoring the 
increase in light scattering at 340 nm. Standards of 10 µM nocodazole (a tubulin assembly inhibitor) and 
10 µM paclitaxel (a tubulin assembly promoter) were used for direct comparison.  
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7.7  Conclusions and outlook 
The triazole derivatives exhibit potent antiproliferative activity against human cancer cell 
lines in culture. The pattern of selectivity against the National Cancer 60 cancer cell line panel 
revealed a strong correlation with other agents that target tubulin as their mode of action. Based 
on this a series of experiments were conduction to determine whether the triazoles share this 
mechanism. Treatment of cells resulted in a strong arrest in the G2/M phase of the cell cycle, 
consistent with a tubulin targeting mechanism. Confocal microscopy revealed the cells are 
arrested in the M-phase with fragmented microtubule networks indicative of tubulin 
polymerization inhibition. In vitro assays confirmed that the compounds are indeed able to 
inhibit tubulin polymerization thus supporting tubulin as the target for the triazoles. The potency 
of the triazoles and the ease with which they can be synthesized and derivatized make this class 
of compounds attractive therapeutic candidates.  
 
7.8  Materials and methods 
General 
Sulforhodamine B sodium salt, propidium iodide, nocodazole, paclitaxel, guanosine 5′-
triphosphate (GTP) sodium salt hydrate and mouse monoclonal anti-α-tubulin−FITC antibody 
were obtained from Sigma Aldrich (Saint Louis, MO).  
 
Cell Culture Conditions 
All cells were grown in RPMI-1640 media supplemented with 10% fetal bovine serum 
(Gemini Bioproducts) and 1% Pen-Strep antibiotic and incubated at 37 ºC in a 5% CO2, 95% 
humidity atmosphere. 
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Sulforhodamine B cell proliferation sssay 
DMSO solutions of compounds were added in replicates of 5 (1 μL to each well) in 96-
well plates and U-937 cells were added (199 μL containing 4 x 104 cells).  The cells were 
incubated in a 37 ºC, 5% CO2, 95% humidity incubator for 72 hours.  Ice-cold trichloroacetic 
acid (50 μL of 50% w/v) was added directly to the wells containing media and the cells fixed 
overnight at 4 ºC. The plates were washed with water 5 times and stained with sulforhodamine B 
(50 μL of a 0.057% solution in 1% acetic acid) at room temperature for 30 min.  The plates were 
washed 5 times with 1% acetic acid to remove excess sulforhodamine B and the bound-dye was 
released by the addition of Tris-base (200 μL of 10 mM solution). The absorbance at 510 nm 
measured on a Molecular Devices SpectraMax 384 plus plate reader. The percentage reduction in 
biomass was calculated using vehicle-treated cells and wells without cells as the 100% and 0% 
biomass controls respectively. IC50 values were determined by fitting the dose response data to 
the logistic dose response equation in the software TableCurve 2D.  
 
Cell cycle arrest 
HeLa cells (8 x 10
5
 in 4 mL) were treated with 5 μM compound (0.05% DMSO final) in 
6-well plates for 18 hours in replicates of three. The cells were harvested, fixed in 70% ice-cold 
ethanol for one hour at -20 ºC, rinsed with phosphate buffered saline (PBS pH 7.4) and RNase 
treated (50 μL of 0.1 mg/mL RNase A in PBS) for two hours and subsequently stained with 
propidium iodide (50 μg/mL in PBS). The DNA content was measured using a Benton 
Dickinson LSR II cell flow cytometer with 20,000 events acquired per sample. The data was 
gated for single cells using propidium iodide-width vs. area. Population distribution in the 
various phases of the cell cycle was determined using the software FCS Express version 3. 
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Confocal microscopy 
HeLa cells (2.5 x 10
6
 cells/mL) were placed on 22 mm Corning type 1 square cover slips 
and incubated for 3 hours to allow the cells to attach. The cells were then incubated for 18 hours 
in media containing DMSO vehicle or 5 μM compound (0.05% DMSO final). The media was 
aspirated and cells treated with microtubule stabilizing buffer (MTSB: 80 mM PIPES pH 6.8, 1 
mM MgCl2, 1 mM EGTA) for 30 seconds after which glutaraldehyde was added to 0.5% final 
and the cells fixed for 10 min. Excess glutaraldehyde was quenched by treating the samples 
twice with a freshly made solution of NaBH4 (1 mg/mL in PBS) for 5 min. The samples were 
rinsed with PBS and blocked for 10 min with antibody diluting solution (PBS pH 7.4, 0.2% 
Triton X-100, 2% BSA, 0.1% sodium azide). Monoclonal anti-α-tubulin mouse FITC conjugated 
antibody (1:50 dilution) in antibody diluting solution containing 0.5 mg/mL RNase A (Qiagen) 
was added and the samples incubated for 2.5 hrs and then treated for 15 min with propidium 
iodide (50 μg/mL in antibody diluting solution). The samples were washed four times (5 min 
each) with PBS containing 0.1% Triton X-100, drained, mounted onto microscope slides using 
10 μL of Vectashield (Vector Technologies) mounting media.  The cover slips were sealed and 
the samples visualized immediately on a Zeiss confocal LSM510 microscope. 
 
In vitro tubulin polymerization assay 
Ice-cold assay buffer (39 μL of 80 mM PIPES pH 6.9, 0.5 mM EGTA, 2 mM MgCl2, 5% 
glycerol) was placed in a 384-well plate.  Compound (1 μL of 0.5 mM in DMSO) was added to 
achieve a final drug concentration of 10 μM.  Tubulin (10 μL of 15 mg/mL in ice-cold 500 mM 
K-PIPES, 0.5 mM MgCl2, pH 6.9 buffer) was added to each well. The plate was cooled on ice 
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for 10 min and GTP (0.5 μL from 100 mM) stock was added using an automated multichannel 
pipette followed by mixing three times (mix volume = 12 μL). The plate was placed immediately 
in a Molecular Devices SpectraMax 384 plus plate reader pre-heated to 37 ºC and the progress of 
polymerization monitored at 340 nm for 30 min.  The microtubule stabilizer and destabilizer, 
paclitaxel and nocodazole respectively were used as controls at final concentrations of 10 μM. 
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